

GLOBAL BURDEN OF DISEASES

Global Burden of Cardiovascular Diseases and Risks, 1990-2022



George A. Mensah, MD,^a Valentin Fuster, MD, PhD,^{b,c} Christopher J.L. Murray, MD, DPHIL,^d
Gregory A. Roth, MD, MPH,^{d,e} on behalf of the Global Burden of Cardiovascular Diseases and Risks Collaborators*

FUNDING SUPPORT AND AUTHOR DISCLOSURES

Funding was provided by the Bill and Melinda Gates Foundation, and the American College of Cardiology Foundation. The authors have reported that they have no relationships relevant to the contents of this paper to disclose. The contents and views expressed in this report are those of the authors and do not necessarily reflect the official views of the National Institutes of Health, the Department of Health and Human Services, the U.S. Government, or the affiliated institutions.

ADDRESS FOR CORRESPONDENCE: Dr Gregory A. Roth, Institute for Health Metrics and Evaluation, 3980 15th Avenue NE, UW Campus Box #351615, Seattle, Washington 98195, USA. E-mail: rothg@uw.edu. #GBDstudy, @IHME_UW, @NHLBI_Translate.

APPENDIX For a complete list of the Global Burden of Cardiovascular Diseases and Risks Collaborators, please see pages 1 to 35 of the Supplemental Appendix, available in the online version of this paper. Please see pages 36 to 47 of the Supplemental Appendix for more detailed information about individual author contributions to the research, divided into the following categories: providing data or critical feedback on data sources; developing methods or computational machinery; providing critical feedback on methods or results; drafting the manuscript or revising it critically for important intellectual content; and managing the estimation or publications process. For author disclosures, please see pages 48 to 56 of the Supplemental Appendix.

From the ^aCenter for Translation Research and Implementation Science, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA; ^bMount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York, USA; ^cCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; ^dDepartment of Health Metrics Sciences, Institute for Health Metrics and Evaluation, School of Medicine, University of Washington, Seattle, Washington, USA; and the ^eDivision of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA. *For a complete list of the Global Burden of Cardiovascular Diseases and Risks Collaborators as well as information about their relationships as they pertain to the contents of this paper, please see the Supplemental Appendix.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

Cardiovascular Disease in all Regions

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates by region ranged from 73.6 per 100,000 in High-income Asia Pacific to 432.3 per 100,000 in Eastern Europe in 2022. Global CVD mortality decreased by 34.9% from 1990 to 2022. Ischemic heart disease had the highest global age-standardized DALYs of all diseases at 2,275.9 per 100,000. Intracerebral hemorrhage and ischemic stroke were the next highest CVD causes for age-standardized DALYs. Age-standardized CVD prevalence ranged from 5,881.0 per 100,000 in South Asia to 11,342.6 per 100,000 in Central Asia. High systolic blood pressure accounted for the largest number of attributable age-standardized CVD DALYs at 2,564.9 per 100,000 globally. Of all risks, household air pollution from solid fuels had the largest change in attributable age-standardized DALYs from 1990 to 2022 with a 65.1% decrease.





Figure 1. Global map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	46,358,651	386,947	575.5	4.5	162.5
Ischemic heart disease	315,390,626	9,239,181	3,610.2	108.8	2,275.9
Ischemic stroke	86,661,746	3,542,299	994.5	42.3	819.5
Intracerebral hemorrhage	20,509,587	3,428,876	237.9	39.4	923.8
Subarachnoid hemorrhage	9,281,913	344,872	107.2	4.0	120.7
Hypertensive heart disease	13,052,641	1,353,074	150.9	16.1	292.7
Non-rheumatic calcific aortic valve disease	13,551,699	146,199	156.6	1.8	26.8
Non-rheumatic degenerative mitral valve disease	15,592,046	37,843	177.9	0.5	11.1
Other non-rheumatic valve diseases	12,130	2,033	0.1	<0.1	0.6
Myocarditis	625,129	26,702	7.8	0.3	11.8
Alcoholic cardiomyopathy	554,214	62,661	6.3	0.7	24.6
Other cardiomyopathy	4,715,332	295,751	58.7	3.5	99.3
Pulmonary arterial hypertension	193,710	20,561	2.3	0.2	7.4
Atrial fibrillation and flutter	55,414,434	362,381	637.5	4.5	102.9
Aortic aneurysm	Not estimated	153,118	Not estimated	1.8	34.6
Lower extremity peripheral arterial disease	105,980,247	73,928	1,213.3	0.9	19.6
Endocarditis	438,374	82,402	5.4	1.0	25.8
Other cardiovascular and circulatory diseases	86,722,785	221,797	1,006.1	2.6	118.8

Table 1. Global cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 2. Global cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Global estimate indicated by a triangle, loess line in blue with shaded 95% uncertainty interval.




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by region and (B) burden attributable to selected risk factors, globally, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and region. Boxplot shows first quartile, median, and third quartile of mortality range.

Cardiovascular Disease in Central Asia

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Central Asia ranged from 331.8 to 542.3 per 100,000 in 2022. CVD mortality decreased by 16.5% from 1990 to 2022. Of the 21 regions, Central Asia ranked 4th in 1990 and 2nd in 2022 for age-standardized CVD mortality, and 1st in CVD age-standardized prevalence in 2022. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 337.4 per 100,000. High systolic blood pressure had the largest number of attributable age-standardized CVD DALYs at 4,875.3 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	618,471	2,480	624.3	2.8	119.3
Ischemic heart disease	7,125,865	182,604	8,573.3	268.9	5,135.8
Ischemic stroke	951,108	45,226	1,091.5	69.6	1,330.9
Intracerebral hemorrhage	184,547	34,154	194.0	45.2	1,008.4
Subarachnoid hemorrhage	102,912	4,109	109.7	5.2	147.4
Hypertensive heart disease	71,919	12,724	96.4	19.0	337.4
Non-rheumatic calcific aortic valve disease	117,564	236	147.0	0.3	8.5
Non-rheumatic degenerative mitral valve disease	375,266	246	500.0	0.3	14.7
Other non-rheumatic valve diseases	220	54	0.3	0.1	1.8
Myocarditis	6,279	303	6.8	0.3	12.0
Alcoholic cardiomyopathy	5,279	861	5.5	0.9	32.5
Other cardiomyopathy	54,216	7,598	60.3	8.7	272.5
Pulmonary arterial hypertension	2,208	330	2.3	0.4	13.1
Atrial fibrillation and flutter	424,061	1,571	565.6	2.6	79.6
Aortic aneurysm	Not estimated	1,326	Not estimated	1.8	37.9
Lower extremity peripheral arterial disease	612,533	349	835.5	0.5	13.2
Endocarditis	854	177	0.9	0.2	7.5
Other cardiovascular and circulatory diseases	427,924	2,008	497.1	2.6	90.7

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, less line in blue with shaded 95% uncertainty interval.




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Cardiovascular Disease in Central Europe

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Central Europe ranged from 132.6 to 581.4 per 100,000 in 2022; a 4.4 fold difference. CVD mortality decreased by 47.0% from 1990 to 2022. Out of the 21 regions, Central Europe was ranked 2nd in 1990 and 7th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 444.3 per 100,000. For all risks, high systolic blood pressure accounted for the largest number of attributable age-standardized CVD DALYs at 2,963.3 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	63,222	2,976	30.7	1.3	30.7
Ischemic heart disease	12,141,290	338,314	5,430.8	141.8	2,601.9
Ischemic stroke	1,841,834	155,795	853.9	63.1	1,063.1
Intracerebral hemorrhage	193,385	46,002	121.7	20.0	443.8
Subarachnoid hemorrhage	177,955	7,020	108.0	3.4	114.2
Hypertensive heart disease	356,261	66,782	151.7	27.6	444.3
Non-rheumatic calcific aortic valve disease	869,200	6,517	377.5	2.7	49.2
Non-rheumatic degenerative mitral valve disease	677,172	2,486	288.1	1.1	24.2
Other non-rheumatic valve diseases	1,303	347	0.8	0.2	3.1
Myocarditis	12,887	1,594	11.1	0.8	19.7
Alcoholic cardiomyopathy	42,646	4,804	25.2	2.4	71.9
Other cardiomyopathy	160,289	20,028	95.7	8.6	169.5
Pulmonary arterial hypertension	3,515	445	2.3	0.2	6.1
Atrial fibrillation and flutter	1,412,498	12,606	604.9	5.1	111.8
Aortic aneurysm	Not estimated	6,482	Not estimated	2.8	61.7
Lower extremity peripheral arterial disease	2,227,532	7,116	942.2	2.9	50.4
Endocarditis	6,884	1,351	5.9	0.7	20.5
Other cardiovascular and circulatory diseases	1,879,255	6,875	951.1	3.1	118.1

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, less line in blue with shaded 95% uncertainty interval.




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Cardiovascular Disease in Eastern Europe

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Eastern Europe ranged from 215.0 to 553.0 per 100,000 in 2022; a 2.6 fold difference. CVD mortality decreased by 24.3% from 1990 to 2022. Out of the 21 regions, Eastern Europe was ranked 1st in both 1990 and 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, alcoholic cardiomyopathy had the highest age-standardized DALYs in 2022 at 521.2 per 100,000. For all risks, high systolic blood pressure accounted for the largest number of attributable age-standardized CVD DALYs at 4,619.4 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	241,126	3,324	73.9	1.0	28.6
Ischemic heart disease	25,389,496	914,066	7,243.7	254.3	4,882.7
Ischemic stroke	3,074,246	348,195	924.7	95.7	1,642.8
Intracerebral hemorrhage	467,843	90,934	159.3	26.4	680.1
Subarachnoid hemorrhage	317,276	16,751	108.9	5.0	154.7
Hypertensive heart disease	171,771	27,760	46.8	7.7	138.5
Non-rheumatic calcific aortic valve disease	963,872	2,470	266.4	0.7	19.2
Non-rheumatic degenerative mitral valve disease	949,952	832	259.7	0.2	9.6
Other non-rheumatic valve diseases	395	131	0.2	<0.1	1.3
Myocarditis	17,479	743	7.7	0.2	8.6
Alcoholic cardiomyopathy	177,153	38,801	63.6	13.2	521.2
Other cardiomyopathy	157,875	25,924	76.2	8.9	339.9
Pulmonary arterial hypertension	7,722	117	2.8	<0.1	1.7
Atrial fibrillation and flutter	2,384,327	19,282	663.1	5.3	119.9
Aortic aneurysm	Not estimated	13,936	Not estimated	4.0	93.8
Lower extremity peripheral arterial disease	4,018,233	13,208	1,099.9	3.6	66.3
Endocarditis	9,142	3,058	4.8	1.1	48.1
Other cardiovascular and circulatory diseases	2,914,750	16,721	863.9	4.9	164.1

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, less line in blue with shaded 95% uncertainty interval.




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Cardiovascular Disease in Australasia

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Australasia ranged from 92.0 to 122.5 per 100,000 in 2022; a 1.3 fold difference. CVD mortality decreased by 65.5% from 1990 to 2022. Of the 21 regions, Australasia ranked 16th in 1990 and 20th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, other cardiovascular and circulatory diseases had the highest age-standardized DALYs in 2022 at 152.2 per 100,000. High systolic blood pressure had the largest number of attributable age-standardized CVD DALYs at 777.3 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	22,224	638	52.9	1.1	27.1
Ischemic heart disease	1,282,122	29,819	2,380.2	47.4	893.0
Ischemic stroke	322,348	9,651	625.8	14.0	250.4
Intracerebral hemorrhage	41,072	4,199	95.2	6.8	130.1
Subarachnoid hemorrhage	34,529	1,457	80.0	2.7	76.8
Hypertensive heart disease	33,550	1,606	56.5	2.4	39.8
Non-rheumatic calcific aortic valve disease	198,197	2,162	331.3	3.2	45.5
Non-rheumatic degenerative mitral valve disease	118,556	373	199.4	0.6	11.7
Other non-rheumatic valve diseases	55	7	0.1	<0.1	0.2
Myocarditis	4,306	73	14.6	0.2	9.0
Alcoholic cardiomyopathy	12,654	470	27.6	0.9	29.8
Other cardiomyopathy	39,079	1,331	107.7	2.3	62.7
Pulmonary arterial hypertension	1,192	62	2.8	0.1	3.8
Atrial fibrillation and flutter	533,587	4,748	918.4	7.0	149.8
Aortic aneurysm	Not estimated	1,764	Not estimated	2.9	49.6
Lower extremity peripheral arterial disease	515,310	1,056	878.6	1.6	23.3
Endocarditis	4,542	755	9.7	1.3	26.1
Other cardiovascular and circulatory diseases	1,018,013	1,335	2,019.0	2.3	152.2

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, less line in blue with shaded 95% uncertainty interval.




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Cardiovascular Disease in High-Income Asia Pacific

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in High-income Asia Pacific ranged from 72.7 to 252.6 per 100,000 in 2022; a 3.5 fold difference. CVD mortality decreased by 64.2% from 1990 to 2022. Out of the 21 regions, High-income Asia Pacific was ranked 20th in 1990 and 21st in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, aortic aneurysm had the highest age-standardized DALYs in 2022 at 79.6 per 100,000. For all risks, high systolic blood pressure accounted for the largest number of attributable age-standardized CVD DALYs at 762.7 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	51,813	5,344	15.8	0.7	11.6
Ischemic heart disease	12,020,073	160,226	2,586.8	26.0	581.2
Ischemic stroke	3,765,022	115,125	900.3	15.5	347.4
Intracerebral hemorrhage	826,618	55,686	238.1	10.1	249.5
Subarachnoid hemorrhage	685,207	18,210	186.2	3.9	133.5
Hypertensive heart disease	310,906	22,366	58.4	3.0	46.7
Non-rheumatic calcific aortic valve disease	1,479,296	20,761	285.1	2.5	32.5
Non-rheumatic degenerative mitral valve disease	1,970,448	4,122	390.3	0.5	11.8
Other non-rheumatic valve diseases	326	31	0.1	<0.1	0.2
Myocarditis	27,538	559	15.7	0.2	8.9
Alcoholic cardiomyopathy	13,218	479	5.0	0.1	4.4
Other cardiomyopathy	201,378	9,689	81.9	1.7	44.0
Pulmonary arterial hypertension	9,259	1,137	3.0	0.2	8.8
Atrial fibrillation and flutter	2,188,998	18,040	461.2	2.5	68.1
Aortic aneurysm	Not estimated	26,762	Not estimated	4.4	79.6
Lower extremity peripheral arterial disease	5,112,414	2,692	951.9	0.4	9.5
Endocarditis	24,892	5,825	6.8	0.8	14.9
Other cardiovascular and circulatory diseases	3,392,925	5,480	962.4	1.0	71.0

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, less line in blue with shaded 95% uncertainty interval.




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Cardiovascular Disease in High-Income North America

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in High-income North America ranged from 99.4 to 191.6 per 100,000 in 2022; a 1.9 fold difference. CVD mortality decreased by 45.9% from 1990 to 2022. High-income North America was ranked 17th in both 1990 and in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 245.2 per 100,000. For all risks, high systolic blood pressure accounted for the largest number of attributable age-standardized CVD DALYs at 1,355.7 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	667,615	6,262	104.0	0.9	22.5
Ischemic heart disease	29,774,092	545,993	4,512.7	75.8	1,572.4
Ischemic stroke	7,310,116	133,791	1,243.8	17.4	392.9
Intracerebral hemorrhage	811,487	64,618	161.1	9.3	217.9
Subarachnoid hemorrhage	424,733	20,234	84.2	3.1	93.3
Hypertensive heart disease	1,030,771	77,701	159.5	11.2	245.2
Non-rheumatic calcific aortic valve disease	2,822,210	26,859	399.9	3.5	51.3
Non-rheumatic degenerative mitral valve disease	3,765,229	4,250	531.1	0.6	16.3
Other non-rheumatic valve diseases	712	78	0.2	<0.1	0.4
Myocarditis	55,489	809	17.3	0.2	11.3
Alcoholic cardiomyopathy	94,817	5,917	18.1	1.0	31.7
Other cardiomyopathy	525,115	23,631	124.8	3.6	95.4
Pulmonary arterial hypertension	8,771	1,888	1.7	0.3	7.5
Atrial fibrillation and flutter	8,517,878	43,337	1,209.9	5.6	161.4
Aortic aneurysm	Not estimated	13,625	Not estimated	2.0	42.2
Lower extremity peripheral arterial disease	12,665,608	12,402	1,784.6	1.7	33.7
Endocarditis	51,368	10,617	10.2	1.6	36.4
Other cardiovascular and circulatory diseases	10,519,632	21,465	1,884.4	3.3	182.8

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, less line in blue with shaded 95% uncertainty interval.




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Cardiovascular Disease in Southern Latin America

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Southern Latin America ranged from 114.9 to 173.6 per 100,000 in 2022; a 1.5 fold difference. CVD mortality decreased by 51.2% from 1990 to 2022. Of the 21 regions, Southern Latin America ranked 13th in 1990 and 16th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, other cardiovascular and circulatory diseases had the highest age-standardized DALYs in 2022 at 281.0 per 100,000. High systolic blood pressure had the largest number of attributable age-standardized CVD DALYs at 1,486.4 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	52,634	1,201	61.0	1.3	26.7
Ischemic heart disease	2,609,524	57,655	2,920.1	62.5	1,287.1
Ischemic stroke	528,575	21,539	615.0	22.7	401.3
Intracerebral hemorrhage	204,460	14,720	253.2	16.4	412.0
Subarachnoid hemorrhage	102,243	3,945	125.9	4.5	144.0
Hypertensive heart disease	98,942	14,678	107.9	15.5	230.0
Non-rheumatic calcific aortic valve disease	244,711	2,972	267.5	3.2	53.0
Non-rheumatic degenerative mitral valve disease	128,886	336	141.0	0.4	9.5
Other non-rheumatic valve diseases	23	7	<0.1	<0.1	0.2
Myocarditis	3,935	87	5.4	0.1	3.7
Alcoholic cardiomyopathy	2,095	172	2.6	0.2	5.9
Other cardiomyopathy	71,655	8,491	97.2	9.3	198.6
Pulmonary arterial hypertension	2,260	132	2.8	0.2	5.7
Atrial fibrillation and flutter	419,791	4,074	459.7	4.3	87.2
Aortic aneurysm	Not estimated	2,380	Not estimated	2.6	55.4
Lower extremity peripheral arterial disease	983,138	567	1,071.6	0.6	14.1
Endocarditis	4,242	1,566	5.6	1.7	41.4
Other cardiovascular and circulatory diseases	1,700,581	8,696	1,970.7	9.5	281.0

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, less line in blue with shaded 95% uncertainty interval.




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Cardiovascular Disease in Western Europe

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Western Europe ranged from 80.2 to 199.9 per 100,000 in 2022; a 2.5 fold difference. CVD mortality decreased by 60.2% from 1990 to 2022. Of the 21 regions, Western Europe ranked 15th in 1990 and 19th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, other cardiovascular and circulatory diseases had the highest age-standardized DALYs in 2022 at 166.7 per 100,000. High systolic blood pressure had the largest number of attributable age-standardized CVD DALYs at 977.2 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	115,044	18,447	14.9	1.6	26.5
Ischemic heart disease	27,188,008	576,481	2,928.5	49.5	957.8
Ischemic stroke	6,280,537	228,785	702.4	17.4	312.8
Intracerebral hemorrhage	795,635	95,176	112.6	8.5	170.5
Subarachnoid hemorrhage	570,991	22,622	84.6	2.3	68.3
Hypertensive heart disease	1,211,065	115,009	108.9	8.6	114.2
Non-rheumatic calcific aortic valve disease	4,297,106	55,830	419.1	4.3	61.9
Non-rheumatic degenerative mitral valve disease	3,167,713	9,420	308.5	0.8	15.4
Other non-rheumatic valve diseases	1,693	298	0.2	<0.1	0.5
Myocarditis	45,972	1,523	9.6	0.2	5.2
Alcoholic cardiomyopathy	95,734	4,892	14.4	0.6	17.2
Other cardiomyopathy	530,824	31,479	86.2	2.7	58.5
Pulmonary arterial hypertension	23,892	1,756	3.6	0.2	4.8
Atrial fibrillation and flutter	7,681,289	81,522	749.7	6.1	128.1
Aortic aneurysm	Not estimated	29,615	Not estimated	2.7	51.0
Lower extremity peripheral arterial disease	20,564,688	17,682	2,099.2	1.4	30.4
Endocarditis	94,539	19,801	12.7	1.7	31.4
Other cardiovascular and circulatory diseases	17,808,574	32,595	2,140.9	3.0	166.7

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, less line in blue with shaded 95% uncertainty interval.




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Cardiovascular Disease in Andean Latin America

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Andean Latin America ranged from 96.1 to 187.2 per 100,000 in 2022; a 1.9 fold difference. CVD mortality decreased by 39.9% from 1990 to 2022. Out of the 21 regions, Andean Latin America was ranked 21st in 1990 and 18th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 169.3 per 100,000. For all risks, high systolic blood pressure accounted for the largest number of attributable age-standardized CVD DALYs at 1,230.6 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	457,455	494	656.7	0.8	53.7
Ischemic heart disease	1,070,915	34,037	1,721.7	59.0	1,173.5
Ischemic stroke	469,672	10,679	756.7	19.0	356.2
Intracerebral hemorrhage	99,306	9,357	150.7	15.6	397.3
Subarachnoid hemorrhage	155,742	3,937	242.6	6.3	216.0
Hypertensive heart disease	85,773	5,595	145.0	9.9	169.3
Non-rheumatic calcific aortic valve disease	80,043	391	134.1	0.7	17.1
Non-rheumatic degenerative mitral valve disease	16,939	144	28.4	0.2	6.7
Other non-rheumatic valve diseases	24	4	<0.1	<0.1	0.1
Myocarditis	3,365	39	5.2	0.1	2.4
Alcoholic cardiomyopathy	27	3	<0.1	<0.1	0.1
Other cardiomyopathy	23,166	660	35.9	1.1	39.2
Pulmonary arterial hypertension	1,809	84	2.8	0.1	5.1
Atrial fibrillation and flutter	402,429	2,532	684.4	4.6	111.4
Aortic aneurysm	Not estimated	563	Not estimated	1.0	20.3
Lower extremity peripheral arterial disease	502,546	116	858.6	0.2	7.8
Endocarditis	2,992	221	4.6	0.4	13.6
Other cardiovascular and circulatory diseases	780,772	1,237	1,247.7	2.1	118.8

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, less line in blue with shaded 95% uncertainty interval.




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Cardiovascular Disease in the Caribbean

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in the Caribbean ranged from 97.3 to 459.2 per 100,000 in 2022; a 4.7 fold difference. CVD mortality decreased by 34.7% from 1990 to 2022. Out of the 21 regions, the Caribbean was ranked 11th in 1990 and 13th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 441.6 per 100,000. For all risks, high systolic blood pressure accounted for the largest number of attributable age-standardized CVD DALYs at 2,605.3 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	261,123	921	540.7	1.8	110.6
Ischemic heart disease	1,659,127	58,168	3,058.2	104.6	2,235.9
Ischemic stroke	490,869	21,153	913.3	38.0	701.9
Intracerebral hemorrhage	105,537	16,704	202.2	30.6	812.9
Subarachnoid hemorrhage	107,267	2,705	203.4	5.1	192.7
Hypertensive heart disease	101,513	12,193	185.4	21.8	441.6
Non-rheumatic calcific aortic valve disease	83,167	473	151.0	0.9	21.6
Non-rheumatic degenerative mitral valve disease	20,214	214	36.9	0.4	12.6
Other non-rheumatic valve diseases	34	10	0.1	<0.1	0.5
Myocarditis	3,162	178	6.5	0.4	21.4
Alcoholic cardiomyopathy	9,102	1,096	17.2	2.0	62.3
Other cardiomyopathy	25,868	2,200	53.5	4.2	138.5
Pulmonary arterial hypertension	1,233	106	2.4	0.2	11.6
Atrial fibrillation and flutter	388,887	2,633	704.9	4.6	112.8
Aortic aneurysm	Not estimated	1,189	Not estimated	2.2	41.2
Lower extremity peripheral arterial disease	602,048	1,111	1,087.3	2.0	37.5
Endocarditis	2,215	444	4.6	0.9	33.3
Other cardiovascular and circulatory diseases	586,853	2,294	1,101.1	4.3	179.7

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, less line in blue with shaded 95% uncertainty interval.




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Cardiovascular Disease in Central Latin America

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Central Latin America ranged from 109.5 to 329.4 per 100,000 in 2022; a 3.0 fold difference. CVD mortality decreased by 25.1% from 1990 to 2022. Out of the 21 regions, Central Latin America was ranked 19th in 1990 and 14th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 185.0 per 100,000. For all risks, high systolic blood pressure accounted for the largest number of attributable age-standardized DALYs at 1,771.4 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	2,180,136	1,085	818.2	0.4	50.5
Ischemic heart disease	6,773,869	266,503	2,606.2	108.9	2,112.4
Ischemic stroke	2,013,978	47,303	782.1	19.9	369.8
Intracerebral hemorrhage	414,191	34,937	156.5	13.8	339.3
Subarachnoid hemorrhage	515,867	11,313	195.6	4.4	145.5
Hypertensive heart disease	293,297	26,580	119.2	11.1	185.0
Non-rheumatic calcific aortic valve disease	415,329	1,998	163.5	0.8	20.0
Non-rheumatic degenerative mitral valve disease	94,050	918	37.1	0.4	9.0
Other non-rheumatic valve diseases	416	53	0.2	<0.1	0.5
Myocarditis	15,823	219	6.2	0.1	4.0
Alcoholic cardiomyopathy	7,615	473	2.8	0.2	6.3
Other cardiomyopathy	98,861	3,939	40.4	1.6	50.8
Pulmonary arterial hypertension	8,503	223	3.2	0.1	3.2
Atrial fibrillation and flutter	1,830,384	11,672	731.2	5.0	121.3
Aortic aneurysm	Not estimated	3,108	Not estimated	1.3	25.9
Lower extremity peripheral arterial disease	3,237,956	906	1,293.0	0.4	13.0
Endocarditis	11,943	1,309	4.8	0.5	17.6
Other cardiovascular and circulatory diseases	3,451,669	6,319	1,330.6	2.6	131.7

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, less line in blue with shaded 95% uncertainty interval.




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Cardiovascular Disease in Tropical Latin America

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Tropical Latin America ranged from 157.7 to 201.8 per 100,000 in 2022; a 1.3 fold difference. CVD mortality decreased by 52.6% from 1990 to 2022. Out of the 21 regions, Tropical Latin America was ranked 12th in 1990 and 15th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 245.4 per 100,000. For all risks, high systolic blood pressure accounted for the largest number of attributable age-standardized DALYs at 1,706.2 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	1,178,179	3,017	492.9	1.2	59.1
Ischemic heart disease	3,706,448	170,497	1,397.5	65.8	1,467.1
Ischemic stroke	2,083,023	77,319	795.6	30.9	545.1
Intracerebral hemorrhage	450,678	46,943	173.2	17.8	462.2
Subarachnoid hemorrhage	394,619	14,180	150.2	5.4	175.8
Hypertensive heart disease	424,780	34,337	166.1	13.6	245.4
Non-rheumatic calcific aortic valve disease	377,483	3,857	143.7	1.5	31.1
Non-rheumatic degenerative mitral valve disease	113,713	1,459	43.2	0.6	14.2
Other non-rheumatic valve diseases	477	73	0.2	<0.1	0.8
Myocarditis	16,568	379	7.1	0.2	6.3
Alcoholic cardiomyopathy	19,642	983	7.5	0.4	13.6
Other cardiomyopathy	276,933	14,154	118.0	5.6	147.0
Pulmonary arterial hypertension	6,328	709	2.5	0.3	9.3
Atrial fibrillation and flutter	2,055,246	14,553	787.2	5.9	136.0
Aortic aneurysm	Not estimated	8,909	Not estimated	3.4	74.5
Lower extremity peripheral arterial disease	2,903,792	3,707	1,118.7	1.5	30.9
Endocarditis	14,833	2,771	6.6	1.1	33.9
Other cardiovascular and circulatory diseases	3,621,645	9,064	1,403.2	3.6	158.2

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, less line in blue with shaded 95% uncertainty interval.




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Cardiovascular Disease in North Africa and Middle East

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in North Africa and Middle East ranged from 132.5 to 578.7 per 100,000 in 2022; a 4.4 fold difference. CVD mortality decreased by 31.6% from 1990 to 2022. Of the 21 regions, North Africa and Middle East ranked 3rd in 1990 and 5th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 654.8 per 100,000. High systolic blood pressure had the largest number of attributable age-standardized CVD DALYs at 3,914.0 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	2,764,881	9,411	420.5	1.9	82.2
Ischemic heart disease	29,397,709	770,738	5,780.2	196.2	4,028.1
Ischemic stroke	4,390,907	254,063	803.4	71.8	1,267.9
Intracerebral hemorrhage	1,207,552	112,756	199.2	26.0	631.2
Subarachnoid hemorrhage	660,160	12,513	115.1	2.8	86.9
Hypertensive heart disease	1,043,500	136,843	240.0	38.0	654.8
Non-rheumatic calcific aortic valve disease	260,404	3,603	56.9	0.9	20.0
Non-rheumatic degenerative mitral valve disease	271,543	3,108	63.3	0.7	18.2
Other non-rheumatic valve diseases	3,516	338	0.6	0.1	2.0
Myocarditis	33,842	3,336	5.8	0.8	22.0
Alcoholic cardiomyopathy	3,065	124	0.5	<0.1	0.8
Other cardiomyopathy	311,277	7,084	52.1	1.5	53.3
Pulmonary arterial hypertension	11,860	1,459	2.0	0.3	11.6
Atrial fibrillation and flutter	1,560,144	11,850	397.3	4.0	78.6
Aortic aneurysm	Not estimated	4,152	Not estimated	1.0	21.5
Lower extremity peripheral arterial disease	3,580,213	1,941	876.0	0.5	13.8
Endocarditis	17,388	2,628	3.0	0.6	17.4
Other cardiovascular and circulatory diseases	8,613,986	30,165	1,640.6	7.2	271.6

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, less line in blue with shaded 95% uncertainty interval.




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Cardiovascular Disease in South Asia

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in South Asia ranged from 225.4 to 326.5 per 100,000 in 2022. CVD mortality decreased by 11.3% from 1990 to 2022. Of the 21 regions, South Asia ranked 14th in 1990 and 10th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, rheumatic heart disease had the highest age-standardized DALYs in 2022 at 466.1 per 100,000. South Asia had the lowest CVD age-standardized prevalence in 2022. High systolic blood pressure had the largest number of attributable age-standardized CVD DALYs at 2,841.1 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	13,791,295	225,729	692.5	15.0	466.1
Ischemic heart disease	36,416,292	2,021,289	2,214.6	147.1	3,285.4
Ischemic stroke	13,333,231	417,001	838.0	34.4	678.0
Intracerebral hemorrhage	4,234,810	538,372	242.9	36.8	902.9
Subarachnoid hemorrhage	1,543,909	61,635	85.1	4.0	126.8
Hypertensive heart disease	1,478,240	194,286	111.8	15.9	285.1
Non-rheumatic calcific aortic valve disease	362,863	10,800	25.1	0.9	16.0
Non-rheumatic degenerative mitral valve disease	505,344	5,230	35.6	0.4	9.1
Other non-rheumatic valve diseases	717	225	<0.1	<0.1	0.4
Myocarditis	112,625	5,127	6.5	0.3	14.2
Alcoholic cardiomyopathy	12,545	1,550	0.7	0.1	3.0
Other cardiomyopathy	797,264	72,352	48.7	5.2	136.8
Pulmonary arterial hypertension	30,055	3,646	1.7	0.3	8.3
Atrial fibrillation and flutter	7,938,649	32,239	589.6	3.2	84.7
Aortic aneurysm	Not estimated	12,746	Not estimated	1.0	19.0
Lower extremity peripheral arterial disease	10,775,328	3,447	798.3	0.3	9.3
Endocarditis	48,426	11,991	2.8	0.8	23.5
Other cardiovascular and circulatory diseases	10,705,232	32,698	707.4	2.4	94.3

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, less line in blue with shaded 95% uncertainty interval.




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Cardiovascular Disease in East Asia

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in East Asia ranged from 91.8 to 352.9 per 100,000 in 2022; a 3.8 fold difference. CVD mortality decreased by 32.4% from 1990 to 2022. Out of the 21 regions, East Asia was ranked 7th in 1990 and 11th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 269.3 per 100,000. For all risks, high systolic blood pressure accounted for the largest number of attributable age-standardized CVD DALYs at 2,745.2 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	5,266,540	75,927	343.8	3.7	89.1
Ischemic heart disease	68,751,838	2,099,130	3,183.8	108.4	1,917.9
Ischemic stroke	23,266,169	1,139,094	1,064.1	57.0	1,072.0
Intracerebral hemorrhage	4,923,009	1,433,592	239.3	68.6	1,361.0
Subarachnoid hemorrhage	1,720,413	91,177	85.9	4.3	111.1
Hypertensive heart disease	4,114,002	331,523	189.0	17.4	269.3
Non-rheumatic calcific aortic valve disease	751,611	1,805	33.5	0.1	2.2
Non-rheumatic degenerative mitral valve disease	2,832,655	1,066	125.3	0.1	2.9
Other non-rheumatic valve diseases	1,382	247	0.1	<0.1	0.3
Myocarditis	165,695	9,139	11.0	0.5	17.5
Alcoholic cardiomyopathy	32,864	1,551	1.8	0.1	2.8
Other cardiomyopathy	280,309	12,430	19.1	0.7	20.0
Pulmonary arterial hypertension	42,191	6,687	2.2	0.3	7.7
Atrial fibrillation and flutter	12,179,180	67,436	551.6	4.0	88.1
Aortic aneurysm	Not estimated	11,241	Not estimated	0.5	14.3
Lower extremity peripheral arterial disease	27,223,946	2,326	1,197.4	0.1	8.3
Endocarditis	37,262	3,171	2.2	0.2	4.8
Other cardiovascular and circulatory diseases	6,009,279	12,839	290.8	0.7	31.2

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, less line in blue with shaded 95% uncertainty interval.




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Cardiovascular Disease in Oceania

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Oceania ranged from 235.0 to 714.5 per 100,000 in 2022; a 3.0 fold difference. CVD mortality decreased by 16.4% from 1990 to 2022. Out of the 21 regions, Oceania was ranked 5th in 1990 and 3rd in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, rheumatic heart disease had the highest age-standardized DALYs in 2022 at 593.7 per 100,000. For all risks, high systolic blood pressure accounted for the largest number of attributable age-standardized CVD DALYs at 4,420.7 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	101,882	1,468	700.3	13.4	593.7
Ischemic heart disease	448,962	13,551	5,133.3	202.7	4,755.9
Ischemic stroke	84,641	1,802	985.3	37.9	790.5
Intracerebral hemorrhage	43,925	6,451	414.8	94.1	2,226.2
Subarachnoid hemorrhage	22,127	646	205.4	7.6	267.2
Hypertensive heart disease	6,669	1,487	102.9	22.6	505.5
Non-rheumatic calcific aortic valve disease	1,718	59	27.0	0.9	22.0
Non-rheumatic degenerative mitral valve disease	4,404	7	71.2	0.1	3.8
Other non-rheumatic valve diseases	5	2	0.1	<0.1	0.6
Myocarditis	670	33	5.5	0.2	14.0
Alcoholic cardiomyopathy	20	6	0.2	0.1	2.0
Other cardiomyopathy	2,892	427	24.5	4.5	159.7
Pulmonary arterial hypertension	198	23	1.8	0.2	8.9
Atrial fibrillation and flutter	33,404	185	542.1	4.2	103.8
Aortic aneurysm	Not estimated	118	Not estimated	1.9	40.0
Lower extremity peripheral arterial disease	65,617	8	1,009.2	0.1	8.9
Endocarditis	450	252	4.2	2.7	93.4
Other cardiovascular and circulatory diseases	30,024	204	392.8	2.3	97.2

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, less line in blue with shaded 95% uncertainty interval.




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Cardiovascular Disease in Southeast Asia

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Southeast Asia ranged from 123.2 to 406.2 per 100,000 in 2022; a 3.3 fold difference. CVD mortality decreased by 16.9% from 1990 to 2022. Out of the 21 regions, Southeast Asia was ranked 8th in 1990 and 6th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 458.5 per 100,000. For all risks, high systolic blood pressure accounted for the largest number of attributable age-standardized CVD DALYs at 3,925.7 per 100,000.






Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	5,706,614	11,882	769.9	1.7	113.3
Ischemic heart disease	31,693,855	656,205	4,589.4	110.7	2,501.3
Ischemic stroke	9,373,197	325,362	1,358.5	63.4	1,239.7
Intracerebral hemorrhage	3,334,389	526,960	441.4	82.5	2,002.4
Subarachnoid hemorrhage	1,194,567	38,419	158.1	6.0	186.6
Hypertensive heart disease	1,017,714	132,805	168.1	22.9	458.5
Non-rheumatic calcific aortic valve disease	157,395	1,425	25.6	0.3	5.1
Non-rheumatic degenerative mitral valve disease	513,144	635	84.3	0.1	3.7
Other non-rheumatic valve diseases	271	62	<0.1	<0.1	0.2
Myocarditis	44,350	1,369	6.5	0.3	7.6
Alcoholic cardiomyopathy	3,649	333	0.5	<0.1	1.7
Other cardiomyopathy	163,221	14,967	26.4	2.7	62.7
Pulmonary arterial hypertension	13,615	661	1.9	0.1	4.0
Atrial fibrillation and flutter	3,614,518	23,517	597.6	5.4	109.4
Aortic aneurysm	Not estimated	7,031	Not estimated	1.3	23.3
Lower extremity peripheral arterial disease	7,493,846	821	1,195.2	0.1	9.8
Endocarditis	37,970	7,559	6.1	1.2	35.5
Other cardiovascular and circulatory diseases	2,746,132	8,101	410.2	1.3	60.1

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.






Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Cardiovascular Disease in Central Sub-Saharan Africa

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Central Sub-Saharan Africa ranged from 323.5 to 464.6 per 100,000 in 2022; a 1.4 fold difference. CVD mortality decreased by 12.3% from 1990 to 2022. Out of the 21 regions, Central Sub-Saharan Africa was ranked 6th in 1990 and 4th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 1,110.7 per 100,000. High systolic blood pressure accounted for the largest number of attributable age-standardized CVD DALYs at 4,339.8 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	1,906,645	3,030	1,380.7	5.1	201.0
Ischemic heart disease	2,207,929	51,104	3,464.7	121.9	2,491.6
Ischemic stroke	781,664	21,875	1,239.4	66.7	1,209.9
Intracerebral hemorrhage	225,657	37,452	259.0	76.5	1,730.8
Subarachnoid hemorrhage	66,885	1,827	77.0	3.0	92.2
Hypertensive heart disease	112,616	23,406	254.0	60.4	1,110.7
Non-rheumatic calcific aortic valve disease	7,840	578	14.4	1.5	27.2
Non-rheumatic degenerative mitral valve disease	7,619	423	13.8	0.9	19.5
Other non-rheumatic valve diseases	46	10	<0.1	<0.1	0.4
Myocarditis	5,594	256	5.1	0.3	11.5
Alcoholic cardiomyopathy	1,823	2	2.1	<0.1	0.3
Other cardiomyopathy	116,974	8,352	112.0	15.5	387.0
Pulmonary arterial hypertension	1,727	134	1.8	0.2	6.1
Atrial fibrillation and flutter	198,070	1,357	443.8	4.8	98.8
Aortic aneurysm	Not estimated	999	Not estimated	2.2	45.6
Lower extremity peripheral arterial disease	306,848	612	726.1	1.8	33.3
Endocarditis	6,117	1,024	4.4	1.8	46.5
Other cardiovascular and circulatory diseases	1,122,426	1,897	1,885.0	3.5	178.8

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, less line in blue with shaded 95% uncertainty interval.




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Cardiovascular Disease in Eastern Sub-Saharan Africa

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Eastern Sub-Saharan Africa ranged from 187.8 to 410.8 per 100,000 in 2022; a 2.2 fold difference. CVD mortality decreased by 23.6% from 1990 to 2022. Of the 21 regions, Eastern Sub-Saharan Africa ranked 10th in 1990 and 12th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 676.3 per 100,000. High systolic blood pressure had the largest number of attributable age-standardized CVD DALYs at 3,193.0 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	5,548,728	6,452	1,295.3	3.8	153.1
Ischemic heart disease	6,423,413	109,091	3,169.3	77.6	1,664.7
Ischemic stroke	2,297,408	61,695	1,147.3	54.1	997.6
Intracerebral hemorrhage	734,889	114,782	270.5	72.4	1,671.9
Subarachnoid hemorrhage	213,645	5,213	78.6	2.6	85.7
Hypertensive heart disease	512,396	46,238	349.8	36.4	676.3
Non-rheumatic calcific aortic valve disease	23,487	1,206	13.8	0.9	16.8
Non-rheumatic degenerative mitral valve disease	22,598	1,266	13.0	0.7	17.9
Other non-rheumatic valve diseases	273	23	0.1	<0.1	0.3
Myocarditis	18,811	365	5.5	0.1	5.4
Alcoholic cardiomyopathy	9,559	3	3.1	<0.1	0.3
Other cardiomyopathy	498,218	8,394	161.4	3.8	134.5
Pulmonary arterial hypertension	6,099	453	2.1	0.2	6.4
Atrial fibrillation and flutter	578,307	3,044	400.7	3.2	71.7
Aortic aneurysm	Not estimated	2,549	Not estimated	1.7	35.8
Lower extremity peripheral arterial disease	933,431	1,280	675.1	1.1	21.9
Endocarditis	33,390	4,027	7.0	1.9	57.3
Other cardiovascular and circulatory diseases	2,582,036	5,139	1,283.6	2.7	135.9

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, less line in blue with shaded 95% uncertainty interval.




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Cardiovascular Disease in Southern Sub-Saharan Africa

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Southern Sub-Saharan Africa ranged from 248.3 to 453.3 per 100,000 in 2022; a 1.8 fold difference. CVD mortality increased by 8.0% from 1990 to 2022. Of the 21 regions, Southern Sub-Saharan Africa ranked 18th in 1990 and 9th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 839.6 per 100,000. High systolic blood pressure had the largest number of attributable age-standardized CVD DALYs at 3,138.2 per 100,000.




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	722,444	1,682	847.1	2.5	133.9
Ischemic heart disease	1,857,089	38,915	2,992.7	81.5	1,680.0
Ischemic stroke	800,106	23,969	1,339.5	58.6	1,038.3
Intracerebral hemorrhage	144,626	26,826	206.0	49.0	1,166.8
Subarachnoid hemorrhage	40,248	1,181	54.0	2.0	63.1
Hypertensive heart disease	80,643	21,221	153.2	47.1	839.6
Non-rheumatic calcific aortic valve disease	13,379	545	23.1	1.3	22.0
Non-rheumatic degenerative mitral valve disease	7,705	232	12.4	0.4	11.6
Other non-rheumatic valve diseases	22	8	<0.1	<0.1	0.4
Myocarditis	4,353	94	5.9	0.1	6.3
Alcoholic cardiomyopathy	374	4	0.5	<0.1	0.2
Other cardiomyopathy	67,206	6,134	91.0	12.1	276.7
Pulmonary arterial hypertension	1,625	66	2.3	0.1	3.9
Atrial fibrillation and flutter	263,389	1,435	510.9	4.2	89.4
Aortic aneurysm	Not estimated	1,246	Not estimated	2.5	50.5
Lower extremity peripheral arterial disease	488,286	940	973.7	2.0	42.8
Endocarditis	3,338	614	4.1	0.9	33.3
Other cardiovascular and circulatory diseases	1,460,546	2,386	2,458.0	4.7	225.9

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country (circle) in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, less line in blue with shaded 95% uncertainty interval.




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

Cardiovascular Disease in Western Sub-Saharan Africa

FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY

Summary: Age-standardized CVD mortality rates among countries in Western Sub-Saharan Africa ranged from 238.1 to 449.7 per 100,000 in 2022; a 1.9 fold difference. CVD mortality decreased by 19.9% from 1990 to 2022. Of the 21 regions, Western Sub-Saharan Africa ranked 9th in 1990 and 8th in 2022 for age-standardized CVD mortality. After ischemic heart disease and all stroke subtypes, hypertensive heart disease had the highest age-standardized DALYs in 2022 at 593.8 per 100,000. High systolic blood pressure had the largest number of attributable age-standardized CVD DALYs at 3,330.4 per 100,000




Figure 1. Regional map of 2022 age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification




Figure 2. Regional cardiovascular disease mortality rate per 100,000 by age and sex in 1990 vs. 2022

Cardiovascular Disease Type	Prevalent Cases (Count)	Deaths (Count)	Prevalence (Rate)	Deaths (Rate)	Disability-Adjusted Life Years (DALYs, Rate)
Rheumatic heart disease	4,640,580	5,175	963.3	2.3	108.1
Ischemic heart disease	7,452,708	144,797	3,228.8	94.4	1,824.3
Ischemic stroke	3,203,095	82,875	1,240.4	60.9	1,114.1
Intracerebral hemorrhage	1,065,970	118,256	336.7	62.8	1,478.2
Subarachnoid hemorrhage	230,618	5,777	73.8	2.5	81.3
Hypertensive heart disease	496,314	47,933	289.7	29.3	593.8
Non-rheumatic calcific aortic valve disease	24,823	1,650	11.3	1.1	19.3
Non-rheumatic degenerative mitral valve disease	28,895	1,077	13.0	0.6	13.0
Other non-rheumatic valve diseases	220	27	0.1	<0.1	0.3
Myocarditis	26,383	478	6.1	0.1	5.8
Alcoholic cardiomyopathy	10,332	139	3.1	0.1	2.1
Other cardiomyopathy	312,714	16,486	83.9	8.2	204.8
Pulmonary arterial hypertension	9,646	444	3.0	0.1	5.4
Atrial fibrillation and flutter	809,397	4,749	474.5	4.6	88.4
Aortic aneurysm	Not estimated	3,377	Not estimated	2.0	40.0
Lower extremity peripheral arterial disease	1,166,933	1,641	708.6	1.3	23.1
Endocarditis	25,587	3,241	5.3	1.4	39.6
Other cardiovascular and circulatory diseases	5,350,530	14,280	2,502.3	7.4	293.3

Table 1. Regional cardiovascular disease in 2022: counts and age-standardized rates per 100,000. Results, uncertainty intervals, and methods available online.




Figure 3. Age-standardized cardiovascular disease mortality rate per 100,000 by country in 2022 by socio-demographic index (0-100), a composite indicator of fertility, income, and education. Focus region countries indicated by triangles, less line in blue with shaded 95% uncertainty interval.




Figure 4. Age-standardized disability-adjusted life years (DALYs) per 100,000 in 2022 for (A) cardiovascular diseases by country and (B) burden attributable to selected risk factors, for the region, compared to the theoretical minimum risk exposure level




Figure 5. Age-standardized mortality rate per 100,000 for cardiovascular diseases in 2022 by cause of death and country. Boxplot shows first quartile, median, and third quartile of mortality range.

AGGREGATE CAUSE: CARDIOVASCULAR DISEASE




Figure 1. Global map of age-standardized cardiovascular disease mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

RHEUMATIC HEART DISEASE




Figure 1. Global map of age-standardized rheumatic heart disease mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global rheumatic heart disease estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Rheumatic heart disease age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global rheumatic heart disease age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

ISCHEMIC HEART DISEASE




Figure 1. Global map of age-standardized ischemic heart disease mortality rate per 100,000 in 2022 with equal interval classification





Figure 2. Global ischemic heart disease estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022



Global Burden of Disease Regions

Figure 3. Ischemic heart disease age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global ischemic heart disease age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

AGGREGATE CAUSE: STROKE




Figure 1. Global map of age-standardized stroke mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global stroke estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Stroke age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global stroke age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

ISCHEMIC STROKE




Figure 1. Global map of age-standardized ischemic stroke mortality rate per 100,000 in 2022 with equal interval classification





Figure 2. Global ischemic stroke estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022



Global Burden of Disease Regions

Figure 3. Ischemic stroke age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global ischemic stroke age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

INTRACEREBRAL HEMORRHAGE




Figure 1. Global map of age-standardized intracerebral hemorrhage mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global intracerebral hemorrhage estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Intracerebral hemorrhage age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global intracerebral hemorrhage age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

SUBARACHNOID HEMORRHAGE




Figure 1. Global map of age-standardized subarachnoid hemorrhage mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global subarachnoid hemorrhage estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Subarachnoid hemorrhage age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global subarachnoid hemorrhage age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

HYPERTENSIVE HEART DISEASE




Figure 1. Global map of age-standardized hypertensive heart disease mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global hypertensive heart disease estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Hypertensive heart disease age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global hypertensive heart disease age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

AGGREGATE CAUSE: NON-RHEUMATIC VALVULAR HEART DISEASE




Figure 1. Global map of age-standardized non-rheumatic valvular heart disease mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global non-rheumatic valvular heart disease estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Non-rheumatic valvular heart disease age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global non-rheumatic valvular heart disease age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

NON-RHEUMATIC CALCIFIC AORTIC VALVE DISEASE




Figure 1. Global map of age-standardized non-rheumatic calcific aortic valve disease mortality rate per 100,000 in 2022 with equal interval classification





Figure 2. Global non-rheumatic calcific aortic valve disease estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022



Global Burden of Disease Regions
 Figure 3. Non-rheumatic calcific aortic valve disease age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global non-rheumatic calcific aortic valve disease age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

NON-RHEUMATIC DEGENERATIVE MITRAL VALVE DISEASE




Figure 1. Global map of age-standardized non-rheumatic degenerative mitral valve disease mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global non-rheumatic degenerative mitral valve disease estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Non-rheumatic degenerative mitral valve disease age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global non-rheumatic degenerative mitral valve disease age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

OTHER NON-RHEUMATIC VALVE DISEASES




Figure 1. Global map of age-standardized other non-rheumatic valve diseases mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global other non-rheumatic valve diseases estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Other non-rheumatic valve diseases age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global other non-rheumatic valve diseases age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

AGGREGATE CAUSE: CARDIOMYOPATHY AND MYOCARDITIS




Figure 1. Global map of age-standardized cardiomyopathy and myocarditis mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiomyopathy and myocarditis estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiomyopathy and myocarditis age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiomyopathy and myocarditis age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

MYOCARDITIS




Figure 1. Global map of age-standardized myocarditis mortality rate per 100,000 in 2022 with equal interval classification





Figure 2. Global myocarditis estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022



Global Burden of Disease Regions

Figure 3. Myocarditis age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global myocarditis age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

ALCOHOLIC CARDIOMYOPATHY




Figure 1. Global map of age-standardized alcoholic cardiomyopathy mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global alcoholic cardiomyopathy estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Alcoholic cardiomyopathy age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global alcoholic cardiomyopathy age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

OTHER CARDIOMYOPATHY




Figure 1. Global map of age-standardized other cardiomyopathy mortality rate per 100,000 in 2022 with equal interval classification





Figure 2. Global other cardiomyopathy estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022



Global Burden of Disease Regions

Figure 3. Other cardiomyopathy age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global other cardiomyopathy age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

PULMONARY ARTERIAL HYPERTENSION




Figure 1. Global map of age-standardized pulmonary arterial hypertension mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global pulmonary arterial hypertension estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Pulmonary arterial hypertension age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global pulmonary arterial hypertension age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

ATRIAL FIBRILLATION AND FLUTTER




Figure 1. Global map of age-standardized atrial fibrillation and flutter mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global atrial fibrillation and flutter estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Atrial fibrillation and flutter age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global atrial fibrillation and flutter age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

AORTIC ANEURYSM




Figure 1. Global map of age-standardized aortic aneurysm mortality rate per 100,000 in 2022 with equal interval classification





Figure 2. Global aortic aneurysm estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022



Global Burden of Disease Regions

Figure 3. Aortic aneurysm age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global aortic aneurysm age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

LOWER EXTREMITY PERIPHERAL ARTERIAL DISEASE




Figure 1. Global map of age-standardized lower extremity peripheral arterial disease mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global lower extremity peripheral arterial disease estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Lower extremity peripheral arterial disease age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global lower extremity peripheral arterial disease age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

ENDOCARDITIS




Figure 1. Global map of age-standardized endocarditis mortality rate per 100,000 in 2022 with equal interval classification





Figure 2. Global endocarditis estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022



Global Burden of Disease Regions

Figure 3. Endocarditis age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global endocarditis age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

OTHER CARDIOVASCULAR AND CIRCULATORY DISEASES




Figure 1. Global map of age-standardized other cardiovascular and circulatory diseases mortality rate per 100,000 in 2022 with equal interval classification




Figure 2. Global other cardiovascular and circulatory diseases estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Other cardiovascular and circulatory diseases age-standardized disability-adjusted life years (DALYs) per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global other cardiovascular and circulatory diseases age-specific estimates per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

AMBIENT PARTICULATE MATTER POLLUTION




Figure 1. Global map of cardiovascular disease mortality attributable to ambient particulate matter pollution per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to ambient particulate matter pollution estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to ambient particulate matter pollution per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to ambient particulate matter pollution per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

HOUSEHOLD AIR POLLUTION FROM SOLID FUELS




Figure 1. Global map of cardiovascular disease mortality attributable to household air pollution from solid fuels per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to household air pollution from solid fuels estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to household air pollution from solid fuels per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to household air pollution from solid fuels per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

HIGH TEMPERATURE




Figure 1. Global map of cardiovascular disease mortality attributable to high temperature per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to high temperature estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to high temperature per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to high temperature per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

LOW TEMPERATURE




Figure 1. Global map of cardiovascular disease mortality attributable to low temperature per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to low temperature estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to low temperature per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to low temperature per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

LEAD EXPOSURE




Figure 1. Global map of cardiovascular disease mortality attributable to lead exposure per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to lead exposure estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to lead exposure per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to lead exposure per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

SMOKING




Figure 1. Global map of cardiovascular disease mortality attributable to smoking per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to smoking estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to smoking per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to smoking per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

SECONDHAND SMOKE




Figure 1. Global map of cardiovascular disease mortality attributable to secondhand smoke per 100,000 in 2022 with equal interval classification





Figure 2. Global cardiovascular disease attributable to secondhand smoke estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022



Global Burden of Disease Regions
Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to secondhand smoke per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to secondhand smoke per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

HIGH ALCOHOL USE




Figure 1. Global map of cardiovascular disease mortality attributable to high alcohol use per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to high alcohol use estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to high alcohol use per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to high alcohol use per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

DIETARY RISKS




Figure 1. Global map of cardiovascular disease mortality attributable to dietary risks per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to dietary risks estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to dietary risks per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to dietary risks per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

LOW PHYSICAL ACTIVITY




Figure 1. Global map of cardiovascular disease mortality attributable to low physical activity per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to low physical activity estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to low physical activity per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to low physical activity per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

HIGH FASTING PLASMA GLUCOSE




Figure 1. Global map of cardiovascular disease mortality attributable to high fasting plasma glucose per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to high fasting plasma glucose estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to high fasting plasma glucose per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to high fasting plasma glucose per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

HIGH LDL CHOLESTEROL




Figure 1. Global map of cardiovascular disease mortality attributable to high LDL cholesterol per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to high LDL cholesterol estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to high LDL cholesterol per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to high LDL cholesterol per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

HIGH SYSTOLIC BLOOD PRESSURE




Figure 1. Global map of cardiovascular disease mortality attributable to high systolic blood pressure per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to high systolic blood pressure estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to high systolic blood pressure per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to high systolic blood pressure per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

HIGH BODY MASS INDEX




Figure 1. Global map of cardiovascular disease mortality attributable to high body mass index per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to high body mass index estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to high body mass index per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to high body mass index per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

KIDNEY DYSFUNCTION




Figure 1. Global map of cardiovascular disease mortality attributable to kidney dysfunction per 100,000 in 2022 with equal interval classification




Figure 2. Global cardiovascular disease attributable to kidney dysfunction estimates per 100,000 by measure with shaded 95% uncertainty interval, 1990-2022




Figure 3. Cardiovascular disease age-standardized disability-adjusted life years (DALYs) attributable to kidney dysfunction per 100,000 by Global Burden of Disease region and sex in 2022, 95% uncertainty interval indicated by black bar




Figure 4. Global cardiovascular disease age-specific estimates attributable to kidney dysfunction per 100,000 by sex in 2022, difference in sex estimates indicated by gray bar

SUMMARY OF GLOBAL BURDEN OF DISEASE STUDY METHODS

BACKGROUND. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) is a multinational collaborative research study with >10,000 collaborators around the world. GBD generates a time series of summary measures of health, including prevalence, cause-specific mortality (CSMR), years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs) to provide a comprehensive view of health burden for a wide range of stakeholders including clinicians, public and private health systems, ministries of health, and other policymakers. These estimates are produced for 371 causes of death and 88 risk factors according to mutually exclusive, collectively exhaustive hierarchies of health conditions and risks. The study is led by a principal investigator and governed by a study protocol, with oversight from a Scientific Council, and an Independent Advisory Committee.¹ GBD is performed in compliance with Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER).² GBD uses de-identified data, and the waiver of informed consent was reviewed and approved by the University of Washington Institutional Review Board (study number 9060).

This almanac presents results for 18 cardiovascular diseases (CVD) and the CVD burden attributed to 15 risk factors (including an aggregate grouping of dietary risks) by GBD region. A summary of methods follows. Additional information can be found online at <https://ghdx.healthdata.org/record/ihme-data/cvd-1990-2022>, including:

- 1) detailed methods, including information on the GBD location hierarchy, the GBD cause hierarchy, mapping of International Classification of Disease (ICD) codes to the GBD cause list, and health states and associated disability weights used in the comorbidity simulation;
- 2) mean values and 95% uncertainty intervals for all estimates presented in the almanac, by country, sex, age group, and year;
- 3) cause-specific write-ups outlining methods for estimation of mortality with details of model parameters for each cause, including selection of location-specific covariates;
- 4) cause-specific write-ups outlining methods for estimation of prevalence, with details of systematic reviews, input data, all data adjustments, modeling frameworks, and model parameter selection;
- 5) risk factor write-ups containing details of systematic reviews, input data, all data adjustments, modeling frameworks, and model parameter selection;
- 6) documentation of compliance with GATHER.

METHODS. Demographic groupings. This study estimated CVD burden for 204 countries and territories grouped into 21 regions and 7 super-regions. GBD regions are made up of countries and territories that are geographically close and epidemiologically similar. GBD regions are grouped into super-regions based on observed cause of death patterns. Estimates presented in this almanac were produced at the sub-national level (eg, region, state, or province) for a subset of locations including Brazil, China, Ethiopia, India, Indonesia, Italy, Iran, Japan, Kenya, Mexico, Nigeria, Norway, Pakistan, the Philippines, Russia, South Africa, the UK, and the USA. Since GBD 2019, the GBD location hierarchy has included all WHO member states. Each epidemiological quantity of interest was estimated for 23 age groups from birth to 95 years and older; males, females, and both sexes combined from 1990 to 2022. Age standardization used the direct method with the GBD standard global population age structure. This standard population is determined by using the population structure of all national locations with a population >5 million people. First, the proportion of the location-specific population in each age group is calculated. Second, these age-specific proportions are averaged across all locations.³

Sociodemographic index. Results are also presented by socio-demographic index (SDI) value. SDI is a composite measure of overall development comprised of lag-distributed income per capita (LDI), average years of education, and fertility rates among females younger than 25 years (TFU25). LDI and education are positively correlated with improved health outcomes, while TFU25 is negatively correlated. SDI is thus calculated as the geometric mean of LDI, education, and the inverse of TFU25.³

TABLE 1 Cardiovascular Case Definitions	
GBD Cause	Definition
Rheumatic heart disease	Diagnosis by a physician with use of echocardiography. This case definition for echocardiographic confirmation of rheumatic heart disease follows the World Heart Federation criteria for echocardiographic diagnosis. ¹²
Ischemic heart disease	1) Myocardial infarction as defined in the Fourth Universal Definition of Myocardial Infarction. ¹³ 2) Coronary artery disease defined as at least moderate (>50%) stenosis of an epicardial coronary vessel based on angiographic or functional diagnostic testing. ^{14,15} 3) Heart failure due to ischemic heart disease defined as a clinical diagnosis based on structured criteria as described. ⁴
Ischemic stroke	Brain imaging showing blood flow to part of the brain being occluded and according to WHO criteria of rapidly developing clinical signs of disturbance of cerebral function lasting >24 h or leading to death. ^{16,17}
Intracerebral hemorrhage	Brain imaging showing bleeding into the tissue of the brain and according to WHO criteria of rapidly developing clinical signs of disturbance of cerebral function lasting >24 h or leading to death. Only nontraumatic events were included. ^{16,17}
Subarachnoid hemorrhage	Brain imaging or lumbar puncture indicating the rupture of a blood vessel resulting in bleeding into the subarachnoid space and according to WHO criteria of rapidly developing clinical signs of disturbance of cerebral function lasting >24 h or leading to death. Only nontraumatic events were included. ^{16,17}
Hypertensive heart disease	Heart condition caused by long-term high blood pressure, resulting in left ventricular hypertrophy, diastolic dysfunction, and clinical heart failure with either preserved or reduced systolic function of the left ventricle. Clinical diagnosis of heart failure is based on structured criteria as described. ⁴
Non-rheumatic calcific aortic valve disease	Diagnosis by a physician based on echocardiographic findings of stenosis or regurgitation caused by progressive calcification of the valve, excluding congenital, rheumatic, or infectious causes but including stenosis of a bicuspid aortic valve. ¹⁸
Non-rheumatic degenerative mitral valve disease	Diagnosis by a physician based on echocardiographic findings of myxomatous degeneration or prolapse of the mitral valve leading to at least moderate mitral regurgitation, excluding disease due to annular dilation, congenital, rheumatic, or infectious causes. ¹⁸
Other non-rheumatic valve diseases	Residual category capturing diagnosis by a physician based on echocardiographic findings of stenosis or regurgitation of pulmonary and tricuspid valves. Valve dysfunction due to congenital, infectious, or rheumatic causes was estimated separately. ¹⁸
Myocarditis	Acute myocarditis is defined by symptoms, clinical examination, cardiac imaging such as cardiac MRI, or endomyocardial biopsy. ¹⁹ Heart failure due to myocarditis is a clinical diagnosis of heart failure based on structured criteria as described with a history of myocarditis. ⁴
Alcoholic cardiomyopathy	Clinical diagnosis of heart failure based on structured criteria as described due to the toxic effects of ingested alcohol. ⁴
Other cardiomyopathy	Residual category capturing a clinical diagnosis of heart failure based on structured criteria as described without a history of other potential causes of heart failure. ⁴
Pulmonary arterial hypertension	Diagnosis by a physician based on findings of restricted blood flow and elevated pressure in the pulmonary arteries based on right heart catheterization or echocardiography. ²⁰
Atrial fibrillation and flutter	ECG studies demonstrating irregularly irregular RR intervals; and no P waves. ^{21,22}
Aortic aneurysm	Abdominal or thoracic aorta is abnormally enlarged and weakened due to atherosclerosis, high blood pressure, or inflammation, which can lead to tearing or rupture of the blood vessel. ²³ Prevalence and YLDs are not currently estimated for aortic aneurysm.
Lower-extremity peripheral artery disease	An ankle-brachial index ≤ 0.90 . ²⁴
Endocarditis	Acute infective endocarditis was diagnosed defined as a clinical diagnosis clinically via based on the Duke Criteria, which includes confirmation through clinical signs and blood tests. ²⁵ Heart failure due to endocarditis was based on a clinical diagnosis of heart failure based on structured criteria as described with a history of acute infective endocarditis. ⁴
Other cardiovascular and circulatory diseases	This aggregate cause incorporates less common cardiovascular diseases that are not modelled independently; for example, pericarditis. Diagnostic criteria vary based on the underlying condition.

ECG = echocardiogram; MRI = magnetic resonance imaging; WHO = World Health Organization; YLDs = years lived with disability.

Cardiovascular disease case definitions. A set of case definitions was used to consistently identify and harmonize data on cardiovascular diseases for all locations across the entire time period. CVD case definitions used by GBD are shown in [Table 1](#). Of note, heart failure is classified as an impairment rather than an underlying cause of death in the GBD classification system. Heart failure is a structural or functional

abnormality of the heart that impairs cardiac filling and output and, within the GBD, contributes burden to many underlying causes of death including all cardiovascular diseases as described with the exception of aortic aneurysm and lower extremity peripheral arterial disease. GBD relies on data in which heart failure has been diagnosed by clinicians using structured criteria, such as the Framingham, European

TABLE 2 Risk Factor Exposure Definitions

Risk Factor	Definition
High systolic blood pressure	Brachial SBP >105-115 mm Hg in adults >25 years of age.
High LDL cholesterol	LDL-cholesterol >0.9-1.4 mmol/L in adults >25 years of age.
High body mass index	Body mass index >20-23 kg/m ² in adults >20 years of age.
High fasting plasma glucose	Serum fasting plasma glucose >4.9-5.3 mmol/L in adults >25 years of age.
Kidney dysfunction	Estimated glomerular filtration rate <60 mL/min/1.73 m ² and/or albumin-to-creatinine ratio ≤30 mg/g.
Ambient particulate matter pollution	Population-weighted annual average mass concentration of PM2.5 in a cubic meter of air >2.4-5.9 µg/m ³ .
Household air pollution from solid fuels	Proportion of individuals exposed to >2.4-5.9 µg/m ³ of PM2.5 due to the use of solid fuels for cooking, including coal, charcoal, wood, agricultural residue, and animal dung.
High temperature	Exposure to temperatures warmer than the temperature associated with the lowest overall mortality attributable to the risk, in a given location and year.
Low temperature	Exposure to temperatures colder than the temperature associated with the lowest overall mortality attributable to the risk, in a given location and year.
Lead exposure	Micrograms of lead per gram of bone greater than the age-specific TMREL.
Dietary risks	Composite risk factor consisting of suboptimal exposure to dietary factors including fruits, vegetables, whole grains, nuts and seeds, fiber, omega-3 fatty acids, polyunsaturated fatty acids, calcium, milk, legumes, red meat, processed meat, sugar-sweetened beverages, trans fatty acids, and sodium.
Smoking	Current or former users of any smoked tobacco product on a daily or occasional basis.
Secondhand smoke	Current exposure of nonsmokers to secondhand tobacco smoke at home, at work, or in other public places.
High alcohol use	Grams per day of pure alcohol consumed among current drinkers greater than the age-, sex-, and region-specific TMREL.
Low physical activity	Physical activity performed by adults >25 years of age, for at least 10 minutes at a time, across all domains of life (leisure/recreation, work/household, and transport) <3,000-4,500 metabolic equivalent-minutes per week.

LDL = low-density lipoprotein; PM2.5 = particulate matter <2.5 µm in diameter; SBP = systolic blood pressure; TMREL = theoretical minimum risk exposure level.

Society of Cardiology, or Universal Definition and Classification of Heart Failure criteria. Prevalent heart failure is defined as structural heart disease with current or previous symptoms of heart failure (ACCF/AHA stages C or D).⁴ As part of the GBD estimation process, heart failure burden is included in the burden estimates for each etiologic underlying cause of death.

All-cause mortality and population estimates. GBD produces estimates of all-cause mortality and population; for cause-specific burden, these are integral inputs into the cause-specific estimation process. Detailed methods have been previously reported.³

Cause-specific mortality. Death records, including vital registration for all cardiovascular causes and verbal autopsy data for total cardiovascular disease, ischemic heart disease, and total stroke, were mapped to the GBD cause list. Records where the underlying cause was considered nonspecific, intermediate, or implausible were reassigned to a valid underlying cause of death via redistribution algorithms which utilized proportional information, cause-specific priors, or data sets with information on all contributing causes of death in addition to the underlying cause.⁵ A counterfactual approach, based on data

from 2014 to 2019, was used to estimate excess cause-specific deaths in 2020 and 2021 and reclassify them as deaths due to COVID-19. A noise reduction algorithm was applied to mortality data and a Bayesian geospatial ensemble regression model (CODEm, the cause of death ensemble model, Institute for Health Metrics and Evaluation [IHME], Seattle, Washington) was used with location-specific covariates to produce smoothed time series for each location, including where data was sparse or missing.⁶ Individual models included in the ensemble are weighted according to performance on out-of-sample predictive validity testing.

CoDCorrect. As each cause-specific model is estimated separately, the sum of these models is not certain to equal the all-cause mortality estimates. The CoDCorrect process rescales each level of the GBD cause hierarchy such that the sum of the cause-specific estimates does not exceed the all-cause mortality estimates.⁶ Using the GBD cause hierarchy, this process begins by rescaling the Level 1 causes to match the all-cause mortality estimates. Level 2 causes are then rescaled to their corrected parent cause estimates. This process continues for Level 3 and Level 4 causes such that all levels of the hierarchy are rescaled.

Prevalence. Prevalence was estimated for each disease using the Disease Model–Bayesian meta-regression (DisMod-MR 2.1 [IHME, Seattle, Washington]), an epidemiologic state-transition disease modeling tool. DisMod-MR evaluates all available high-quality, population-representative data for disease incidence, prevalence, remission, and mortality, while enforcing consistency among these various parameters.⁶ Possible input data sources included scientific literature identified via systematic reviews of published literature and expert review, population surveys, and administrative health facility data. Where applicable, network meta-analysis was performed using the meta-regression–Bayesian, regularized, trimmed software (MR-BRT, IHME, Seattle, Washington) to allow adjustment for study-level differences in case definition or measurement method.⁷ If necessary, correction factors were calculated to adjust tabulated inpatient-only health facility data to account for readmission, nonprimary diagnoses, and outpatient visits.

Risk factors. Definitions used for each risk factor can be found in [Table 2](#).

Attributable burden estimation. The GBD estimates disease burden attributable to risk factors using a comparative risk assessment framework.⁸

Population-level exposure to each risk factor was estimated using statistical models. Most risk exposure was estimated using spatiotemporal Gaussian process regression (ST-GPR) or DisMod-MR, as described. ST-GPR is a geospatial Gaussian process regression model that borrows strength between locations and over time to generate estimates of mean risk factor exposures.⁸ Input data sources included scientific literature identified via systematic reviews of published literature and expert review, population health surveys, and, for ambient air pollution, satellite data. Person-level data from cohort studies were used to determine the standard deviation of the risk factor exposure and to estimate the shape of the exposure distribution.

Each risk was assigned outcomes from the GBD study list of diseases to form risk-outcome pairs based on the availability of convincing or probable evidence of a disease-risk association. For each risk factor, the level of exposure where disease risk is

minimized, or theoretical minimum risk exposure level (TMREL), was determined.

Relative risks were estimated for each risk outcome pair following the burden of proof (BoP) method, previously reported.⁹ Briefly, following PRISMA guidelines, systematic reviews were performed for studies reporting relative risk or hazard ratios, and data were extracted using a standardized template.¹⁰ Using MR-BRT, the relative risk between risk and disease outcome was modeled, integrating over the exposure ranges reported. This approach allows us to identify publication or reporting bias and to account for between-study heterogeneity and within-study correlation. An example of this approach has been reported in detail for the relationship between systolic blood pressure and ischemic heart disease.¹¹

Population-attributable fractions (PAF) were then calculated for each risk-outcome pair using the exposure levels, the estimated relative risk, and the TMREL to generate the amount of burden for each disease due to risk factor exposure. Attributable burden was then estimated as the PAF for that risk-outcome pair multiplied by the burden measure of interest.

Summary measures of disease burden. YLDs were estimated by multiplying disease prevalence by the relevant disability weight after accounting for comorbidity in a simulation process.⁶ Disability weights, which represent the magnitude of health loss associated with the outcome were constructed based on surveys of the general population, with a statistical adjustment made to account for comorbidity. YLLs due to premature mortality were computed by multiplying the number of estimated deaths by the standard life expectancy at age of death.⁶ The standard life expectancy was determined by using the lowest observed age-specific mortality rates by location and sex across all estimation years from locations with total populations >5 million in 2016 to establish a theoretical minimum risk reference life table. DALYs were calculated as the sum of YLLs and YLDs and represent the total health burden associated with each cause. All summary measures were estimated using 500 draws, and uncertainty intervals were determined as the 2.5th and 97.5th values of the posterior distribution of model draws.

REFERENCES

1. Murray CJL. Protocol for the Global Burden Of Diseases, Injuries, And Risk Factors Study (GBD). Accessed November 10, 2023. https://www.healthdata.org/sites/default/files/files/Projects/GBD/March2020_GBD%20Protocol_v4.pdf
2. Stevens GA, Alkema L, Black RE, et al. Guidelines for accurate and transparent health estimates reporting: the GATHER statement. *The Lancet*. 2016;388:e19-e23.
3. Wang H, Abbas KM, Abbasifard M, et al. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. *The Lancet*. 2020;396:1160-1203.
4. Gibson G, Blumer V, Mentz RJ, Lala A. Universal Definition and Classification of Heart Failure: A Step in the Right Direction from Failure to Function. Accessed November 8, 2023. <https://www.acc.org/Latest-in-Cardiology/Articles/2021/07/12/12/31/Universal-Definition-and-Classification-of-Heart-Failure>
5. Johnson SC, Cunningham M, Dippenaar IN, et al. Public health utility of cause of death data: applying empirical algorithms to improve data quality. Accessed November 8, 2023. <https://bmcmmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-021-01501-1>
6. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet*. 2020;396:1204-1222.
7. Zheng P, Barber R, Sorensen RJD, Murray CJL, Aravkin AY. Trimmed constrained mixed effects models: formulations and algorithms. *Journal of Computational and Graphical Statistics*. 2021;30:544-556.
8. GBD 2019 Risk Factor Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Accessed November 8, 2023. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30752-2/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30752-2/fulltext)
9. Zheng P, Afshin A, Biryukov S, et al. The burden of proof studies: assessing the evidence of risk. *Nat Med*. 2022;28:2038-2044.
10. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Syst Rev*. 2021;10:89.
11. Razo C, Welgan CA, Johnson CO, et al. Effects of elevated systolic blood pressure on ischemic heart disease: a burden of proof study. *Nat Med*. 2022;28:2056-2065.
12. Rwebembera J, Marangou J, Mwita JC, et al. 2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease. *Nat Rev Cardiol*. Published online November 2, 2023. <https://doi.org/10.1038/s41569-023-00940-9>
13. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Accessed November 9, 2023. <https://www.ahajournals.org/doi/10.1161/CIR.0000000000000617>
14. Jones WB, Riley CP, Reeves TJ, Sheffield LT. Natural history of coronary artery disease. *Bull N Y Acad Med*. 1972;48:1109-1125.
15. Raff GL, Abidov A, Achenbach S, et al. SCCT guidelines for the interpretation and reporting of coronary computed tomographic angiography. *J Cardiovasc Comput Tomogr*. 2009;3:122-136.
16. Donkor ES. Stroke in the 21st century: a snapshot of the burden, epidemiology, and quality of life. *Stroke Res Treat*. 2018;2018:3238165.
17. Aho K, Harmsen P, Hatano S, Marquardsen J, Smirnov VE, Strasser T. Cerebrovascular disease in the community: results of a WHO collaborative study. *Bull World Health Organ*. 1980;58:113-130.
18. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2021;77:e25-e197.
19. Ammirati E, Frigerio M, Adler ED, et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy. *Circ Heart Fail*. 2020;13:e007405.
20. Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J*. 2016;37:67-119.
21. Iwasaki Y, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: implications for management. *Circulation*. 2011;124:2264-2274.
22. Saleh K, Haldar S. Atrial fibrillation: a contemporary update. *Clin Med (Lond)*. 2023;23:437-441.
23. Isselbacher EM, Preventza O, Hamilton Black J, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2022;80:e223-e393.
24. Criqui MH, Matsushita K, Aboyans V, et al. Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association. *Circulation*. 2021;144:e171-e191.
25. Fowler VG, Durack DT, Selton-Suty C, et al. The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for infective endocarditis: updating the Modified Duke Criteria. *Clin Infect Dis*. 2023;77:518-526.

Global Burden of Cardiovascular Diseases and Risks Collaborators

George A. Mensah, MD,^{1,2} Yohannes Habtegiorgis Abate, MSc,³ Mohammadreza Abbasian, MD,^{4,5} Foad Abd-Allah, MD,⁶ Ashkan Abdollahi, MD,^{7,8} Mohammad Abdollahi, PhD,^{9,10} Deldar Morad Abdulah, MPH,¹¹ Auwal Abdullahi, PhD,^{12,13} Ayele Mamo Abebe, MSc,¹⁴ Aidin Abedi, MD,^{15,16} Armita Abedi, MD,¹⁷ Olugbenga Olusola Abiodun, FWACP,¹⁸ Hiwa Abubaker Ali, PhD,¹⁹ Eman Abu-Gharbieh, PhD,²⁰ Niveen M.E. Abu-Rmeileh, PhD,²¹ Salahdein Aburuz, PhD,^{22,23} Abdelrahman I Abushouk, MD,^{24,25} Ahmed Abu-Zaid, MD,^{26,27} Tigist Demssew Adane, MSc,²⁸ Nicola J Adderley, PhD,²⁹ Oladimeji M Adebayo, MD,³⁰ Bashir Aden, PhD,^{31,32} Temitayo Esther Adeyeoluwa, PhD,^{33,34} Olorunsola Israel Adeyomoye, PhD,³⁵ Qorinah Estiningtyas Sakilah Adnani, PhD,³⁶ Fatemeh Afrashteh, MD,³⁷ Shadi Afyouni, PhD,³⁸ Saira Afzal, PhD,^{39,40} Pradyumna Agasthi, MD,⁴¹ Antonella Agodi, PhD,⁴² Constanza Elizabeth Aguilera Arriagada, MD,⁴³ Williams Agyemang-Duah, MSc,⁴⁴ Bright Opoku Ahinkorah, MPhil,⁴⁵ Aqeel Ahmad, PhD,⁴⁶ Danish Ahmad, PhD,^{47,48} Firdos Ahmad, PhD,⁴⁹ Muayyad M Ahmad, PhD,⁵⁰ Ayman Ahmed, MSc,^{51,52} Haroon Ahmed, PhD,⁵³ Muktar Beshir Ahmed, MPH,^{54,55} Syed Anees Ahmed, PhD,⁵⁶ Marjan Ajami, PhD,^{57,58} Karolina Akinosoglou, PhD,^{59,60} Moein Ala, MD,⁶¹ Tareq Mohammed Ali AL-Ahdal, MPH,⁶² Samer O. Alalalmeh, BPharm,⁶³ Ziyad Al-Aly, MD,^{64,65} Nazmul Alam, DrPH,^{66,67} Rasmieh Mustafa Al-amer, PhD,^{68,69} Alaa Alashi, MD,⁷⁰ Mohammed Albashtawy, PhD,⁷¹ Mohammad T AlBataineh, PhD,⁷² Haileselesie Berhane Alema, MPH,⁷³ Sharifullah Alemi, PhD,⁷⁴ Yihun Mulugeta Alemu, MPH,^{75,76} Adel Ali Saeed Al-Gheethi, PhD,^{77,78} Khalid F Alhabib, MD,⁷⁹ Fadwa Alhalaiqa Naji Alhalaiqa, PhD,^{80,81} Mohammed Usman Ali, MSc,^{82,13} Rafat Ali, pursuing PhD,⁸³ Syed Shujait Shujait Ali, PhD,⁸⁴ Gianfranco Alicandro, PhD,^{85,86} Reyhaneh Alikhani, MD,⁸⁷ Syed Mohamed Aljunid, PhD,^{88,89} François Alla, PhD,⁹⁰ Wael Almahmeed, MD,^{91,92} Sabah Al-Marwani, MSc,^{93,94} Jordi Alonso, MD,^{95,96} Rajaa M Al-Raddadi, PhD,⁹⁷ Farrukh Jawad Alvi, MPH,⁹⁸ Nelson Alvis-Guzman, PhD,^{99,100} Nelson J. Alvis-Zakzuk, MSc,^{101,102} Hassan Alwafi, PhD,¹⁰³ Hany Aly, MD,¹⁰⁴ Prince M. Amegbor, PhD,¹⁰⁵ Tarek Tawfik Amin, MD,¹⁰⁶ Alireza Amindarolzari, MD,¹⁰⁷ Mostafa Amini-Rarani, PhD,¹⁰⁸ Sohrab Amiri, PhD,¹⁰⁹ Enrico Ammirati, MD,¹¹⁰ Tanu Anand, MD,¹¹¹ Robert Ancuceanu, PhD,¹¹² Deanna Anderlini, MD,^{113,114} Abhishek Anil, MD,^{115,116} Golnoosh Ansari, MD,¹⁰⁷ Philip Emeka Anyanwu, PhD,¹¹⁷ Anayochukwu Edward Anyasodor, PhD,¹¹⁸ Geminn Louis Carace Apostol, MD,^{119,120} Jalal Arabloo, PhD,¹²¹ Mosab Arafat, PhD,¹²² Aleksandr Y Aravkin, PhD,^{123,124,125} Olatunde Aremu, PhD,¹²⁶ Benedetta Armocida, MSc,¹²⁷ Johan Ärnlov, PhD,^{128,129} Oluwaseyi Olalekan Arowosegbe, MPH,^{130,131} Anton A. Artamonov, PhD,¹³² Kurnia Dwi Artanti, MSc,¹³³ Judie Arulappan, DSc,¹³⁴ Idowu Thomas Aruleba, MSc,¹³⁵ Ashokan Arumugam, PhD,^{136,137} Zahra Aryan, MD,^{138,139} Mohammad Asghari-Jafarabadi, PhD,^{140,141} Thomas Astell-Burt, PhD,^{142,143} Mahshid Ataei, PharmD,^{144,145} Mohammad Athar, PhD,^{146,147} Alok Atreya, MD,¹⁴⁸ Avinash Aujayeb, MBBS,¹⁴⁹ Adedapo Wasiu Awotidebe, PhD,^{12,150} Amdehiwot A. Aynalem, MSc,¹⁵¹ Zahra Azizi, MD,¹⁵² Ahmed Y. Azzam, MBCh,^{153,154} Abraham Samuel Babu, PhD,^{155,156} Muhammad Badar, PhD,¹⁵⁷ Feras Bader, MD,^{91,158} Ashish D. Badiye, PhD,¹⁵⁹ Arvind Bagga, MD,¹⁶⁰ Sara Bagherieh, BSc,¹⁶¹ Farshad Bahrami Asl, PhD,^{162,163} Ruhai Bai, MD,¹⁶⁴ Jennifer L. Baker, PhD,¹⁶⁵ Shankar M. Bakkannavar, MD,¹⁶⁶ Abdulaziz T. Bako, PhD,¹⁶⁷ Ravleen Kaur Bakshi, MD,¹⁶⁸ Saliu A. Balogun, PhD,¹⁶⁹ Ovidiu Constantin Baltatu, PhD,¹⁷⁰ Kiran Bam, MPH,¹⁷¹ Maciej Banach, PhD,^{172,173} Soham Bandyopadhyay, BA,^{174,175} Biswajit Banik, PhD,^{176,177} Palash Chandra Banik, MPhil,¹⁷⁸ Kannu Bansal, MD,^{179,180} Hamid Reza Baradaran, PhD,^{181,182} Franca Barbic, PhD,^{183,184} Martina Barchitta, PhD,⁴² Mainak Bardhan, MD,¹⁸⁵ Suzanne Lyn Barker-Collo, PhD,¹⁸⁶ Till Winfried Bärnighausen, MD,^{187,188} Francesco Barone-Adesi, PhD,¹⁸⁹ Sandra Barteit, PhD,¹⁹⁰ Lingkan Barua, MPH,¹⁷⁸ Azadeh Bashiri, PhD,¹⁹¹ Mohsen Bayati, PhD,¹⁹² Nebiyou Simegnew Bayileyeegn, MD,¹⁹³ Emad Behboudi, PhD,¹⁹⁴ Amir Hossein Behnoush, BS,^{195,196} Yannick Béjot, PhD,^{197,198} Sefealem Assefa Belay, MSc,¹⁹⁹ Melaku Ashagrie Belete, MSc,²⁰⁰ Uzma

Iqbal Belgaumi, MD,²⁰¹ Michelle L. Bell, PhD,²⁰² Luis Belo, PhD,^{203,204} Salaheddine Bendak, PhD,²⁰⁵ Bright Benfor, MD,^{206,207} Derrick A. Bennett, PhD,²⁰⁸ Isabela M. Bensenor, PhD,²⁰⁹ Catherine P. Benziger, MD,²¹⁰ Azizullah Beran, MD,²¹¹ Adam E. Berman, MD,²¹² Amiel Nazer C. Bermudez, MD,^{213,214} Gregory J. Bertolacci, BS,¹²⁴ Habtamu B. Beyene, PhD,^{215,216} Kebede A. Beyene, PhD,^{217,218} Akshaya Srikanth Srikanth Bhagavathula, PhD,²¹⁹ Nikha Bhardwaj, MD,²²⁰ Pankaj Bhardwaj, MD,^{221,222} Prarthna V. Bhardwaj, MD,²²³ Vivek Bhat, MBBS,²²⁴ Gurjit Kaur Bhatti, PhD,²²⁵ Jasvinder Singh Bhatti, PhD,²²⁶ Boris Bikbov, MD,²²⁷ Andras Bikov, PhD,^{228,229} Marina G. Birck, PhD,^{230,231} Bijit Biswas, MD,²³² Saeid Bitaraf, PhD,²³³ Aadam Olalekan Bodunrin, MSc,²³⁴ Eyob Ketema Bogale, MPH,²³⁵ Kassawmar Angaw Bogale, MPH,⁷⁵ Archith Bloor, MD,²³⁶ Milad Bonakdar Hashemi, MD,²³⁷ Hamed Borhany, MD,²³⁸ Edward J. Boyko, MD,^{239,240} Dejana Braithwaite, PhD,^{241,242} Luisa C. Brant, PhD,²⁴³ Michael Brauer, DSc,^{244,124} Susanne Breitner, DSc,^{245,246} Andrey Briko, PhD,²⁴⁷ Lemma N. Bulto, PhD,²⁴⁸ Yasser Bustanji, PhD,^{249,250} Zahid A. Butt, PhD,^{251,252} Daniela Calina, PhD,²⁵³ Fan Cao, MD,²⁵⁴ Rosario Cárdenas, DSc,²⁵⁵ Sinclair Carr, MS,²⁵⁶ Giulia Carreras, PhD,²⁵⁷ Juan J. Carrero, PhD,²⁵⁸ Márcia Carvalho, PhD,^{259,204} Joao Mauricio Castaldelli-Maia, PhD,²⁶⁰ Carlos A. Castañeda-Orjuela, MD,^{261,262} Maria Sofia Cattaruzza, PhD,²⁶³ Luca Cegolon, PhD,^{264,265} Ester Cerin, PhD,^{266,267} Yaacoub Chahine, MD,^{268,269} Jeffrey Shi Kai Chan, MBChB,²⁷⁰ Mei Yen Chan, PhD,^{271,272} Raymond N. C. Chan, MBChB,²⁷³ Periklis Charalampous, MSc,²⁷⁴ Jaykaran Charan, MD,¹¹⁵ Vijay Kumar Chattu, MD,^{275,276} An-Tian Chen, PhD,^{277,278} Catherine S. Chen, BA,¹²⁴ Haowei Chen, MB,²⁷⁹ Suma Sri Chennapragada, MD,²⁸⁰ Derek S. Chew, MD,²⁸¹ Gerald Chi, MD,²⁸² Patrick R. Ching, MD,²⁸³ Abdulaal Chitheer, MD,²⁸⁴ So Mi Jemma Cho, PhD,^{285,286} William C. S. Cho, PhD,²⁸⁷ Bryan Chong, MBBS,²⁸⁸ Hitesh Chopra, PhD,²⁸⁹ Rahul Choudhary, MD,²⁹⁰ Enayet Karim Chowdhury, PhD,^{291,292} Rajiv Chowdhury, PhD,^{293,294} Dinh-Toi Chu, PhD,²⁹⁵ Isaac Sunday Chukwu, BMedSc,²⁹⁶ Arrigo Francesco Giuseppe Cicero, PhD,²⁹⁷ Zinhle Cindi, PhD,²⁹⁸ Iolanda Cioffi, PhD,²⁹⁹ Kaleb Coberly, BS,¹²⁴ Sean Coffey, MB,³⁰⁰ Alyssa Columbus, MS,³⁰¹ Joao Conde, PhD,³⁰² Sara Conti, PhD,³⁰³ Barbara Corso, PhD,³⁰⁴ Sandra Cortés, DrPH,^{305,306} Paolo Angelo Cortesi, PhD,³⁰³ Vera Marisa Costa, PhD,²⁰⁴ Rosa A. S. Couto, MD,³⁰⁷ Emma Johnson Cowart, BS,¹²⁴ Michael H. Criqui, MD,³⁰⁸ Jessica A. Cruz, BS,¹²⁴ Sriharsha Dadana, MD,³⁰⁹ Omid Dadras, DrPH,^{310,311} Xiaochen Dai, PhD,^{124,125} Zhaoli Dai, PhD,^{312,313} Maxwell Ayindenaba Dalaba, PhD,³¹⁴ Albertino Antonio Moura Damasceno, PhD,³¹⁵ Giovanni Damiani, MD,^{316,317} Emanuele D'Amico, MD,⁴² Saswati Das, MD,³¹⁸ Subasish Das, PhD,³¹⁹ Mohsen Dashti, MD,³²⁰ Mohammad Dashtkoohi, MD,^{321,322} Maedeh Dastmardi, MD,^{323,324} Kairat Davletov, PhD,³²⁵ Aklilu Tamire Debele, MSc,³²⁶ Shayom Debopadhaya, BS,³²⁷ Nicole K. DeCleene, BS,¹²⁴ Ivan Delgado-Enciso, DSc,^{328,329} Juana Maria Delgado-Saborit, PhD,³³⁰ Berecha Hundessa Demessa, MPH,³³¹ Andreas K. Demetriades, MD,^{332,333} Xinlei Deng, PhD,³³⁴ Edgar Denova-Gutiérrez, DSc,³³⁵ Nebiyu Dereje Dereje, PhD,^{336,337} Awoke Masrie Asrat Derese, MPH,³³⁸ Hardik Dineshbhai Desai, MD,³³⁹ Rupak Desai, MBBS,³⁴⁰ Vinoth Gnana Chellaiyan Devanbu, MD,³⁴¹ Syed Masudur Rahman Dewan, PhD,^{342,343} Sourav Dey, MPhil,³⁴⁴ Vishal R. Dhulipala, MD,³⁴⁵ Daniel Diaz, PhD,^{346,347} Michael J. Diaz, BS,³⁴⁸ Delaney D. Ding, BS,³⁴⁹ Ricardo Jorge Dinis-Oliveira, PhD,^{350,351} Thanh Chi Do, MD,³⁵² Thao Huynh Phuong Do, MD,³⁵³ Saeid Doaei, PhD,^{354,355} Sushil Dohare, MD,³⁵⁶ Wanyue Dong, MD,³⁵⁷ Mario D'Oria, MD,^{264,358} Wendel Mombaque dos Santos, PhD,^{359,360} Abdel Douiri, PhD,³⁶¹ Robert Kokou Dowou, Mphil,³⁶² Ashel Chelsea Dsouza, MBBS,³⁶³ Haneil Larson Dsouza, MD,^{364,365} Viola Dsouza, MSc,³⁶⁶ Mi Du, MSc,^{367,368} Andre Rodrigues Duraes, PhD,^{369,370} Oyewole Christopher Durojaiye, MPH,³⁷¹ Sulagna Dutta, PhD,^{372,373} Arkadiusz Marian Dziedzic, DSc,³⁷⁴ Alireza Ebrahimi, MD,³⁷⁵ Defi Efendi, MSN,^{376,377} Ferry Efendi, PhD,³⁷⁸ Diyan Ermawan Effendi, MA,³⁷⁹ Ebrahim Eini, DDS,³⁸⁰ Michael Ekholuenetale, MSc,^{381,382} Temitope Cyrus Ekundayo, PhD,³⁸³ Iman El Sayed, PhD,³⁸⁴ Maha El Tantawi, PhD,³⁸⁵ Iffat Elbarazi, DrPH,³⁸⁶ Frank J. Elgar, PhD,³⁸⁷ Islam Y. Elgendy, MD,^{388,389} Muhammed Elhadi, MD,³⁹⁰ Waseem El-Huneidi, PhD,³⁹¹ Mehdi Emamverdi, MD,³⁹² Theophilus I Emeto, PhD,³⁹³

Ryenchindorj Erkhembayar, MD,³⁹⁴ Tesfahun C Eshetie, PhD,^{395,396} Juan Espinosa-Montero, PhD,³⁹⁷ Farshid Etaee, MD,³⁹⁸ Natalia Fabin, MD,²⁹⁷ Ibtihal Fadhil, PhD,³⁹⁹ Adeniyi Francis Fagbamigbe, PhD,^{381,400} Luca Falzone, PhD,^{401,402} Carla Sofia e Sá Farinha, MSc,^{403,404} MoezAllIslam Ezzat Mahmoud Faris, PhD,⁴⁰⁵ Andre Faro, PhD,⁴⁰⁶ Mithila Faruque, MPH,¹⁷⁸ Medhat Farwati, MD,^{407,408} Abidemi Omolara Fasanmi, PhD,^{409,410} Ali Fatehizadeh, PhD,⁴¹¹ Pooria Fazeli, MSc,^{412,413} Valery L. Feigin, PhD,^{414,124,415} Xiaoyi Feng, PhD,^{312,416} Seyed-Mohammad Fereshtehnejad, PhD,^{128,417} Abdullah Hamid Feroze, MD,^{418,419} Pietro Ferrara, MD,⁴²⁰ Nuno Ferreira, PhD,⁴²¹ Irina Filip, MD,^{422,423} Laura Fleszar, MPH,¹²⁴ David Flood, MD,^{424,425} Morenike Oluwatoyin Folayan, FWACS,^{426,427} Artem Alekseevich Fomenkov, PhD,⁴²⁸ Diogo A. Fonseca, PhD,^{429,430} Carla Fornari, PhD,³⁰³ Matteo Foschi, MD,^{431,432} Richard Charles Franklin, PhD,⁴³³ Takeshi Fukumoto, PhD,⁴³⁴ BlimaFux, PhD,⁴³⁵ Peter Andras Gaal, PhD,^{436,437} Muktar A. Gadanya, FMCPh,^{438,439} Shilpa Gaidhane, PhD,⁴⁴⁰ Abdughappar Gaipov, PhD,⁴⁴¹ Emmanuela Gakidou, PhD,^{124,125} Yaseen Galali, ResM,^{442,443} Silvano Gallus, DSc,⁴⁴⁴ Aravind P. Gandhi, MD,⁴⁴⁵ Balasankar Ganesan, PhD,⁴⁴⁶ Rupesh K. Gautam, PhD,⁴⁴⁷ Miglas W. W. Gebregergis, MSc,⁴⁴⁸ Kahsu Gebrekirstos Gebrekidan, PhD,⁴⁴⁹ Johanna M. Geleijnse, PhD,⁴⁵⁰ Urge Gerema, MSc,⁴⁵¹ Alireza Ghajar, MD,⁴⁵² Seyyed-Hadi Ghamari, MD,^{139,453} MohammadReza Ghasemi, PhD,^{454,455} Ghazal Ghasempour Dabaghi, MD,¹⁶¹ Afsaneh Ghasemzadeh, MD,³²⁰ Ramy Mohamed Ghazy, PhD,⁴⁵⁶ Maryam Gholamalizadeh, PhD,⁴⁵⁷ Arun Digambarrao Ghuge, MPhil,^{458,459} Paramjit Singh Gill, DM,¹¹⁷ Tiffany K. Gill, PhD,⁴⁶⁰ Richard F. Gillum, MD,^{461,462} Elena V. Gnedovskaya, PhD,⁴⁶³ Ali Golchin, PhD,^{464,465} Pouya Goleij, MSc,^{466,467} Giuseppe Gorini, MD,⁴⁶⁸ Alessandra C. Goulart, PhD,⁴⁶⁹ Anmol Goyal, MD,⁴⁷⁰ Kashish Goyal, MBBS,⁴⁷¹ Shi-Yang Guan, MD,⁴⁷² Giovanni Guarducci, MD,⁴⁷³ Mesay Dechasa Gudeta, MSc,⁴⁷⁴ Avirup Guha, MD,^{475,476} Stefano Guicciardi, MD,^{477,478} David Gulisashvili, MD,⁴⁷⁹ Damitha Asanga Gunawardane, MD,⁴⁸⁰ Cui Guo, PhD,⁴⁸¹ Anish Kumar Gupta, PharmD,^{482,483} Bhawna Gupta, PhD,⁴⁸⁴ Indarchand Ratanlal Gupta, PhD,^{485,486} Kartik Gupta, MD,⁴⁸⁷ Mohak Gupta, MD,⁴⁸⁸ Rajat Das Gupta, MPH,^{489,490} Rajeev Gupta, MD,^{491,492} Renu Gupta, MD,²²⁰ Sapna Gupta, MSc,⁴⁹³ Veer Bala Gupta, PhD,⁴⁹⁴ Vijai Kumar Gupta, PhD,⁴⁹⁵ Vivek Kumar Gupta, PhD,⁴⁹⁶ Lami Gurmessa, MSc,⁴⁹⁷ Reyna Alma Gutiérrez, PhD,⁴⁹⁸ Farrokh Habibzadeh, MD,⁴⁹⁹ Mostafa Hadei, PhD,⁵⁰⁰ Helia Sadat Haeri Borojeni, DMD,⁵⁰¹ Aram Halimi, BSc,⁵⁰² Sebastian Haller, MD,^{503,504} Rabih Halwani, PhD,^{20,49} Randah R. Hamadeh, PhD,⁵⁰⁵ Nadia M. Hamdy, PhD,⁵⁰⁶ Samer Hamidi, DrPH,⁵⁰⁷ Chieh Han, BA,¹²⁴ Qiuxia Han, PhD,⁵⁰⁸ Graeme J. Hankey, MD,^{509,510} Md. Abdul Hannan, PhD,^{511,512} Arief Hargono, DMD,¹³³ Josep Maria Haro, MD,^{513,514} Faizul Hasan, MSc,⁵¹⁵ Ikramul Hasan, MPharm,⁵¹⁶ Hamidreza Hasani, MD,⁵¹⁷ Maryam Hashemian, PhD,^{518,519} Md Saquib Hasnain, PhD,⁵²⁰ Amr Hassan, MD,⁶ Ikrama Hassan, MPH,^{521,522} Johannes Haubold, MD,^{523,524} Rasmus J. Havmoeller, PhD,⁵²⁵ Simon I. Hay, FMedSci,^{124,125} Khezar Hayat, MS,^{526,527} Youssef Hbid, PhD,⁵²⁸ Omar E. Hegazi, BPharm,⁶³ Tadele Yohannes Hegena, MPH,³³⁶ Mohammad Heidari, PhD,⁵²⁹ Bartosz Helfer, PhD,^{530,531} Brenda Yuliana Herrera-Serna, PhD,⁵³² Claudiu Herteliu, PhD,^{533,534} Hamed Hesami, MD,^{535,536} Kamran Hessami, MD,^{537,538} Keyvan Heydari, MD,⁵³⁹ Kamal Hezam, PhD,^{540,541} Yuta Hiraike, PhD,⁵⁴² Nguyen Quoc Hoan, DDS,⁵⁴³ Ramesh Holla, MD,⁵⁴⁴ Md Mahbub Hossain, MPH,^{545,546} Md. Belal Hossain, MSc,^{244,547} Hassan Hosseinzadeh, PhD,¹⁴² Mehdi Hosseinzadeh, PhD,^{548,549} Mihaela Hostiuc, PhD,⁵⁵⁰ Sorin Hostiuc, PhD,^{551,552} Mohamed Hsairi, MPH,⁵⁵³ Junjie Huang, MD,⁵⁵⁴ Michael Hultström, PhD,^{555,556} Hong-Han Huynh, BS,⁵⁵⁷ Bing-Fang Hwang, PhD,^{558,559} Khalid S Ibrahim, PhD,⁵⁶⁰ Oluwatope Olaniyi Idowu, MSc,⁵⁶¹ Olayinka Stephen Ilesanmi, PhD,^{562,563} Irena M. Ilic, PhD,⁵⁶⁴ Milena D. Ilic, PhD,⁵⁶⁵ Mustapha Immurana, PhD,⁵⁶⁶ Leeberk Raja Inbaraj, MD,⁵⁶⁷ Muhammad Iqhrammullah, PhD,⁵⁶⁸ Sheikh Mohammed Shariful Islam, PhD,^{569,570} Faisal Ismail, PhD,^{571,572} Nahlah Elkudssiah Ismail, PhD,^{573,574} Gaetano Isola, PhD,⁵⁷⁵ Masao Iwagami, PhD,^{576,577} Linda Merin J, BDS,⁵⁷⁸ Jalil Jaafari, PhD,⁵⁷⁹ Louis Jacob, MD,^{580,581} Abdollah Jafarzadeh, PhD,^{582,583} Khushleen Jaggi, MD,^{584,585} Haitham Jahrami, PhD,^{586,587} Akhil Jain, MD,⁵⁸⁸ Nityanand Jain, MD,⁵⁸⁹ Ammar Abdulrahman

Jairoun, PhD,^{590,591} Mihajlo Jakovljevic, PhD,^{592,593} Roland Dominic G. Jamora, PhD,^{594,595} Nilofer Javadi, MD,^{596,597} Sathish Kumar Jayapal, PhD,⁵⁹⁸ Shubha Jayaram, MD,⁵⁹⁹ Rime Jebai, MPH,⁶⁰⁰ Rebuma Sorsa Jeben, MSc,⁶⁰¹ Sun Ha Jee, PhD,⁶⁰² Anil K. Jha, MD,⁶⁰³ Ravi Prakash Jha, MSc,^{604,605} Vivekanand Jha, MD,^{606,607} Heng Jiang, PhD,^{608,609} Yinzi Jin, PhD,⁶¹⁰ Yash B. Jobanputra, MD,⁶¹¹ Catherine Owens Johnson, PhD,¹²⁴ Mohammad Jokar, DVM,^{612,613} Tamas Joo, PhD,^{436,614} Abel Joseph, MD,⁶¹⁵ Nitin Joseph, MD,⁶¹⁶ Charity Ehimwenma Joshua, BSc,⁶¹⁷ Jacek Jerzy Jozwiak, PhD,⁶¹⁸ Mikk Jürisson, PhD,⁶¹⁹ Ali Kabir, MD,⁶²⁰ Zubair Kabir, PhD,⁶²¹ Vidya Kadashetti, MDS,²⁰¹ Farima Kahe, MD,⁶²² Rizwan Kalani, MD,⁶²³ Laleh R. Kalankesh, PhD,⁶²⁴ Farnaz Kalantar, BPharm,⁶²⁵ Yogeshwar Kalkonde, MD,⁶²⁶ Sanjay Kalra, DM,^{627,628} Ashwin Kamath, MD,⁵⁴⁴ Sagarika Kamath, MHA,⁶²⁹ Arun Kamireddy, MD,¹⁰⁷ Tanuj Kanchan, MD,⁶³⁰ Himalkandel, PhD,^{631,632} Arun R. Kanmanthareddy, MD,^{633,634} Kehinde Kazeem Kanmodi, MPH,^{635,636} Sushil Kumar Kansal, PhD,⁶³⁷ Daniel John Kapner, PhD,¹²⁴ Sitanshu Sekhar Kar, MD,⁶³⁸ Paschalis Karakasis, MSc,⁶³⁹ Prabin Karki, BHLthSci,⁶⁴⁰ Faizan Zaffar Kashoo, MS Neurophysiotherapy,⁶⁴¹ Hengameh Kasraei, MD,^{642,643} Eskeziaw Abebe Kassahun, MPH,⁶⁴⁴ Nicholas J. Kassebaum, MD,^{645,124,125} Patrick D. M. C. Katoto, PhD,^{646,647} Neda Kaydi, PhD,⁶⁴⁸ Foad Kazemi, MD,⁶⁴⁹ Sina Kazemian, MD,^{650,651} Sara Kazemina, MD,⁶⁵² Jessica A. Kerr, PhD,^{653,654} Emmanuelle Kesse-Guyot, PhD,^{655,656} Mohammad Keykhaei, MD,^{139,657} Mohamad Mehdi Khadembashiri, MD,^{658,323} Mohammad Amin Khadembashiri, MD,^{659,660} Morteza Abdullatif Khafaie, PhD,⁶⁶¹ Himanshu Khajuria, PhD,⁶⁶² Amirmohammad Khalaji, BS,^{195,196} Nauman Khalid, PhD,⁶⁶³ Alireza Khalilian, PhD,⁶⁶⁴ Rovshan Khalilov, PhD,^{665,666} Asaduzzaman Khan, PhD,⁶⁶⁷ Ejaz Ahmad Khan, MPH,⁶⁶⁸ Junaid Khan, PhD,⁶⁶⁹ M Nuruzzaman Khan, PhD,^{670,671} Maseer Khan, MD,³⁵⁶ Mohammad Jobair Khan, MPH,¹³ Muhammad Shahzeb Khan, MD,^{672,673} Yusra H. Khan, PhD,⁶⁷⁴ Mahammed Ziauddin Khan suheb, MD,⁶⁷⁵ Shaghayegh Khanmohammadi, MD,^{676,195} Khaled Khatab, PhD,^{677,678} Sorour Khateri, MD,⁶⁷⁹ Hamid Reza Khayat Kashani, MD,⁶⁸⁰ Khalid A. Kheirallah, PhD,⁶⁸¹ Feriha Fatima Khidri, PhD,⁶⁸² Saeid Kian, MD,⁶⁸³ Zemene Demelash Kifle, MSc,⁶⁸⁴ Ruth W. Kimokoti, MD,⁶⁸⁵ Adnan Kisa, PhD,^{686,687} Sezer Kisa, PhD,⁶⁸⁸ Ali-Asghar Kolahi, MD,⁴⁵³ Farzad Kompani, MD,⁶⁸⁹ Gerbrand Koren, PhD,⁶⁹⁰ Ashwin Laxmikant Kotnis, PhD,⁶⁹¹ Parvaiz A. Koul, MD,⁶⁹² Ai Koyanagi, MD,⁶⁹³ Kewal Krishan, PhD,⁶⁹⁴ Hare Krishna, MD,²²⁰ Vijay Krishnamoorthy, MD,^{695,645} Yuvaraj Krishnamoorthy, MD,⁶⁹⁶ Md Abdul Kuddus, PhD,⁶⁹⁷ Mohammed Kuddus, PhD,⁶⁹⁸ Mukhtar Kulimbet, MSc,^{699,700} Vishnutheertha Kulkarni, MS,⁷⁰¹ Akshay Kumar, MD,^{702,703} Ashish Kumar, MD,⁷⁰⁴ Naveen Kumar, PhD,⁷⁰⁵ Nithin Kumar, MD,⁶¹⁶ Rahul Kumar, PhD,^{706,707} Netsanet Bogale Kumsa, MSc,⁷⁰⁸ Kunle Rotimi Kunle, MSc,^{709,710} Dian Kusuma, DSc,^{711,712} Ilias Kyriopoulos, PhD,⁷¹³ Carlo La Vecchia, MD,⁷¹⁴ Ben Lacey, PhD,^{208,715} Muhammad Awwal Ladan, PhD,⁷¹⁶ Lucie Laflamme, PhD,^{717,718} Chandrakant Lahariya, MD,^{719,720} Arista Lahiri, MD,⁷²¹ Daphne Teck Ching Lai, PhD,^{722,723} Tea Lallukka, PhD,⁷²⁴ Qing Lan, PhD,⁷²⁵ Iván Landires, MD,^{726,727} Francesco Lanfranchi, MD,⁷²⁸ Bagher Larijani, FACE,⁷²⁹ Anders O. Larsson, PhD,^{730,731} Savita Lasrado, MS,⁷³² Kamaluddin Latief, MS Epidemiology,^{733,734} Kaveh Latifinaibin, MD,⁷³⁵ Jerrald Lau, MPH,⁷³⁶ Paolo Lauriola, MD,⁷³⁷ Khuong Le, MSc,⁷³⁸ Long Khanh Dao Le, PhD,⁷³⁹ Nhi Huu Hanh Le, MD,^{740,741} Thao Thi Thu Le, MD,⁷⁴² Trang Diep Thanh Le, MD,^{742,743} Trang Thi Bich Le, MD,^{741,744} Caterina Ledda, PhD,⁷⁴⁵ Munjae Lee, PhD,⁷⁴⁶ Paul H. Lee, PhD,⁷⁴⁷ Seung Won Lee, MD,⁷⁴⁸ Wei-Chen Lee, PhD,⁷⁴⁹ Yo Han Lee, PhD,⁷⁵⁰ Kate E. LeGrand, MPH,¹²⁴ Mall Leinsalu, PhD,^{751,752} Matilde Leonardi, MD,⁷⁵³ Temesgen L. Lerango, MPH,⁷⁵⁴ An Li, PhD,^{755,756} Ming-Chieh Li, PhD,⁷⁵⁷ Wei Li, PhD,⁷⁵⁸ Xiaopan Li, PhD,⁷⁵⁹ Yichong Li, PhD,⁷⁶⁰ Lee-Ling Lim, MRCP,^{761,762} Stephen S. Lim, PhD,^{124,125} Ro-Ting Lin, PhD,^{763,764} Megan Lindstrom, PhD,¹²⁴ Shai Linn, DrPH,⁷⁶⁵ Gang Liu, PhD,^{766,767} Simin Liu, MD,²¹⁴ Xiaofeng Liu, PhD,^{768,769} Xuefeng Liu, PhD,^{770,771} Katherine M. Livingstone, PhD,⁵⁶⁹ Erand Llanaj, PhD,^{772,773} Platon D. Lopukhov, Cand of Sci (Med),⁷⁷⁴ Arianna Maeve Loreche, BS,^{775,119} László Lorenzovici, MSc,^{776,777} Stefan Lorkowski, PhD,^{778,779} Paulo A. Lotufo, DrPH,⁷⁸⁰ Giancarlo Lucchetti, PhD,⁷⁸¹ Alessandra Lugo, PhD,⁴⁴⁴ Zheng Feei Ma, PhD,⁷⁸² Farzan

Madadzadeh, PhD,⁷⁸³ Ralph Maddison, PhD,⁷⁸⁴ Javier A. Magaña Gómez, PhD,⁷⁸⁵ Julien Magne, PhD,⁷⁸⁶ D. R. Mahadeshwara Prasad, MD,^{787,788} Mehrdad Mahalleh, MD,⁸⁷ Mansour Adam Mahmoud, PhD,⁷⁸⁹ Elham Mahmoudi, MD,⁸⁷ Behnaz Mahmoudvand, MD,⁷⁹⁰ Omar Mohamed Makram, MD,^{791,792} Elaheh Malakan Rad, MD,⁷⁹³ Reza Malekzadeh, MD,^{519,794} Kashish Malhotra, MBBS,⁷⁹⁵ Iram Malik, PhD,⁷⁹⁶ Muhammad Sajeel Ahmed Malik, PharmD,⁷⁹⁷ Tauqeer Hussain Mallhi, PhD,⁶⁷⁴ Deborah Carvalho Malta, PhD,⁷⁹⁸ Aseer Manilal, PhD,⁷⁹⁹ Yosef Manla, MD,⁹¹ Yasaman Mansoori, MD,⁸⁰⁰ Borhan Mansouri, PhD,⁸⁰¹ Pejman Mansouri, MD,⁸⁷ Mohammad Ali Mansournia, PhD,⁸⁰² Hamid Reza Marateb, PhD,^{803,804} Mirko Marino, PhD,⁸⁰⁵ Daniela Martini, PhD,⁸⁰⁶ Santi Martini, PhD,^{807,808} Sharmeen Maryam, PharmD,⁸⁰⁹ Roy Rillera Marzo, MD,^{810,811} Alireza Masoudi, PhD,⁸¹² Sahar Masoudi, MSc,⁵¹⁹ Clara N. Matei, PhD,^{813,814} Yasith Mathangasinghe, MD,^{815,816} Elezabeth Mathews, PhD,⁸¹⁷ Manu Raj Mathur, PhD,^{818,819} Jishanth Mattumpuram, MD,⁸²⁰ Richard James Maude, PhD,^{821,822} Andrea Maugeri, PhD,⁸²³ Mahsa Mayeli, MD,¹⁹⁵ Mohsen Mazidi, PhD,⁸²⁴ John J. McGrath, MD,^{825,826} Steven M. McPhail, PhD,^{827,828} Enkeleint A. Mechili, PhD,^{829,830} John Robert Carabeo Medina, MD,^{213,831} Jitendra Kumar Meena, MD,⁸³² Kamran Mehrabani-Zeinabad, PhD,⁸³³ Max Alberto Mendez Mendez-Lopez, PhD,⁸³⁴ Walter Mendoza, MD,⁸³⁵ Ritesh G. Menezes, MD,⁸³⁶ Belayneh Mengist, MPH,⁸³⁷ Sultan Ayoub Meo, PhD,⁸³⁸ Haftu Asmerom Meresa, MSc,⁸³⁹ Atte Meretoja, MD,^{840,841} Tuomo J Meretoja, MD,^{842,843} Tomislav Mestrovic, PhD,^{844,124} Kukulege Chamila Dinushi Mettananda, PhD,^{845,846} Sachith Mettananda, DPhil,^{847,848} Laurette Mhlanga, PhD,^{849,850} Tianyue Mi, PhD,⁸⁵¹ Junmei Miao Jonasson, PhD,⁸⁵² Tomasz Miazgowski, MD,⁸⁵³ Irmina Maria Michalek, PhD,^{854,855} Ted R. Miller, PhD,^{856,291} Le Huu Nhat Minh, MD,^{857,858} Neema W. Minja, MD,^{859,860} Pouya Mir Mohammad Sadeghi, MD,⁸⁶¹ Niloofar Mirdamadi, MD,^{729,862} Andreea Mirica, PhD,⁵³³ Erkin M. Mirrakhimov, PhD,^{863,864} Moonis Mirza, MD,⁸⁶⁵ Mohammad Mirza-Aghazadeh-Attari, MD,^{320,866} Prasanna Mithra, MD,⁶¹⁶ Zahra Moghimi, MD,⁸⁶⁷ Jama Mohamed, MSc,⁸⁶⁸ Mouhand F. H. Mohamed, MSc,⁸⁶⁹ Nouh Saad Mohamed, MSc,^{870,871} Soheil Mohammadi, MD,¹⁹⁵ Hussien Mohammed, MPH,⁸⁷² Mustapha Mohammed, MSc,^{873,874} Salahuddin Mohammed, PhD,^{875,876} Shafiu Mohammed, PhD,^{877,878} Nagabhishek Moka, MD,^{879,880} Ali H. Mokdad, PhD,^{124,125} Hossein Molavi Vardanjani, PhD,⁸⁸¹ Sara Momtazmanesh, MD,^{195,139} Lorenzo Monasta, DSc,⁸⁸² Fateme Montazeri, MD,^{139,883} AmirAli Moodi Ghalibaf, MD,⁸⁸⁴ Yousef Moradi, PhD,⁸⁸⁵ Paula Moraga, PhD,⁸⁸⁶ Lidia Morawska, PhD,⁸⁸⁷ Negar Morovatdar, MD,⁸⁸⁸ Shane Douglas Morrison, MD,⁸⁸⁹ Jakub Morze, PhD,⁸⁹⁰ Ebrahim Mostafavi, PhD,^{152,891} Amirmahdi Mostofinejad, MSc,⁸⁹² Vincent Mouglin, BS,¹²⁴ Parsa Mousavi, MD,⁸⁹³ Seyed Ehsan Mousavi, MD,^{894,895} Dariush Mozaffarian, DrPH,⁸⁹⁶ Ahmed Msherghi, MD,⁸⁹⁷ Lorenzo Muccioli, MD,⁴⁷⁸ Ulrich Otto Mueller, MD,^{898,899} Sumoni Mukherjee, PhD,^{900,901} Kavita Munjal, PhD,⁹⁰² Efrén Murillo-Zamora, PhD,^{903,904} Ghulam Mustafa, MD,^{905,906} Sathish Muthu, MS,^{907,908} Julius C. Mwita, MD,⁹⁰⁹ Woojae Myung, PhD,⁹¹⁰ Ahamarshan Jayaraman Nagarajan, MTech,^{911,912} Shankar Prasad Nagaraju, DM,⁹¹³ Ganesh R. Naik, PhD,^{914,915} Gurudatta Naik, MPH,⁹¹⁶ Tapas Sadasivan Nair, MD,⁹¹⁷ Mohammad Sadeq Najafi, MD,^{918,919} Nouredin Nakhostin Ansari, PhD,^{920,921} Vinay Nangia, MD,⁹²² Sreenivas Narasimha Swamy, MD,⁹²³ Shumaila Nargus, PhD,^{98,98} Bruno Ramos Nascimento, PhD,^{924,925} Gustavo G Nascimento, PhD,⁹²⁶ Hadis Nasoori, PharmD,⁹²⁷ Zuhair S. Natto, DrPH,^{928,929} Javaid Nauman, PhD,^{930,931} Muhammad Naveed, PhD,⁹³² Biswa Prakash Nayak, PhD,⁶⁶² Vinod C. Nayak, MD,¹⁶⁶ Hadush Negash, MSc,⁹³³ Ionut Negoii, PhD,^{934,935} Ruxandra Irina Negoii, PhD,^{936,937} Reza Nejad Shahrokh Abadi, MD,⁹³⁸ Seyed Aria Nejadghaderi, MD,^{883,676} Chakib Nejjari, PhD,^{939,940} Mohammad Hadi Nematollahi, PhD,⁹⁴¹ Samata Nepal, MD,⁹⁴² Nawi Ng, PhD,^{852,943} Dang H. Nguyen, BS,^{388,944} Phat Tuan Nguyen, MD,⁹⁴⁵ Van Thanh Nguyen, MD,⁹⁴⁶ Robina Khan Niazi, PhD,⁹⁴⁷ Shawn S. Nijjar, MSc,^{948,949} Muhammad A. Nizam, MD,⁹⁵⁰ Efaq Ali Noman, PhD,^{951,952} Shuhei Nomura, PhD,^{953,954} Mamoona Noreen, PhD,⁹⁵⁵ Bo Norrving, PhD,⁹⁵⁶ Jean Jacques Noubiap, MD,⁹⁵⁷ Chisom Adaobi Nri-Ezedi, MD,⁹⁵⁸ Mpiko Ntsekhe, PhD,^{959,960} Dieta Nurriika, PhD,^{961,962} Chimezie Igwegbe Nzopotam, MPH,⁹⁶³ Ogochukwu Janet

Nzopotam, PhD,^{964,965} Kehinde O. Obamiro, PhD,⁹⁶⁶ Martin James O'Donnell, PhD,⁹⁶⁷ Onome Bright Oghenetega, MSc,⁹⁶⁸ Ayodipupo Sikiru Oguntade, MSc,^{969,970} James Odhiambo Oguta, MSc,⁹⁷¹ Sylvester Reuben Okeke, PhD,^{972,973} Akinkunmi Paul Okekunle, PhD,^{974,975} Lawrence Okidi, MSc,⁹⁷⁶ Osaretin Christabel Okonji, MSc,⁹⁷⁷ Patrick Godwin Okwute, MSc,^{978,979} Andrew T Olagunju, MD,^{980,981} Muideen Tunbosun Olaiya, PhD,¹⁷¹ Matifan Dereje Olana, PhD,^{982,983} Matthew Idowu Olatubi, PhD,⁹⁸⁴ Gláucia Maria Moraes Oliveira, PhD,⁹⁸⁵ Abdulhakeem Abayomi Olorukooba, MSc,⁹⁸⁶ Isaac Iyinoluwa Olufadewa, MHS,^{987,988} Yinka Doris Oluwafemi, PhD,⁹⁸⁸ Gideon Olamilekan Oluwatunase, MSc,^{989,990} Goran Latif Omer, MD,^{991,992} Mohammad Mehdi Ommati, PhD,⁹⁹³ Kanyin Liane Ong, PhD,¹²⁴ Sokking Ong, FAMS,^{994,995} Kenneth Ikenna Onyedibe, PhD,⁹⁹⁶ Michal Ordak, PhD,⁹⁹⁷ Doris V. Ortega-Altamirano, DrPH,⁹⁹⁸ Alberto Ortiz, MD,^{999,1000} Esteban Ortiz-Prado, PhD,¹⁰⁰¹ Wael M. S. Osman, PhD,¹⁰⁰² Uchechukwu Levi Osuagwu, PhD,^{1003,1004} Adrian Otoiu, PhD,⁵³³ Stanislav S. Otstavnov, PhD,^{1005,1006} Mayowa O. Owolabi, DrM,^{1007,969} Mahesh Padukudru P A, DNB,¹⁰⁰⁸ Alicia Padron-Monedero, PhD,¹⁰⁰⁹ Jagadish Rao Padubidri, MD,¹⁰¹⁰ Mahsa Pahlavikhah Varnosfaderani, MSc,¹⁰¹¹ Tamás Palicz, MD,^{436,1012} Raffaele Palladino, MD,^{1013,1014} Feng Pan, PhD,¹⁶⁹ Hai-Feng Pan, PhD,¹⁰¹⁵ Seithikurippu R. Pandi-Perumal, MSc,^{1016,1017} Paraskevi Papadopoulou, PhD,^{1018,1019} Seoyeon Park, MD,¹⁰²⁰ Roberto Passera, PhD,^{1021,1022} Jay Patel, BSc,^{1023,1024} Shankargouda Patil, PhD,^{1025,1026} Dimitrios Patoulias, PhD,^{1027,1028} Venkata Suresh Patthipati, MD,^{1029,1030} Shrikant Pawar, PhD,¹⁰³¹ Amy E. Peden, PhD,^{1032,1033} Paolo Pedersini, MSc,¹⁰³⁴ Minjin Peng, MPH,^{1035,1036} Veincent Christian Filipino Pepito, MSc,¹⁰³⁷ Emmanuel K. Peprah, PhD,¹⁰⁵ Marcos Pereira, PhD,¹⁰³⁸ Maria Odete Pereira, PhD,¹⁰³⁹ Mario F. P. Peres, MD,^{1040,1041} Arokiasamy Perianayagam, PhD,¹⁰⁴² Norberto Perico, MD,¹⁰⁴³ Fanny Emily Petermann-Rocha, PhD,^{1044,1045} Hoang Tran Pham, MD,¹⁰⁴⁶ Anil K. Philip, PhD,¹⁰⁴⁷ David M. Pigott, PhD,^{124,125} Thomas Pilgrim, MD,¹⁰⁴⁸ Michael A. Piradov, DSc,⁴¹⁵ Evgenii Plotnikov, PhD,^{1049,1050} Dimitri Poddighe, PhD,^{1051,1052} Roman V. Polibin, PhD,⁷⁷⁴ Ramesh Poluru, PhD,¹⁰⁵³ Ghazaleh Pourali, MD,^{1054,1055} Akram Pourshams, MD,⁵¹⁹ Pranil Man Singh Pradhan, MD,^{1056,1057} Manya Prasad, MD,¹⁰⁵⁸ Elton Junio Sady Prates, BS,⁷⁹⁸ Bharathi M. Purohit, MDS,¹⁰⁵⁹ Jagadeesh Puvvula, PhD,¹⁰⁶⁰ Ibrahim Qattea, MD,¹⁰⁶¹ Gangzhen Qian, MS,¹⁰⁶² Maryam Faiz Qureshi, MD,¹⁰⁶³ Mehrdad Rabiee rad, MD,^{161,1064} Amir Radfar, MD,¹⁰⁶⁵ Seyedeh Niloufar Rafiei Alavi, MD,¹⁰⁶⁶ Ibrar Rafique, PhD,¹⁰⁶⁷ Alberto Raggi, PhD,¹⁰⁶⁸ Fakher Rahim, PhD,^{1069,1070} Md Jillur Rahim, MA,^{1071,1072} Mehran Rahimi, MD,¹⁰⁷³ Mosiur Rahman, DrPH,¹⁰⁷⁴ Muhammad Aziz Rahman, PhD,^{1075,1076} Amir Masoud Rahmani, PhD,¹⁰⁷⁷ Bitra Rahmani, MSc,¹⁰⁷⁸ Shayan Rahmani, MD,^{883,139} Vahid Rahmanian, PhD,¹⁰⁷⁹ Pramila Rai, MPH,¹⁰⁸⁰ Sathish Rajaa, MD,⁶⁹⁶ Ali Rajabpour-Sanati, MD,¹⁰⁸¹ Prashant Rajput, PhD,¹⁰⁸² Pradhun Ram, MD,¹⁰⁸³ Prasanna Ram, MS,¹⁰⁸⁴ Sudha Ramalingam, MD,¹⁰⁸⁵ Shakthi Kumaran Ramasamy, MD,¹⁰⁸⁶ Sheena Ramazan, PhD,¹⁰⁸⁷ Pushkal Sinduvadi Ramesh, PhD,¹⁰⁸⁸ Jewel Rana, MPH,^{1089,1090} Kritika Rana, PhD,¹⁰⁹¹ Chhabi Lal Ranabhat, PhD,^{1092,1093} Nemanja Rancic, PhD,^{1094,1095} Amey Rane, MS,^{1096,1097} Shubham Ranjan, MA,¹⁰⁹⁸ Annemarei Ranta, PhD,^{1099,1100} Indu Ramachandra Rao, DM,⁹¹³ Mithun Rao, MD,¹¹⁰¹ Sowmya J. Rao, MDS,¹¹⁰² Sina Rashedi, MD,^{87,676} Vahid Rashedi, PhD,¹¹⁰³ Ahmed Mustafa Rashid, MD,¹¹⁰⁴ Azad Rasul, PhD,¹¹⁰⁵ Zubair Ahmed Ratan, MSc,^{1106,142} Giridhara Rathnaiah Babu, PhD,¹¹⁰⁷ Nakul Ravikumar, MD,¹¹⁰⁸ Salman Rawaf, MD,^{1014,1109} Iman Razeghian-Jahromi, PhD,¹¹¹⁰ Christian Razo, PhD,¹²⁴ Murali Mohan Rama Krishna Reddy, MD,²³⁶ Elrashdy Moustafa Mohamed Redwan, PhD,^{1111,1112} Giuseppe Remuzzi, MD,¹⁰⁴³ Luis Felipe Reyes, PhD,^{1113,1114} Nazila Rezaei, MD,¹³⁹ Mohsen Rezaeian, PhD,¹¹¹⁵ Antonio Luiz P. Ribeiro, MD,^{243,1116} Daniela Ribeiro, PhD,^{1117,1118} Reza Rikhtegar, MD,¹¹¹⁹ Leonardo Roever, PhD,^{1120,1121} Debby Syahru Romadlon, PhD,¹¹²² Luca Ronfani, PhD,⁸⁸² Himanshu Sehar Sekhar Rout, PhD,¹¹²³ Nitai Roy, PhD,¹¹²⁴ Priyanka Roy, PhD,¹¹²⁵ Andrzej Rynkiewicz, PhD,¹¹²⁶ Aly M. A. Saad, MD,¹¹²⁷ Zahra Saadatian, PhD,^{1128,1129} Siamak Sabour, PhD,¹¹³⁰ Simona Sacco, MD,¹¹³¹ Rajesh Sachdeva, MD,^{1132,1133} Basema Saddik, PhD,¹¹³⁴ Erfan Sadeghi, PhD,⁸⁸¹ Umar Saeed, PhD,^{1135,1136} Fahimeh Safaeinejad, PhD,¹¹³⁷ Fatemeh Saheb Sharif-Askari,

PhD,¹¹³⁸ Narjes Saheb Sharif-Askari, PhD,²⁰ Amirhossein Sahebkar, PhD,^{1139,1140} Soumya Swaroop Sahoo, MD,¹¹⁴¹ Seyed Aidin Sajedi, MD,¹¹⁴² Mirza Rizwan Sajid, PhD,¹¹⁴³ Joseph W. Sakshaug, PhD,^{1144,1145} Nasir Salam, PhD,⁸³ Afeez Abolarinwa Salami, BDS,^{1146,1147} Mohamed A. Saleh, PhD,^{49,1148} Sana Salehi, MD,¹¹⁴⁹ Marwa Rashad Salem, MD,¹¹⁵⁰ Mohammed Z. Y. Salem, PhD,¹¹⁵¹ Sara Samadzadeh, MD,^{1152,1153} Saad Samargandy, PhD,⁹⁷ Vijaya Paul Samuel, PhD,¹¹⁵⁴ Abdallah M. Samy, PhD,^{1155,1156} Juan Sanabria, MD,^{1157,1158} Rama Krishna Sanjeev, MD,¹¹⁵⁹ Milena M. Santric-Milicevic, PhD,^{564,1160} Muhammad Arif Nadeem Saqib, PhD,^{1161,1162} Made Ary Sarasmita, PharmD,^{1163,1164} Aswini Saravanan, MD,^{1165,1166} Yaser Sarikhani, PhD,^{1167,643} Tanmay Sarkar, PhD,¹¹⁶⁸ Rodrigo Sarmiento-Suárez, MPH,^{1169,1170} Gargi Sachin Sarode, PhD,¹¹⁷¹ Sachin C. Sarode, PhD,¹¹⁷² Thirunavukkarasu Sathish, PhD,¹¹⁷³ Anudeep Sathyanarayan, MD,¹¹⁷⁴ Monika Sawhney, PhD,¹¹⁷⁵ Mehdi Sayyah, MD,¹¹⁷⁶ Nikolaos Scarmeas, PhD,^{1177,1178} Benedikt Michael Schaarschmidt, MD,⁵²³ Art Schuermans, BSc,^{1179,1180} Austin E. Schumacher, PhD,¹²⁴ Aletta Elisabeth Schutte, PhD,^{1032,1181} David C. Schwebel, PhD,¹¹⁸² Mansour Sedighi, PhD,¹¹⁸³ Abdul-Aziz Seidu, MPhil,^{1184,1185} Farbod Semnani, BMedSc,¹¹⁸⁶ Sabyasachi Senapati, PhD,²²⁶ Pallav Sengupta, PhD,^{1187,1188} Subramanian Senthilkumaran, MD,¹¹⁸⁹ Sadaf G. Sepanlou, MD,^{519,794} Yashendra Sethi, MBBS,¹¹⁹⁰ Seyed Arsalan Seyedi, MD,¹¹⁹¹ Allen Seylani, BS,¹¹⁹² Maryam Shabany, PhD,^{1193,1194} Melika Shafeghat, MD,¹⁹⁵ Mahan Shafie, MD,³²¹ Pritik A. Shah, MBBS,^{1195,1196} Ataollah Shahbandi, MD,¹¹⁹⁷ Izza Shahid, MBBS,¹¹⁹⁸ Samiah Shahid, PhD,^{1199,1200} Wajeehah Shahid, PhD,¹²⁰¹ Moyad Jamal Shahwan, PhD,¹²⁰² Masood Ali Shaikh, MD,¹²⁰³ Sunder Sham, MD,¹²⁰⁴ Muhammad Aaqib Shamim, MBBS,¹¹⁵ Mohd Shanawaz, MD,¹²⁰⁵ Sadaf Sharfaei, MD,^{1206,1207} Amin Sharifan, PharmD,^{1208,1209} Javad Sharifi-Rad, PhD,¹²¹⁰ Purva Sharma, MD,¹²¹¹ Saurab Sharma, PhD,^{1212,1213} Ujjawal Sharma, PhD,¹²¹⁴ Vishal Sharma, PhD,¹²¹⁵ Aziz Sheikh, MD,^{1216,1217} Desalegn Shiferaw Shiferaw, MPH,^{1218,54} Mika Shigematsu, PhD,¹²¹⁹ Min-Jeong Shin, PhD,¹²²⁰ Rahman Shiri, PhD,¹²²¹ Kawkab Shishani, PhD,¹²²² Aminu Shittu, MSc,¹²²³ Ivy Shiue, PhD,^{1224,1225} K M Shivakumar, PhD,¹²²⁶ Sunil Shrestha, PharmD,¹²²⁷ Kerem Shuval, PhD,¹²²⁸ Migbar Mekonnen Sibhat, MSc,¹²²⁹ Inga Dora Sigfusdottir, PhD,^{1230,1231} Colin R. Simpson, PhD,^{1232,1233} Abhinav Singh, MD,¹²³⁴ Aditya Singh, PhD,¹²³⁵ Ambrish Singh, MTech,¹⁶⁹ Jasvinder A. Singh, MD,^{1236,1237} Paramdeep Singh, MD,¹²³⁸ Rajat Singh, PhD,¹²³⁹ Surjit Singh, MD,¹¹⁵ Md Shahjahan Siraj, MSc,¹²⁴⁰ Valentin Yurievich Skryabin, MD,^{1241,1242} Anna Aleksandrovna Skryabina, MD,¹²⁴³ David A. Sleet, PhD,^{1244,1245} Hamidreza Soleimani, MD,⁶⁷⁶ Solikhah Solikhah, DrPH,¹²⁴⁶ Sameh S. M. Soliman, PhD,¹²⁴⁷ Juyeon Son, PhD,¹²⁴⁸ Suhang Song, PhD,¹²⁴⁹ Yi Song, PhD,¹²⁵⁰ Joan B. Soriano, MD,^{1251,1252} Michael Spartalis, PhD,¹²⁵³ Chandrashekhar T. Sreeramareddy, MD,¹²⁵⁴ Lauryn K. Stafford, BS,¹²⁴ Benjamin A. Stark, MA,¹²⁴ Paschalis Steiropoulos, MD,¹²⁵⁵ Stefan Stortecky, MD,¹⁰⁴⁸ Rizwan Suliankatchi Abdulkader, MD,¹²⁵⁶ Abida Sultana, MD,^{1257,1258} Johan Sundström, PhD,^{730,1181} Chandan Kumar Swain, MPhi,¹²⁵⁹ Payam Tabaei Damavandi, MD,¹²⁶⁰ Seyed Mohammad Tabatabaei, PhD,^{1261,1262} Ozra Tabatabaei Malazy, PhD,⁷²⁹ Seyed-Amir Tabatabaeizadeh, PhD,^{1263,1264} Shima Tabatabai, PhD,¹²⁶⁵ Karen M. Tabb, PhD,¹²⁶⁶ Mohammad Tabish, MPharm,¹²⁶⁷ Takahiro Tabuchi, MD,¹²⁶⁸ Fentaw Tadese, MPH,¹²⁶⁹ Yasaman Taheri Abkenar, PharmD,¹²⁷⁰ Jabeen Taiba, MPH,¹²⁷¹ Iman M. Talaat, PhD,^{20,1272} Mircea Tampa, PhD,^{813,1273} Jacques J.L. Lukenze Tamuzi, MSc,^{1274,1275} Ker-Kan Tan, PhD,⁷³⁶ Haosu Tang, PhD,¹²⁷⁶ Elvis Enowbeyang Tarkang, PhD,^{1277,150} Nathan Y. Tat, MS,^{1278,1279} Seyed Mohammad Tavangar, MD,¹²⁸⁰ Hadi Tehrani, PhD,¹²⁸¹ Mojtaba Teimoori, MD,¹²⁸² Mohamad-Hani Temsah, MD,¹²⁸³ Reem Mohamad Hani Temsah, PharmD,¹²⁸⁴ Masayuki Teramoto, MD,¹²⁸⁵ Pugazhenthan Thangaraju, MD,¹²⁸⁶ Kavumpurathu Raman Thankappan, MD,¹²⁸⁷ Rajshree Thapa, PhD,^{1288,1289} Rekha Thapar, MD,⁶¹⁶ Aravind Thavamani, MD,^{1290,1291} Rasiyah Thayakaran, PhD,^{1292,1293} Nikhil Kenny Thomas, MD,¹²⁹⁴ Jing Tian, PhD,¹⁶⁹ Ales Tichopad, PhD,¹²⁹⁵ Tala Tillawi, MD,¹²⁹⁶ Marcello Tonelli, MD,¹²⁹⁷ Roman Topor-Madry, PhD,^{1298,1299} Mathilde Touvier, PhD,^{1300,1301} Marcos Roberto Tovani-Palone, PhD,^{1302,1303} Jasmine T. Tran, BS,¹³⁰⁴ Nghia Minh Tran, MD,¹³⁰⁵ Phu Van Tran, BSc,¹³⁰⁶ Indang Trihandini, PhD,⁷¹² Avnish

Tripathi, PhD,¹³⁰⁷ Samuel Joseph Tromans, PhD,^{747,1308} Vien T. Truong, MD,¹³⁰⁹ Thien Tan Tri Tai Truyen, MD,¹³¹⁰ Aristidis Tsatsakis, DSc,¹³¹¹ Guesh Mebrahtom Tsegay, MSc,¹³¹² Evangelia Eirini Tsermpini, PhD,¹³¹³ Munkhtuya Tumurkhuu, PhD,¹³¹⁴ Kang Tung, PhD,¹³¹⁵ Chukwudi S. Ubah, MPH,^{1316,1317} Aniefiok John Udoakang, PhD,¹³¹⁸ Arit Udoh, PhD,¹³¹⁹ Atta Ullah, MS,¹³²⁰ Sana Ullah, PhD,^{1321,1322} Muhammad Umair, PhD,^{1323,1324} Tungki Pratama Umar, MD,¹³²⁵ Brigid Unim, PhD,¹³²⁶ Bhaskaran Unnikrishnan, MD,¹³²⁷ Era Upadhyay, PhD,⁷⁰⁵ Jibrin Sammani Usman, PhD,^{1328,13} Seyed Mohammad Vahabi, MD,¹¹⁸⁶ Asokan Govindaraj Vaithinathan, MSc,¹³²⁹ Rohollah Valizadeh, PhD,¹³³⁰ Jef Van den Eynde, BSc,¹¹⁸⁰ Orsolya Varga, PhD,¹³³¹ Siddhartha Alluri Varma, MDS,¹³³² Priya Vart, PhD,¹³³³ Shoban Babu Varthya, MD,¹¹⁵ Tommi Juhani Vasankari, MD,^{1334,1335} Balachandar Vellingiri, PhD,^{1336,1337} Dominique Vervoort, MD,¹³³⁸ Jorge Hugo Villafañe, PhD,¹⁰³⁴ Francesco S Violante, MD,^{297,1339} Maria Viskadourou, MD,¹³⁴⁰ Simona Ruxandra Volovat, PhD,^{1341,1342} Theo Vos, PhD,^{124,125} Isidora S. Vujcic, PhD,¹³⁴³ Hatem A. Wafa, MPH,¹³⁴⁴ Feras Wahab, MSc,¹²⁴ Cong Wang, MPH,^{1345,1346} Fang Wang, PhD,¹³⁴⁷ Nelson Wang, MD,^{1348,1349} Shu Wang, MD,¹³⁵⁰ Yanzhong Wang, PhD,¹³⁴⁴ Yuan-Pang Wang, PhD,¹⁰⁴⁰ Melissa Y. Wei, MD,^{1351,1352} Andrea Werdecker, PhD,¹³⁵³ Nuwan Darshana Wickramasinghe, MD,¹³⁵⁴ Tissa Wijeratne, MD,^{1355,1356} Angga Wilandika, Mkep,¹³⁵⁷ Shadrach Wilson, BS,¹²⁴ Charles D. A. Wolfe, MD,^{1344,1358} Utoomporn Wongsin, MS,¹³⁵⁹ Zenghong Wu, PhD,¹³⁶⁰ Hong Xiao, PhD,^{1361,1362} Suowen Xu, PhD,^{1363,1364} Xiaoyue Xu, PhD,^{312,1365} Lalit Yadav, PhD,^{1366,460} Yuichiro Yano, MD,¹³⁶⁷ Habib Yaribeygi, PhD,¹³⁶⁸ Yuichi Yasufuku, MSc,^{1369,1370} Iman Yazdani Nia, MD,¹³⁷¹ Pengpeng Ye, MPH,^{1372,1373} Subah Abderehim Yesuf, MSc,^{1374,1375} Saber Yezli, PhD,¹³⁷⁶ Arzu Yiğit, PhD,¹³⁷⁷ Vahit Yiğit, PhD,¹³⁷⁷ Mekdes Tigistu Yilma, MPH,¹³⁷⁸ Dong Keon Yon, MD,¹³⁷⁹ Naohiro Yonemoto, PhD,^{1380,1381} Zabihollah Yousefi, PhD,¹³⁸² Laetitia Yperzeele, PhD,^{1383,1384} Chuanhua Yu, PhD,¹³⁸⁵ Ismaeel Yunusa, PhD,¹³⁸⁶ Nima Zafari, MD,¹³⁸⁷ Farbod Zahedi Tajrishi, MD,¹³⁸⁸ Fathiah Zakham, PhD,^{1389,1390} Mikhail Sergeevich Zastrozhin, PhD,^{1391,1392} Mohammad A. Zeineddine, MD,¹³⁹³ Dawit T. Zemedikun, PhD,^{1394,29} Youjie Zeng, MD,¹³⁹⁵ Chunxia Zhai, MD,^{1396,1397} Chen Zhang, MD,^{1398,1399} Haijun Zhang, MS,^{1400,1401} Hongwei Zhang, MD,¹⁴⁰² Liqun Zhang, MS,^{1403,1404} Ning Zhang, PhD,¹⁴⁰⁵ Yunquan Zhang, PhD,^{1406,1407} Hanqing Zhao, MD,¹⁴⁰⁸ Peng Zheng, PhD,^{124,125} Chenwen Zhong, MD,⁵⁵⁴ Shuduo Zhou, PhD,^{610,1401} Bin Zhu, PhD,¹⁴⁰⁹ Lei Zhu, PhD,¹⁴¹⁰ Magdalena Zielińska, MPharm,¹⁴¹¹ Yossef Teshome Zikarg, MSc,¹⁴¹² Mohammad Zmaili, MD,¹⁴¹³ Leo Zucker Zoekler, BA,¹²⁴ Zhiyong Zou, MD,¹²⁵⁰ Alimuddin Zumla, PhD,^{1414,1415} Elric Zweck, MD,^{1416,188} Samer H. Zyoud, PhD,^{1417,1418} Valentin Fuster, MD,^{1419,1420} Christopher J. L. Murray, DPhil,^{124,125} Gregory A. Roth, MD.^{1421,124,125}

Affiliations

¹Center for Translation Research and Implementation Science, National Institutes of Health, Bethesda, MD, USA; ²Department of Medicine, University of Cape Town, Cape Town, South Africa; ³Department of Clinical Governance and Quality Improvement, Aleta Wondo Hospital, Aleta Wondo, Ethiopia; ⁴Department of Orthopedic Surgery, Harvard University, Boston, MA, USA; ⁵Department of Orthopaedic Surgery, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ⁶Department of Neurology, Cairo University, Cairo, Egypt; ⁷Department of Cardiovascular Medicine, Johns Hopkins University, Baltimore, MD, USA; ⁸Department of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; ⁹The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran; ¹⁰School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; ¹¹Community and Maternity Nursing Unit, University of Duhok, Duhok, Iraq; ¹²Department of Physiotherapy, Bayero University Kano, Kano, Nigeria; ¹³Department of Rehabilitation Sciences, Hong Kong Polytechnic University, Hong Kong, China; ¹⁴Pediatrics Nursing Department, Debre Berhan University, Debre Berhan, Ethiopia; ¹⁵Department of

Neurosurgery, University of Southern California, Los Angeles, CA, USA; ¹⁶Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; ¹⁷Department of Emergency Medicine, Zanjan University of Medical Sciences, Zanjan, Iran; ¹⁸Department of Internal Medicine, Federal Medical Centre, Abuja, Nigeria; ¹⁹Department of Banking and Finance, University of Human Development, Sulaymaniyah, Iraq; ²⁰Clinical Sciences Department, University of Sharjah, Sharjah, United Arab Emirates; ²¹Institute of Community and Public Health, Birzeit University, Ramallah, Palestine; ²²Department of Therapeutics, United Arab Emirates University, Al Ain, United Arab Emirates; ²³College of Pharmacy, University of Jordan, Amman, Jordan; ²⁴Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; ²⁵Department of Medicine, Ain Shams University, Cairo, Egypt; ²⁶Department of Surgery, Alfaisal University, Riyadh, Saudi Arabia; ²⁷College of Graduate Health Sciences, University of Tennessee, Memphis, TN, USA; ²⁸Department of Clinical and Psychosocial Epidemiology, University of Groningen, Groningen, Netherlands; ²⁹Institute of Applied Health Research, University of Birmingham, Birmingham, UK; ³⁰College of Medicine, University College Hospital, Ibadan, Ibadan, Nigeria; ³¹Khalifa University, Abu Dhabi, United Arab Emirates; ³²Institute of Public Health, Walden University, Al Ain, United Arab Emirates; ³³Department of Bioscience and Biotechnology, University of Medical Sciences, Ondo, Ondo city, Nigeria; ³⁴Department of Veterinary Medicine, University of Ibadan, Ibadan, Nigeria; ³⁵Department of Physiology, University of Medical Sciences, Ondo, Ondo City, Nigeria; ³⁶Faculty of Medicine, Universitas Padjadjaran (Padjadjaran University), Bandung, Indonesia; ³⁷Department of Medicine, Iran University of Medical Sciences, Tehran, Iran; ³⁸Johns Hopkins Radiology Department, Jackson State University, Baltimore, MD, USA; ³⁹Department of Community Medicine, King Edward Memorial Hospital, Lahore, Pakistan; ⁴⁰Department of Public Health, Public Health Institute, Lahore, Pakistan; ⁴¹Department of Cardiovascular Medicine, Mayo Clinic, Scottsdale, AZ, USA; ⁴²Department of Medical and Surgical Sciences and Advanced Technologies "GF Ingrassia", University of Catania, Catania, Italy; ⁴³Unidad de Emergencia Adulto, Complejo Asistencial Dr. Sótero del Río, Santiago, Chile; ⁴⁴Department of Geography and Planning, Queen's University, Kingston, ON, Canada; ⁴⁵School of Public Health, University of Technology Sydney, Sydney, NSW, Australia; ⁴⁶Department of Medical Biochemistry, Shaqra University, Shaqra, Saudi Arabia; ⁴⁷School of Medicine and Psychology, Australian National University, Canberra, ACT, Australia; ⁴⁸Public Health Foundation of India, Gandhinagar, India; ⁴⁹College of Medicine, University of Sharjah, Sharjah, United Arab Emirates; ⁵⁰Department of Clinical Nursing, University of Jordan, Amman, Jordan; ⁵¹Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan; ⁵²Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland; ⁵³Department of Biosciences, COMSATS Institute of Information Technology, Islamabad, Pakistan; ⁵⁴Department of Epidemiology, Jimma University, Jimma, Ethiopia; ⁵⁵Australian Center for Precision Health, University of South Australia, Adelaide, SA, Australia; ⁵⁶Brody School of Medicine, East Carolina University, Greenville, NC, USA; ⁵⁷Department of Food and Nutrition Policy and Planning Research, National Institute of Nutrition, Tehran, Iran; ⁵⁸National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ⁵⁹Department of Internal Medicine, University of Patras, Patras, Greece; ⁶⁰Internal Medicine and Infectious Diseases, University General Hospital of Patras, Patras, Greece; ⁶¹Department of Pharmacology, Tehran University of Medical Sciences, Tehran, Iran; ⁶²Institute of Global Health, Heidelberg University, Heidelberg, Germany; ⁶³Department of Clinical Sciences, Ajman University, Ajman, United Arab Emirates; ⁶⁴John T. Milliken Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO, USA; ⁶⁵Clinical Epidemiology Center, US Department of Veterans Affairs (VA), St. Louis, MO, USA; ⁶⁶Department of Public Health, Asian University for Women, Chittagong, Bangladesh; ⁶⁷Asian University for Women, McGill University, Chittagong, Bangladesh; ⁶⁸School of Nursing, Yarmouk University, Irbid, Jordan; ⁶⁹School of Nursing and Midwifery, Western Sydney University, Sydney, NSW, Australia; ⁷⁰Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, OH, USA; ⁷¹Community and Mental Health Department, Al al-Bayt University, Mafrq, Jordan; ⁷²Department of Molecular Biology and Genetics, Khalifa University, Abu

Dhabi, United Arab Emirates; ⁷³Department of Public Health, Aksum University, Axum, Ethiopia; ⁷⁴Department of Global Health Entrepreneurship, Tokyo Medical and Dental University, Tokyo, Japan; ⁷⁵Department of Epidemiology and Biostatistics, Bahir Dar University, Bahir Dar, Ethiopia; ⁷⁶Epidemiology and Population Health, Australian National University, Canberra, ACT, Australia; ⁷⁷Global Centre for Environmental Remediation, University of Newcastle, Newcastle, NSW, Australia; ⁷⁸Cooperative Research Centre for Contamination Assessment and Remediation of the Environment, Newcastle, NSW, Australia; ⁷⁹Department of Cardiac Sciences, King Saud University, Riyadh, Saudi Arabia; ⁸⁰College of Nursing, Qatar University, Doha, Qatar; ⁸¹Psychological Sciences Association, Amman, Jordan; ⁸²Department of Medical Rehabilitation (Physiotherapy), University of Maiduguri, Maiduguri, Nigeria; ⁸³Department of Biosciences, Jamia Millia Islamia, New Delhi, India; ⁸⁴Center for Biotechnology and Microbiology, University of SWAT, Swat, Pakistan; ⁸⁵Department of Pathophysiology and Transplantation, Università degli Studi di Milano (University of Milan), Milan, Italy; ⁸⁶Cystic Fibrosis Center, Fondazione IRCCS Ospedale Maggiore Policlinico (IRCCS "Ca' Granda Maggiore Policlinico" Hospital Foundation), Milan, Italy; ⁸⁷Department of Cardiology, Tehran University of Medical Sciences, Tehran, Iran; ⁸⁸Department of Health Policy and Management, Kuwait University, Kuwait, Kuwait; ⁸⁹International Centre for Casemix and Clinical Coding, National University of Malaysia, Bandar Tun Razak, Malaysia; ⁹⁰Bordeaux School of Public Health, University of Bordeaux, Bordeaux, France; ⁹¹Department of Cardiology, Heart, Vascular, and Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates; ⁹²College of Medicine and Health Sciences Academic Programs, Khalifa University, Abu Dhabi, United Arab Emirates; ⁹³Department of Dentistry, Independent Consultant, Sana'a, Yemen; ⁹⁴Department of Public Health and Community Medicine, Independent Consultant, Irbid, Jordan; ⁹⁵Research Program of Epidemiology and Public Health, Pompeu Fabra University, Barcelona, Spain; ⁹⁶Department of Experimental and Health Sciences, Biomedical Research Networking Center in Epidemiology and Public Health (CiberESP), Madrid, Spain; ⁹⁷Department of Community Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; ⁹⁸University Institute of Public Health, The University of Lahore, Lahore, Pakistan; ⁹⁹Research Group in Hospital Management and Health Policies, Universidad de la Costa (University of the Coast), Barranquilla, Colombia; ¹⁰⁰Research Group in Health Economics, University of Cartagena, Cartagena, Colombia; ¹⁰¹Department of Economic Sciences, Universidad de la Costa (University of the Coast), Barranquilla, Colombia; ¹⁰²National Health Observatory, National Institute of Health, Bogota, Colombia; ¹⁰³Department of Clinical Pharmacology and Toxicology, Umm Al-Qura University, Makkah, Saudi Arabia; ¹⁰⁴Department of Pediatrics, Cleveland Clinic, Cleveland, OH, USA; ¹⁰⁵School of Global Public Health, New York University, New York, NY, USA; ¹⁰⁶Public Health Department, Cairo University, Cairo, Egypt; ¹⁰⁷Department of Radiology, Johns Hopkins University, Baltimore, MD, USA; ¹⁰⁸Health Management and Economics Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; ¹⁰⁹Medicine, Quran and Hadith Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran; ¹¹⁰De Gasperis Cardio Center, Niguarda Hospital, Milano, Italy; ¹¹¹Clinical Studies and Trials Unit, Indian Council of Medical Research, Delhi, India; ¹¹²Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; ¹¹³Centre for Sensorimotor Performance, The University of Queensland, Brisbane, QLD, Australia; ¹¹⁴Neurology Department, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia; ¹¹⁵Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India; ¹¹⁶All India Institute of Medical Sciences, Bhubaneswar, India; ¹¹⁷Warwick Medical School, University of Warwick, Coventry, UK; ¹¹⁸School of Dentistry and Medical Sciences, Charles Sturt University, Orange, NSW, Australia; ¹¹⁹School of Medicine and Public Health, Ateneo De Manila University, Pasig City, Philippines; ¹²⁰Inter-Agency Committee on Environmental Health, Department of Health Philippines, City of Manila, Philippines; ¹²¹Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran; ¹²²College of Pharmacy, Al Ain University, Abu Dhabi, United Arab Emirates; ¹²³Department of Applied Mathematics, University of Washington, Seattle, WA, USA; ¹²⁴Institute for Health Metrics and

Evaluation, University of Washington, Seattle, WA, USA; ¹²⁵Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA; ¹²⁶Department of Public Health, Birmingham City University, Birmingham, UK; ¹²⁷Department of Cardiovascular, Endocrine-Metabolic Diseases and Aging, National Institute of Health, Rome, Italy; ¹²⁸Department of Neurobiology, Care Sciences, and Society, Karolinska Institute, Stockholm, Sweden; ¹²⁹School of Health and Social Studies, Dalarna University, Falun, Sweden; ¹³⁰Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland; ¹³¹Department of Epidemiology and Public Health, University of Basel, Basel, Switzerland; ¹³²Department of Biophysics, Russian Academy of Sciences, Moscow, Russia; ¹³³Department of Epidemiology, Universitas Airlangga (Airlangga University), Surabaya, Indonesia; ¹³⁴Department of Maternal and Child Health, Sultan Qaboos University, Muscat, Oman; ¹³⁵Department of Electrical and Electronics Engineering Science, University of Johannesburg, Johannesburg, South Africa; ¹³⁶Department of Physiotherapy, University of Sharjah, Sharjah, United Arab Emirates; ¹³⁷Department of Community Medicine and Rehabilitation, Umeå University, Umea, Sweden; ¹³⁸Brigham and Women's Hospital, Harvard University, Boston, MA, USA; ¹³⁹Non-communicable Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran; ¹⁴⁰Cabrini Research, Cabrini Health, Malvern, VIC, Australia; ¹⁴¹School of Public Health and Preventative Medicine, Monash University, Melbourne, VIC, Australia; ¹⁴²School of Health and Society, University of Wollongong, Wollongong, NSW, Australia; ¹⁴³Menzies Centre for Health Policy, University of Sydney, Sydney, NSW, Australia; ¹⁴⁴Department of Toxicology and Pharmacology, Tehran University of Medical Sciences, Tehran, Iran; ¹⁴⁵Birjand University of Medical Sciences, Birjand University of Medical Sciences, Birjand, Iran; ¹⁴⁶Department of Medical Genetics, Umm Al-Qura University, Makkah, Saudi Arabia; ¹⁴⁷Science and Technology Unit, Umm Al-Qura University, Makkah, Saudi Arabia; ¹⁴⁸Department of Forensic Medicine, Lumbini Medical College, Palpa, Nepal; ¹⁴⁹Northumbria HealthCare NHS Foundation Trust, Newcastle upon Tyne, UK; ¹⁵⁰School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa; ¹⁵¹School of Nursing, Hawassa University, Hawassa, Ethiopia; ¹⁵²Department of Medicine, Stanford University, Palo Alto, CA, USA; ¹⁵³Department of Neurovascular Research, Nested Knowledge, Inc., Saint Paul, MN, USA; ¹⁵⁴Faculty of Medicine, October 6 University, 6th of October City, Egypt; ¹⁵⁵Department of Physiotherapy, Manipal Academy of Higher Education, Manipal, India; ¹⁵⁶Department of Medicine, University of Melbourne, Melbourne, VIC, Australia; ¹⁵⁷Gomal Center of Biochemistry and Biotechnology, Gomal University, Dera Ismail Khan, Pakistan; ¹⁵⁸Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA; ¹⁵⁹Department of Forensic Science, Government Institute of Forensic Science, Nagpur, India; ¹⁶⁰Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India; ¹⁶¹School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; ¹⁶²Department of Environmental Health Engineering, Urmia University of Medical Sciences, Urmia, Iran; ¹⁶³Department of Environmental Health Engineering, Tehran University of Medical Sciences, Hamadan, Iran; ¹⁶⁴School of Public Affairs, Nanjing University of Science and Technology, Nanjing, China; ¹⁶⁵Center for Clinical Research and Prevention, Bispebjerg University Hospital, Frederiksberg, Denmark; ¹⁶⁶Department of Forensic Medicine and Toxicology, Manipal Academy of Higher Education, Manipal, India; ¹⁶⁷Department of Neurosurgery, Houston Methodist Hospital, Houston, TX, USA; ¹⁶⁸Maternal and Child Health Unit, Indian Council of Medical Research, New Delhi, India; ¹⁶⁹Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia; ¹⁷⁰Center of Innovation, Technology and Education (CITE), Anhembi Morumbi University, Sao Jose dos Campos, Brazil; ¹⁷¹Department of Medicine, Monash University, Clayton, VIC, Australia; ¹⁷²Department of Hypertension, Medical University of Lodz, Lodz, Poland; ¹⁷³Polish Mothers' Memorial Hospital Research Institute, Lodz, Poland; ¹⁷⁴Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK; ¹⁷⁵Department of Neurosurgery, University of Southampton, Southampton, UK; ¹⁷⁶Institute of Health and Wellbeing (IHW), Federation University Australia, Melbourne, VIC, Australia; ¹⁷⁷Manna Institute, University of New England, Armidale, NSW, Australia; ¹⁷⁸Department of Non-communicable Diseases, Bangladesh University of Health Sciences,

Dhaka, Bangladesh; ¹⁷⁹Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA; ¹⁸⁰Department of Medicine, Saint Vincent Hospital, Worcester, MA, USA; ¹⁸¹Department of Epidemiology, Iran University of Medical Sciences, Tehran, Iran; ¹⁸²Ageing Clinical and Experimental Research (ACER) Team, University of Aberdeen, Aberdeen, UK; ¹⁸³Department of Biomedical Sciences, Humanitas University, Milan, Italy; ¹⁸⁴Department of Epidemiology and Biostatistics, Western University, London, ON, Canada; ¹⁸⁵Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA; ¹⁸⁶School of Psychology, University of Auckland, Auckland, New Zealand; ¹⁸⁷Heidelberg Institute of Global Health (HIGH), Heidelberg University, Heidelberg, Germany; ¹⁸⁸T.H. Chan School of Public Health, Harvard University, Boston, MA, USA; ¹⁸⁹Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy; ¹⁹⁰Heidelberg Institute of Global Health, Heidelberg University Hospital, Heidelberg, Germany; ¹⁹¹Health Information Management, Shiraz University of Medical Sciences, Shiraz, Iran; ¹⁹²Health Human Resources Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; ¹⁹³Department of Surgery, Jimma University, Jimma, Ethiopia; ¹⁹⁴Department of Basic Sciences, Khoj University of Medical Sciences, Khoj, Iran; ¹⁹⁵School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; ¹⁹⁶Non-Communicable Diseases Research Center (NCDRC), Tehran, Iran; ¹⁹⁷Department of Neurology, University Hospital of Dijon, Dijon, France; ¹⁹⁸Dijon Stroke Registry, University of Burgundy, Dijon, France; ¹⁹⁹College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia; ²⁰⁰Department of Medical Laboratory Science, Wollo University, Dessie, Ethiopia; ²⁰¹Department of Oral and Maxillofacial Pathology, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, India; ²⁰²School of the Environment, Yale University, New Haven, CT, USA; ²⁰³Biological Sciences Department, University of Porto, Porto, Portugal; ²⁰⁴Research Unit on Applied Molecular Biosciences (UCIBIO), University of Porto, Porto, Portugal; ²⁰⁵Department of Industrial Engineering, Haliç University, Istanbul, Türkiye; ²⁰⁶Debakey Heart and Vascular Center, Houston Methodist Academic Institute, Houston, FL, USA; ²⁰⁷Department of Cardiovascular Surgery, Houston Methodist Hospital, Houston, TX, USA; ²⁰⁸Nuffield Department of Population Health, University of Oxford, Oxford, UK; ²⁰⁹Department of Internal Medicine, Universidade de São Paulo (University of São Paulo), São Paulo, Brazil; ²¹⁰Heart and Vascular Center, Essentia Health, Duluth, MN, USA; ²¹¹Department of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN, USA; ²¹²Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, USA; ²¹³Department of Epidemiology and Biostatistics, University of the Philippines Manila, Manila, Philippines; ²¹⁴Department of Epidemiology, Brown University, Providence, RI, USA; ²¹⁵Department of Metabolomics, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia; ²¹⁶Department of Microbiology, Addis Ababa University, Addis Ababa, Ethiopia; ²¹⁷School of Pharmacy, University of Auckland, Auckland, New Zealand; ²¹⁸Department of Pharmaceutical and Administrative Sciences, University of Health Sciences and Pharmacy in St. Louis, St. Louis, MO, USA; ²¹⁹Department of Public Health, North Dakota State University, Fargo, ND, USA; ²²⁰Department of Anatomy, All India Institute of Medical Sciences, Jodhpur, India; ²²¹Department of Community and Family Medicine, All India Institute of Medical Sciences, Jodhpur, India; ²²²School of Public Health, All India Institute of Medical Sciences, Jodhpur, India; ²²³Department of Hematology Oncology, University of Massachusetts Medical School, Springfield, MA, USA; ²²⁴Department of Internal Medicine, St. John's National Academy of Health Sciences, Bangalore, India; ²²⁵Medical Lab Technology, Chandigarh University, Mohali, India; ²²⁶Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, India; ²²⁷Scientific-Tools, Bergamo, Italy; ²²⁸Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK; ²²⁹Department of Pulmonology, Semmelweis University, Budapest, Hungary; ²³⁰Department of Medicine, Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada; ²³¹Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada; ²³²Department of Community and Family Medicine, All India Institute of Medical Sciences, Deoghar, India; ²³³Department of Biostatistics and Epidemiology, Ahvaz Jundishapur University of Medical

Sciences, Ahvaz, Iran; ²³⁴Department of Computer Science, East Carolina University, Greenville, NC, USA; ²³⁵Health Promotion and Behavioural Science Department, Bahir Dar University, Bahir Dar, Ethiopia; ²³⁶Department of Internal Medicine, Manipal Academy of Higher Education, Mangalore, India; ²³⁷Urology Department, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ²³⁸Internal Medicine Department of SBMU, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ²³⁹School of Medicine, University of Washington, Seattle, WA, USA; ²⁴⁰General Medicine Service, Department of Veterans Affairs, Seattle, WA, USA; ²⁴¹Department of Epidemiology, University of Florida, Gainesville, FL, USA; ²⁴²Cancer Population Sciences Program, University of Florida Health Cancer Center, Gainesville, FL, USA; ²⁴³Department of Internal Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil; ²⁴⁴School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada; ²⁴⁵Institute for Medical Information Processing, Biometry, and Epidemiology, Ludwig Maximilian University of Munich, Munich, Germany; ²⁴⁶Institute of Epidemiology, Helmholtz Zentrum München German Research Center for Environmental Health, Neuherberg, Germany; ²⁴⁷Department of IT, Technologies in Biomedical Engineering for Research, Bauman Moscow State Technical University, Moscow, Russia; ²⁴⁸College of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia; ²⁴⁹Department of Biopharmaceutics and Clinical Pharmacy, The University of Jordan, Amman, Jordan; ²⁵⁰Department of Basic Biomedical Sciences, University of Sharjah, Sharjah, United Arab Emirates; ²⁵¹School of Public Health and Health Systems, University of Waterloo, Waterloo, ON, Canada; ²⁵²Al Shifa School of Public Health, Al Shifa Trust Eye Hospital, Rawalpindi, Pakistan; ²⁵³Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova, Romania; ²⁵⁴Department of Ophthalmology, Capital Medical University, Beijing, China; ²⁵⁵Department of Health Care, Metropolitan Autonomous University, Mexico City, Mexico; ²⁵⁶Department of Epidemiology, Harvard University, Boston, MA, USA; ²⁵⁷Institute for Cancer Research, Prevention and Clinical Network, Florence, Italy; ²⁵⁸Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden; ²⁵⁹Faculty of Health Sciences, University Fernando Pessoa, Porto, Portugal; ²⁶⁰Department of Psychiatry, Universidade de São Paulo (University of São Paulo), São Paulo, Brazil; ²⁶¹Colombian National Health Observatory, National Institute of Health, Bogota, Colombia; ²⁶²Epidemiology and Public Health Evaluation Group, National University of Colombia, Bogota, Colombia; ²⁶³Department of Public Health and Infectious Diseases, La Sapienza University, Rome, Italy; ²⁶⁴Department of Medical, Surgical, and Health Sciences, University of Trieste, Trieste, Italy; ²⁶⁵Public Health Unit, University Health Agency Giuliano-Isontina (ASUGI), Trieste, Italy; ²⁶⁶Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, VIC, Australia; ²⁶⁷School of Public Health, University of Hong Kong, Hong Kong, China; ²⁶⁸Department of Internal Medicine, University of Washington, Seattle, WA, USA; ²⁶⁹Department of Cardiology, University of Washington, Seattle, WA, USA; ²⁷⁰Heart Failure and Structural Heart Disease Unit, Cardiovascular Analytics Group, Hong Kong, China; ²⁷¹Department of Preventive Medicine (Nutrition), Astana Medical University, Nur-Sultan, Kazakhstan; ²⁷²Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; ²⁷³Department of Medicine and Therapeutic, Prince of Wales Hospital, Hong Kong, China; ²⁷⁴Department of Public Health, Erasmus University Medical Center, Rotterdam, Netherlands; ²⁷⁵Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; ²⁷⁶Saveetha Dental College, Saveetha University, Chennai, India; ²⁷⁷Department of Cardiology, Peking Union Medical College, Beijing, China; ²⁷⁸Department of Computer Science, University of Texas Austin, Texas, TX, USA; ²⁷⁹Clinical Research Center, Southern Medical University, Guangzhou, China; ²⁸⁰Department of Hematology-Oncology, LSU Health Shreveport, Shreveport, LA, USA; ²⁸¹Department of Cardiac Sciences, University of Calgary, Calgary, AB, Canada; ²⁸²Division of Cardiovascular Medicine, Harvard University, Boston, MA, USA; ²⁸³Division of Infectious Diseases, Virginia Commonwealth University, Richmond, VA, USA; ²⁸⁴Iraq Field Epidemiology Training Program (I-FETP), Ministry of Health, Baghdad, Iraq; ²⁸⁵Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, MA, USA;

²⁸⁶Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA; ²⁸⁷Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China; ²⁸⁸Department of Medicine, National University of Singapore, Singapore, Singapore; ²⁸⁹Chitkara College of Pharmacy, Chitkara University, Punjab, India; ²⁹⁰Department of Cardiology, All India Institute of Medical Sciences, Jodhpur, India; ²⁹¹School of Public Health, Curtin University, Perth, WA, Australia; ²⁹²Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, VIC, Australia; ²⁹³Florida International University, Florida International University, Miami, FL, USA; ²⁹⁴Department of Epidemiology, University of Bern, Bern, Switzerland; ²⁹⁵Center for Biomedicine and Community Health, VNU-International School, Hanoi, Viet Nam; ²⁹⁶Department of Paediatric Surgery, Federal Medical Centre, Umuahia, Nigeria; ²⁹⁷Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; ²⁹⁸Department of Genetics, University of Pennsylvania, Philadelphia, PA, USA; ²⁹⁹Department of Food, Environmental and Nutritional Sciences (DEFENS), University of Milan, Università degli Studi di Milano, Italy; ³⁰⁰Department of Medicine, University of Otago, Dunedin, New Zealand; ³⁰¹Department of Biostatistics, Johns Hopkins University, Baltimore, MD, USA; ³⁰²Nova Medical School, Nova University of Lisbon, Lisbon, Portugal; ³⁰³School of Medicine and Surgery, University of Milan Bicocca, Monza, Italy; ³⁰⁴Institute of Neuroscience, National Research Council, Pisa, Italy; ³⁰⁵Department of Public Health, Pontifical Catholic University of Chile, Santiago, Chile; ³⁰⁶Research Line in Environmental Exposures and Health Effects at Population Level, Centro de Desarrollo Urbano Sustentable (CEDEUS) (Advanced Center for Chronic Diseases [ACCDIS]), Santiago, Chile; ³⁰⁷Department of Chemical Sciences, University of Porto, Porto, Portugal; ³⁰⁸Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA, USA; ³⁰⁹Department of Internal Medicine, Cheyenne Regional Medical Center, Cheyenne, WY, USA; ³¹⁰Department of Addiction Medicine, Haukland University Hospital, Bergen, Norway; ³¹¹Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway; ³¹²School of Population Health, University of New South Wales, Sydney, NSW, Australia; ³¹³School of Pharmacy and Charles Perkins Centre, University of Sydney, Sydney, Australia; ³¹⁴Institute of Health and Allied Sciences, University of Health and Allied Sciences, Ho, Ghana; ³¹⁵Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique; ³¹⁶IRCCS Istituto Ortopedico Galeazzi, Galeazzi Orthopedic Institute IRCCS (University of Milan), Milan, Italy; ³¹⁷Department of Dermatology, Case Western Reserve University, Cleveland, OH, USA; ³¹⁸Department of Biochemistry, Ministry of Health and Welfare, New Delhi, India; ³¹⁹Ingram School of Engineering, Texas State University, San Marcos, TX, USA; ³²⁰Department of Radiology, Tabriz University of Medical Sciences, Tabriz, Iran; ³²¹Department of Neurology, Tehran University of Medical Sciences, Tehran, Iran; ³²²Interdisciplinary Neuroscience Research Program, Tehran University of Medical Sciences, Tehran, Iran; ³²³Iran University of Medical Sciences, Tehran, Iran; ³²⁴Tehran University of Medical Science, Tehran University of Medical Sciences, Tehran, Iran; ³²⁵Health Research Institute, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan; ³²⁶Department of Health Policy and Management, Haramaya University, Harar, Ethiopia; ³²⁷Medical College, Albany Medical College, Albany, NY, USA; ³²⁸School of Medicine, University of Colima, Colima, Mexico; ³²⁹Department of Research, Colima State Health Services, Colima, Mexico; ³³⁰Department of Medicine, Universitat Jaume I, Castellon, Spain; ³³¹USAID-JSI, Jimma University, Addis Ababa, Ethiopia; ³³²Department of Neurosurgery, University of Edinburgh, Edinburgh, UK; ³³³Department of Neurosurgery, National Health Service (NHS) Scotland, Edinburgh, UK; ³³⁴Epidemiology Branch, National Institute of Health, Durham, NC, USA; ³³⁵Center for Nutrition and Health Research, National Institute of Public Health, Cuernavaca, Mexico; ³³⁶Department of Public Health, Wachemo University, Hossana, Ethiopia; ³³⁷School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia; ³³⁸School of Public Health, Haramaya University, Harar, Ethiopia; ³³⁹Graduate Medical Education, Gujarat Adani Institute of Medical Sciences, Bhuj, India; ³⁴⁰Division of Cardiology, Atlanta Veterans Affairs Medical Center, Decatur, GA, USA; ³⁴¹Department of Community Medicine, Chettinad Hospital and Research Institute, Chennai, India; ³⁴²Department of Pharmacy, University of Asia Pacific, Dhaka, Bangladesh;

³⁴³Pharmacology Department, Center for Life Sciences Research Bangladesh, Dhaka, Bangladesh; ³⁴⁴Department of Biostatistics and Epidemiology, International Institute for Population Sciences, Mumbai, India; ³⁴⁵The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; ³⁴⁶Center of Complexity Sciences, National Autonomous University of Mexico, Mexico City, Mexico; ³⁴⁷Faculty of Veterinary Medicine and Zootechnics, Autonomous University of Sinaloa, Culiacán Rosales, Mexico; ³⁴⁸College of Medicine, University of Florida, Gainesville, FL, USA; ³⁴⁹Department of Epidemiology, University of Florida, Gainesville, USA; ³⁵⁰Department of Public Health and Forensic Sciences, and Medical Education, University of Porto, Porto, Portugal; ³⁵¹Department of Sciences, TOXRUN – Toxicology Research Unit, University Institute of Health Sciences, Advanced Polytechnic and University Cooperative (CESPU), CRL, Gandra, Portugal; ³⁵²Department of Medicine, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Viet Nam; ³⁵³Department of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Viet Nam; ³⁵⁴School of Health, Guilan University of Medical Sciences, Rasht, Iran; ³⁵⁵Department of Community Nutrition, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ³⁵⁶Department of Epidemiology, Jazan University, Jazan, Saudi Arabia; ³⁵⁷School of Elderly Care Services and Management, Nanjing University of Chinese Medicine, Nanjing, China; ³⁵⁸Cardio-Thoraco-Vascular Department, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy; ³⁵⁹Responsabilidade Social, Oswaldo Cruz German Hospital, São Paulo, Brazil; ³⁶⁰Brazilian Centre for Evidence-based Healthcare, Joanna Briggs Institute, São Paulo, Brazil; ³⁶¹Department of Population Health Sciences, King's College London, London, UK; ³⁶²Department of Epidemiology and Biostatistics, University of Health and Allied Sciences, Hohoe, Ghana; ³⁶³Department of General Medicine, Bangalore Medical College and Research Institute, Bangalore, India; ³⁶⁴Department of Forensic Medicine and Toxicology, Manipal Academy of Higher Education, Mangalore, India; ³⁶⁵Forensic Medicine and Toxicology Department, Kasturba Medical College Mangalore, Mangalore, India; ³⁶⁶Department of Health Policy, Manipal Academy of Higher Education, Manipal, India; ³⁶⁷School of Public Health, University of Adelaide, Adelaide, SA, Australia; ³⁶⁸Department of Periodontology, Shandong University, Jinan, China; ³⁶⁹School of Medicine, Federal University of Bahia, Salvador, Brazil; ³⁷⁰Department of Internal Medicine, Escola Bahiana de Medicina e Saúde Pública (Bahiana School of Medicine and Public Health), Salvador, Brazil; ³⁷¹Department of Infection and Tropical Medicine, University of Sheffield, Sheffield, UK; ³⁷²Department of Oral Biology and Biomedical Sciences, MAHSA University, Jenjarom, Malaysia; ³⁷³Department of Medical Sciences, Bharath Institute of Higher Education and Research (BIHER), Chennai, India; ³⁷⁴Department of Conservative Dentistry with Endodontics, Medical University of Silesia, Katowice, Poland; ³⁷⁵Department of Orthopaedics, Massachusetts General Hospital, Boston, MA, USA; ³⁷⁶Department Pediatric Nursing, University of Indonesia, Depok, Indonesia; ³⁷⁷Neonatal Intensive Care Unit, University of Indonesia Hospital, Depok, Indonesia; ³⁷⁸Advanced Nursing Department, Universitas Airlangga, Surabaya, Indonesia; ³⁷⁹Research Center for Public Health and Nutrition, National Research and Innovation Agency Republic of Indonesia (BRIN), Jakarta, Indonesia; ³⁸⁰Department of Orthodontics, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; ³⁸¹Department of Epidemiology and Medical Statistics, University of Ibadan, Ibadan, Nigeria; ³⁸²Faculty of Public Health, University of Ibadan, Ibadan, Nigeria; ³⁸³Department of Biological Sciences, University of Medical Sciences, Ondo, Ondo, Nigeria; ³⁸⁴Biomedical Informatics and Medical Statistics Department, Alexandria University, Alexandria, Egypt; ³⁸⁵Pediatric Dentistry and Dental Public Health Department, Alexandria University, Alexandria, Egypt; ³⁸⁶Institute of Public Health, United Arab Emirates University, Al Ain, United Arab Emirates; ³⁸⁷School of Population and Global Health, McGill University, Montreal, QC, Canada; ³⁸⁸Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA; ³⁸⁹Division of Cardiology, Harvard University, Boston, MA, USA; ³⁹⁰Faculty of Medicine, University of Tripoli, Tripoli, Libya; ³⁹¹Department of Basic Medical Sciences, University of Sharjah, Sharjah, United Arab Emirates; ³⁹²Department of Ophthalmology, University of California Los Angeles, Los Angeles, CA, USA; ³⁹³Department of Public Health and Tropical Medicine, James Cook University, Townsville, QLD,

Australia; ³⁹⁴Department of International Cyber Education, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia; ³⁹⁵Registry of Senior Australians (ROSA), South Australian Health and Medical Research Institute, Adelaide, SA, Australia; ³⁹⁶UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia; ³⁹⁷Department of Obesity, Diabetes and Cardiovascular Risk, National Institute of Public Health, Cuernavaca, Mexico; ³⁹⁸Department of Internal Medicine, Yale University, New Haven, CT, USA; ³⁹⁹Division of Non-Communicable Diseases, Ministry of Public Health and Population, Dubai, United Arab Emirates; ⁴⁰⁰Research Centre for Healthcare and Community, Coventry University, Coventry, UK; ⁴⁰¹Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy; ⁴⁰²Epidemiology and Biostatistics Unit IRCCS Pascale, IRCCS, Naples, Italy; ⁴⁰³Dissemination Division, National Institute of Statistics, Lisbon, Portugal; ⁴⁰⁴Activity Planning and Control Unit, Directorate-General of Health (DGS), Lisbon, Portugal; ⁴⁰⁵Department of Clinical Nutrition and Dietetics, University of Sharjah, Sharjah, United Arab Emirates; ⁴⁰⁶Department of Psychology, Federal University of Sergipe, São Cristóvão, Brazil; ⁴⁰⁷Internal Medicine Department, Cleveland Clinic, Cleveland, OH, USA; ⁴⁰⁸Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA; ⁴⁰⁹Satcher Health Leadership Institute, Morehouse School of Medicine, Atlanta, GA, USA; ⁴¹⁰School of Medicine, Emory University, Atlanta, GA, USA; ⁴¹¹Department of Environmental Health Engineering, Isfahan University of Medical Sciences, Isfahan, Iran; ⁴¹²Trauma Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; ⁴¹³Department of Medical Immunology, Shiraz University of Medical Sciences, Shiraz, Iran; ⁴¹⁴National Institute for Stroke and Applied Neurosciences, Auckland University of Technology, Auckland, New Zealand; ⁴¹⁵Research Center of Neurology, Moscow, Russia; ⁴¹⁶National Institute of Environmental Health, Chinese Center for Disease Control and Prevention, Beijing, China; ⁴¹⁷Division of Neurology, University of Ottawa, Ottawa, ON, Canada; ⁴¹⁸Department of Neurological Surgery, Harvard University, Boston, MA, USA; ⁴¹⁹USA; ⁴²⁰Research Center on Public Health, National Research and Innovation Agency Republic of Indonesia (BRIN), Monza, Italy; ⁴²¹Department of Social Sciences, University of Nicosia, Nicosia, Cyprus; ⁴²²Psychiatry Department, Kaiser Permanente, Fontana, CA, USA; ⁴²³School of Health Sciences, A.T. Still University, Mesa, AZ, USA; ⁴²⁴Center for Research in Indigenous Health, Maya Health Alliance, Tecpán, Guatemala; ⁴²⁵Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA; ⁴²⁶Department of Child Dental Health, Obafemi Awolowo University, Ile-Ife, Nigeria; ⁴²⁷Department of Clinical Science, Nigerian Institute of Medical Research, Yaba, Nigeria; ⁴²⁸Department of Cell Biology and Biotechnology, K.A. Timiryazev Institute of Plant Physiology, Moscow, Russia; ⁴²⁹Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal; ⁴³⁰CIBB Centre for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal; ⁴³¹Department of Biotechnological and Applied Clinical Sciences (DISCAB), Multiple Sclerosis Research Center, L'Aquila, Italy; ⁴³²Department of Neuroscience, Multiple Sclerosis Research Center, Ravenna, Italy; ⁴³³School of Public Health, Medical, and Veterinary Sciences, James Cook University, Douglas, QLD, Australia; ⁴³⁴Department of Dermatology, Kobe University, Kobe, Japan; ⁴³⁵Department of Pathology, Federal University of Espirito Santo, Vitória, Brazil; ⁴³⁶Health Services Management Training Centre, Semmelweis University, Budapest, Hungary; ⁴³⁷Department of Applied Social Sciences, Sapientia Hungarian University of Transylvania, Târgu-Mureș, Romania; ⁴³⁸Community Medicine Department, Bayero University Kano, Kano, Nigeria; ⁴³⁹Department of Community Medicine, Aminu Kano Teaching Hospital, Kano, Nigeria; ⁴⁴⁰Department of Medicine, Datta Meghe Institute of Medical Sciences, Wardha, India; ⁴⁴¹Department of Medicine, Nazarbayev University School of Medicine, Astana, Kazakhstan; ⁴⁴²Food Technology Department, Salahaddin University-Erbil, Erbil, Iraq; ⁴⁴³Department of Nutrition and Dietetics, Cihan University-Erbil, Erbil, Iraq; ⁴⁴⁴Department of Environmental Health Sciences, Mario Negri Institute for Pharmacological Research, Milan, Italy; ⁴⁴⁵Department of Community Medicine, ESIC Medical College & Hospital, Hyderabad, India; ⁴⁴⁶Institute of Health and Wellbeing, Federation University, Churchill, VIC, Australia; ⁴⁴⁷Department of Pharmacology, Indore Institute of Pharmacy, Indore, India; ⁴⁴⁸Department of Midwifery, Adigrat University, Adigrat, Ethiopia; ⁴⁴⁹Department of

Nursing, Mekelle University, Mekelle, Ethiopia; ⁴⁵⁰Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, Netherlands; ⁴⁵¹Department of Public Health, Jimma University, Jimma, Ethiopia; ⁴⁵²Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA; ⁴⁵³Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ⁴⁵⁴Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ⁴⁵⁵Center for Comprehensive Genetic Services, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ⁴⁵⁶Tropical Health Department, Alexandria University, Alexandria, Egypt; ⁴⁵⁷Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ⁴⁵⁸Department of Forensic Biology, Government Institute of Forensic Science, Aurangabad, India; ⁴⁵⁹Department of Clinical Research, National Institute For Research In Reproductive and Child Health, Mumbai, India; ⁴⁶⁰Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia; ⁴⁶¹Division of General Internal Medicine, Howard University, Washington, DC, USA; ⁴⁶²Department of Community and Family Medicine, Howard University, Washington, DC, USA; ⁴⁶³Third Department of Neurology, Research Center of Neurology, Moscow, Russia; ⁴⁶⁴Department of Applied Cell Sciences, Urmia University of Medical Sciences, Urmia, Iran; ⁴⁶⁵Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran; ⁴⁶⁶Department of Genetics, Sana Institute of Higher Education, Sari, Iran; ⁴⁶⁷Universal Scientific Education and Research Network (USERN), Kermanshah University of Medical Sciences, Kermanshah, Iran; ⁴⁶⁸Oncological Network, Prevention and Research Institute, Institute for Cancer Research, Prevention and Clinical Network, Florence, Italy; ⁴⁶⁹Department of Epidemiology, Universidade de São Paulo (University of São Paulo), São Paulo, Brazil; ⁴⁷⁰Blood and Marrow Transplantation and Cellular Therapy Program, Stanford University, Palo Alto, CA, USA; ⁴⁷¹Department of Internal Medicine, Sharda University, Noida, India; ⁴⁷²Department of Epidemiology and Biostatistics, Anhui Medical University, Hefei, China; ⁴⁷³Post Graduate School of Public Health, University of Siena, Siena, Italy; ⁴⁷⁴Department of Clinical Pharmacy, Haramaya University, Harar, Ethiopia; ⁴⁷⁵Harrington Heart and Vascular Institute, Case Western Reserve University, Cleveland, OH, USA; ⁴⁷⁶Division of Cardiovascular Medicine, Ohio State University, Columbus, OH, USA; ⁴⁷⁷Health Directorate, Local Health Authority of Bologna, Bologna, Italy; ⁴⁷⁸Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy; ⁴⁷⁹Diagnostic Radiology and Nuclear Medicine, University of Maryland, Baltimore, MD, USA; ⁴⁸⁰Department of Community Medicine, University of Peradeniya, Kandy, Sri Lanka; ⁴⁸¹Department of Urban Planning and Design, University of Hong Kong, Hong Kong Island, China; ⁴⁸²Department of Internal Medicine, Shree Guru Gobind Singh Tricentenary University, Gurugram, India; ⁴⁸³Non-communicable Division (NCD), Indian Council of Medical Research, Delhi, India; ⁴⁸⁴Department of Public Health, Torrens University Australia, Melbourne, VIC, Australia; ⁴⁸⁵Department of Biotechnology, Government Institute of Science, Aurangabad, India; ⁴⁸⁶Department of Biotechnology, Sant Gadge Baba Amravati University, Amravati, India; ⁴⁸⁷Department of Medicine, Henry Ford Health System, Detroit, MI, USA; ⁴⁸⁸Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA; ⁴⁸⁹Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, SC, USA; ⁴⁹⁰Centre for Noncommunicable Diseases and Nutrition, BRAC University, Dhaka, Bangladesh; ⁴⁹¹Department of Preventive Cardiology, Eternal Heart Care Centre & Research Institute, Jaipur, India; ⁴⁹²Department of Medicine, Mahatma Gandhi University Medical Sciences, Jaipur, India; ⁴⁹³Toxicology Department, Shriram Institute for Industrial Research, Delhi, India; ⁴⁹⁴School of Medicine, Deakin University, Geelong, VIC, Australia; ⁴⁹⁵Biorefining and Advanced Materials Research Center, Scotland's Rural College (SRUC), Edinburgh, UK; ⁴⁹⁶Faculty of Medicine Health and Human Sciences, Macquarie University, Sydney, NSW, Australia; ⁴⁹⁷Department of Nursing, Wollega University, Nekemte, Ethiopia; ⁴⁹⁸Department of Epidemiology and Psychosocial Research, Ramón de la Fuente Muñiz National Institute of Psychiatry, Mexico City, Mexico; ⁴⁹⁹Global Virus Network, Middle East Region, Shiraz, Iran; ⁵⁰⁰Department of Health in Emergencies and Disasters, Tehran University of Medical Sciences, Tehran, Iran; ⁵⁰¹Oral and Maxillofacial Surgery Department, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ⁵⁰²Research Institute for Endocrine

Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ⁵⁰³Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany; ⁵⁰⁴Department of Public Health, Charité Institute of Public Health, Berlin, Germany; ⁵⁰⁵Department of Family and Community Medicine, Arabian Gulf University, Manama, Bahrain; ⁵⁰⁶Biochemistry Department, Ain Shams University, Cairo, Egypt; ⁵⁰⁷School of Health and Environmental Studies, Hamdan Bin Mohammed Smart University, Dubai, United Arab Emirates; ⁵⁰⁸Department of Nephrology, Capital Medical University, Beijing, China; ⁵⁰⁹Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Perth, WA, Australia; ⁵¹⁰Perron Institute for Neurological and Translational Science, Perth, WA, Australia; ⁵¹¹Department of Biochemistry and Molecular Biology, Bangladesh Agricultural University, Mymensingh, Bangladesh; ⁵¹²Department of Anatomy, Dongguk University, Gyeongju, South Korea; ⁵¹³Research Unit, University of Barcelona, Barcelona, Spain; ⁵¹⁴Biomedical Research Networking Center for Mental Health Network (CiberSAM), Barcelona, Spain; ⁵¹⁵Department of Nursing, Taipei Medical University, Taipei, Taiwan; ⁵¹⁶Department of Pharmaceutical Technology, University of Dhaka, Dhaka, Bangladesh; ⁵¹⁷Department of Ophthalmology, Iran University of Medical Sciences, Karaj, Iran; ⁵¹⁸Biology Department, Utica University, Utica, NY, USA; ⁵¹⁹Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran; ⁵²⁰Pharmacy Department, Palamau Institute of Pharmacy, Daltonganj, India; ⁵²¹Department of Public Health, Dalhatu Araf Specialist Hospital, Lafia, Nigeria; ⁵²²Department of Public Health, Federal University of Lafia, Lafia, Nigeria; ⁵²³Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany; ⁵²⁴Institute of Artificial Intelligence in Medicine, University Hospital Essen, Essen, Germany; ⁵²⁵Skaane University Hospital, Skaane County Council, Malmoe, Sweden; ⁵²⁶Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences, Lahore, Pakistan; ⁵²⁷Department of Pharmacy Administration and Clinical Pharmacy, Xian Jiaotong University, Xian, China; ⁵²⁸School of Life Course & Population Sciences, King's College London, London, UK; ⁵²⁹Community-Oriented Nursing Midwifery Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran; ⁵³⁰Institute of Psychology, University of Wroclaw, Wroclaw, Poland; ⁵³¹Meta Research Centre, University of Wrocław, Wrocław, Poland; ⁵³²Departamento de Salud Oral (Department of Oral Health), Universidad Autónoma de Manizales (Autonomous University of Manizales), Manizales, Colombia; ⁵³³Department of Statistics and Econometrics, Bucharest University of Economic Studies, Bucharest, Romania; ⁵³⁴School of Business, London South Bank University, London, UK; ⁵³⁵Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ⁵³⁶Ophthalmic Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ⁵³⁷Maternal Fetal Care Center, Harvard University, Boston, MA, USA; ⁵³⁸Maternal Fetal Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; ⁵³⁹Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran; ⁵⁴⁰Department of Microbiology, Taiz University, Taiz, Yemen; ⁵⁴¹School of Medicine, Nankai University, Tianjin, China; ⁵⁴²Division for Health Service Promotion, University of Tokyo, Tokyo, Japan; ⁵⁴³School of Dentistry, Hanoi Medical University, Hanoi, Viet Nam; ⁵⁴⁴Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India; ⁵⁴⁵Department of Social and Environmental Health Research, Nature Study Society of Bangladesh, Khulna, Bangladesh; ⁵⁴⁶Department of Health Promotion and Community Health Sciences, Texas A&M University, College Station, TX, USA; ⁵⁴⁷James P Grant School of Public Health, BRAC University, Dhaka, Bangladesh; ⁵⁴⁸Institute of Research and Development, Duy Tan University, Da Nang, Viet Nam; ⁵⁴⁹Department of Computer Science, University of Human Development, Sulaymaniyah, Iraq; ⁵⁵⁰Internal Medicine Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; ⁵⁵¹Department of Legal Medicine and Bioethics, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; ⁵⁵²Clinical Legal Medicine Department, National Institute of Legal Medicine Mina Minovici, Bucharest, Romania; ⁵⁵³Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia; ⁵⁵⁴Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China; ⁵⁵⁵Department of Surgical Sciences, Anaesthesiology and Intensive Care

Medicine, Uppsala University, Uppsala, Sweden; ⁵⁵⁶Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden; ⁵⁵⁷School of Biotechnology, Tan Tao University, Long An, Viet Nam; ⁵⁵⁸Department of Occupational Safety and Health, China Medical University, Taichung, Taiwan; ⁵⁵⁹Department of Occupational Therapy, Asia University, Taichung, Taiwan; ⁵⁶⁰Department of Biology, University of Zakho, Zakho, Iraq; ⁵⁶¹Department of Chemistry, University of Medical Sciences, Ondo, Ondo, Nigeria; ⁵⁶²Department of Community Medicine, University of Ibadan, Ibadan, Nigeria; ⁵⁶³Department of Community Medicine, University College Hospital, Ibadan, Ibadan, Nigeria; ⁵⁶⁴Faculty of Medicine, University of Belgrade, Belgrade, Serbia; ⁵⁶⁵Department of Epidemiology, University of Kragujevac, Kragujevac, Serbia; ⁵⁶⁶Institute of Health Research, University of Health and Allied Sciences, Ho, Ghana; ⁵⁶⁷Department of Health Research, ICMR National Institute for Research in Tuberculosis, Chennai, India; ⁵⁶⁸Faculty of Public Health, Universitas Muhammadiyah Aceh, Banda Aceh, Indonesia; ⁵⁶⁹Institute for Physical Activity and Nutrition, Deakin University, Burwood, VIC, Australia; ⁵⁷⁰Sydney Medical School, University of Sydney, Sydney, NSW, Australia; ⁵⁷¹Clinical Laboratory Department, Tobruk University, Tobruk, Libya; ⁵⁷²Blood Transmitted Diseases, National Center for Disease Control, Tobruk, Libya; ⁵⁷³Department of Clinical Pharmacy & Pharmacy Practice, Asian Institute of Medicine, Science and Technology, Kedah, Malaysia; ⁵⁷⁴Malaysian Academy of Pharmacy, Puchong, Malaysia; ⁵⁷⁵Department of General Surgery and Surgical-Medical Specialties, University of Catania, Catania, Italy; ⁵⁷⁶Department of Health Services Research, University of Tsukuba, Tsukuba, Japan; ⁵⁷⁷Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK; ⁵⁷⁸Department of Orthodontics & Dentofacial Orthopedics, Dr. D. Y. Patil University, Pune, India; ⁵⁷⁹Department of Environmental Health Engineering, Guilan University of Medical Sciences, Rasht, Iran; ⁵⁸⁰Research and Development Unit, Biomedical Research Networking Center for Mental Health Network (CiberSAM), Sant Boi de Llobregat, Spain; ⁵⁸¹Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France; ⁵⁸²Department of Immunology, Kerman University of Medical Sciences, Kerman, Iran; ⁵⁸³Department of Immunology, Rafsanjan University of Medical Sciences, Rafsanjan, Iran; ⁵⁸⁴Department of Nephrology, San Mateo Medical Center, San Mateo, CA, USA; ⁵⁸⁵Department of Nephrology, Mills Peninsula Medical Center, Burlingame, CA, USA; ⁵⁸⁶College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain; ⁵⁸⁷Ministry of Health, Ministry of Health, Manama, Bahrain; ⁵⁸⁸Department of Leukemia, The University of MD Anderson Cancer Center, Houston, Texas, USA; ⁵⁸⁹Statistics Unit, Riga Stradins University, Riga, Latvia; ⁵⁹⁰Department of Clinical Pharmacy, University of Science Malaysia, Penang, Malaysia; ⁵⁹¹Department of Health and Safety, United Arab Emirates University, Dubai, United Arab Emirates; ⁵⁹²Institute of Advanced Manufacturing Technologies, Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russia; ⁵⁹³Institute of Comparative Economic Studies, Hosei University, Tokyo, Japan; ⁵⁹⁴Department of Neurosciences, University of the Philippines Manila, Manila, Philippines; ⁵⁹⁵Institute for Neurosciences, St. Luke's Medical Center, Bonifacio Global City, Philippines; ⁵⁹⁶Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran; ⁵⁹⁷Department of Pediatrics, Isfahan University of Medical Sciences, Isfahan, Iran; ⁵⁹⁸Centre of Studies and Research, Ministry of Health, Muscat, Oman; ⁵⁹⁹Department of Biochemistry, Government Medical College, Mysuru, India; ⁶⁰⁰Department of Epidemiology, Florida International University, Miami, FL, USA; ⁶⁰¹Department of Biomedical Sciences, Jimma University, Jimma, Ethiopia; ⁶⁰²Department of Epidemiology and Health Promotion, Yonsei University, Seoul, South Korea; ⁶⁰³Department of Cardiovascular Medicine, Saint Vincent Hospital, Worcester, MA, USA; ⁶⁰⁴Department of Community Medicine, Dr. Baba Saheb Ambedkar Medical College & Hospital, Delhi, India; ⁶⁰⁵Department of Community Medicine, Banaras Hindu University, Varanasi, India; ⁶⁰⁶The George Institute for Global Health, New Delhi, India; ⁶⁰⁷Manipal Academy of Higher Education, Manipal, India; ⁶⁰⁸Department of Public Health, La Trobe University, Melbourne, VIC, Australia; ⁶⁰⁹Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia; ⁶¹⁰Department of Global Health, Peking University, Beijing, China; ⁶¹¹Department of Medicine, University of Miami,

Atlantis, FL, USA; ⁶¹²Zoonoses Research Center, Islamic Azad University, Karaj, Iran; ⁶¹³Department of Clinical Sciences, Jahrom University of Medical Sciences, Jahrom, Iran; ⁶¹⁴Hungarian Health Management Association, Budapest, Hungary; ⁶¹⁵Department of Gastroenterology and Hepatology, Stanford University, Stanford, CA, USA; ⁶¹⁶Department of Community Medicine, Manipal Academy of Higher Education, Mangalore, India; ⁶¹⁷Department of Economics, National Open University, Benin City, Nigeria; ⁶¹⁸Department of Family Medicine and Public Health, University of Opole, Opole, Poland; ⁶¹⁹Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia; ⁶²⁰Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran; ⁶²¹School of Public Health, University College Cork, Cork, Ireland; ⁶²²Department of Internal Medicine, Wayne State University, Detroit, MI, USA; ⁶²³Department of Neurology, University of Washington, Seattle, WA, USA; ⁶²⁴Social Determinants of Health Research Center, Gonabad University of Medical Sciences, Gonabad, Iran; ⁶²⁵Department of Pharmaceutical Sciences, Faran Shimi Pharmaceutical Company, Tehran, Iran; ⁶²⁶Public Health Division, National Research and Innovation Agency Republic of Indonesia (BRIN), Gadchiroli, India; ⁶²⁷Department of Endocrinology, Bharti Hospital Karnal, Karnal, India; ⁶²⁸University Centre for Research and Development, Chandigarh University, Mohali, India; ⁶²⁹Manipal Institute of Management, Manipal Academy of Higher Education, Manipal, India; ⁶³⁰Department of Forensic Medicine and Toxicology, All India Institute of Medical Sciences, Jodhpur, India; ⁶³¹Save Sight Institute, University of Sydney, Sydney, NSW, Australia; ⁶³²Sydney Eye Hospital, South Eastern Sydney Local Health District, Sydney, NSW, Australia; ⁶³³Department of Cardiovascular Medicine, Creighton University, Omaha, NE, USA; ⁶³⁴Department of Public Health, University of Nebraska Medical Center, Omaha, NE, USA; ⁶³⁵Faculty of Dentistry, University of Puthisastra, Phnom Penh, Cambodia; ⁶³⁶Office of the Executive Director, Cephas Health Research Initiative Inc, Ibadan, Nigeria; ⁶³⁷Dr. S S Bhatnagar University Institute of Chemical Engineering and Technology, Panjab University, Chandigarh, India; ⁶³⁸Department of Preventive & Social Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India; ⁶³⁹Second Cardiology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece; ⁶⁴⁰Central Department of Public Health, Institute of Medicine, Kathmandu, Nepal; ⁶⁴¹Department of Physical Therapy and Health Rehabilitation, Majmaah University, Majmaah, Saudi Arabia; ⁶⁴²Eye Research Center, Iran University of Medical Sciences, Tehran, Iran; ⁶⁴³Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; ⁶⁴⁴Department of Reproductive Health, Woldia University, Woldia, Ethiopia; ⁶⁴⁵Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA, USA; ⁶⁴⁶Centre for Tropical Diseases and Global Health, Catholic University of Bukavu, Bukavu, Democratic Republic of the Congo; ⁶⁴⁷Department of Global Health, Stellenbosch University, Cape Town, South Africa; ⁶⁴⁸Environmental Technologies Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; ⁶⁴⁹Department of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA; ⁶⁵⁰Cardiac Primary Prevention Research Center, Tehran University of Medical Sciences, Tehran, Iran; ⁶⁵¹Department of Cardiac Electrophysiology, Tehran University of Medical Sciences, Tehran, Iran; ⁶⁵²Department of HTN and Nephrology, Mayo Clinic, Rochester, MN, USA; ⁶⁵³Centre for Adolescent Health, Murdoch Childrens Research Institute, Melbourne, VIC, Australia; ⁶⁵⁴Department of Psychological Medicine, University of Otago, Christchurch, New Zealand; ⁶⁵⁵Department of Human Nutrition, National Research Institute for Agriculture, Food and Environment, Jouy-en-Josas, France; ⁶⁵⁶Sorbonne Paris Nord University, Bobigny, France; ⁶⁵⁷Students' Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran; ⁶⁵⁸Tehran University of Medical Sciences, Tehran, Iran; ⁶⁵⁹Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran; ⁶⁶⁰Neuro Musculoskeletal Research Center, Iran University of Medical Sciences, Tehran, Iran; ⁶⁶¹Department of Public Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; ⁶⁶²Amity Institute of Forensic Sciences, Amity University, Noida, India; ⁶⁶³College of Health Sciences, Abu Dhabi University, Adu Dhabi, United Arab Emirates; ⁶⁶⁴Department of Biostatistics, Mazandaran University of Medical Sciences, Mazandaran, Iran; ⁶⁶⁵Department of Biophysics and Biochemistry, Baku State University, Baku, Azerbaijan;

⁶⁶⁶Azerbaijan State University of Economics (UNEC), Baku, Azerbaijan; ⁶⁶⁷School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, QLD, Australia; ⁶⁶⁸Department of Epidemiology and Biostatistics, Health Services Academy, Islamabad, Pakistan; ⁶⁶⁹Department of Population Studies, International Institute for Population Sciences, Mumbai, India; ⁶⁷⁰Population Science Department, Jatiya Kabi Kazi Nazrul Islam University, Mymensingh, Bangladesh; ⁶⁷¹Department of Public Health, University of Sydney, Sydney, NSW, Australia; ⁶⁷²Department of Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA; ⁶⁷³Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan; ⁶⁷⁴Department of Clinical Pharmacy, Jouf University, Sakaka, Saudi Arabia; ⁶⁷⁵Department of Critical Care Medicine, St. Luke's Aurora Medical Center, Milwaukee, WI, USA; ⁶⁷⁶Department of Epidemiology, Non-Communicable Diseases Research Center (NCDRC), Tehran, Iran; ⁶⁷⁷College of Health, Wellbeing and Life Sciences, Sheffield Hallam University, Sheffield, UK; ⁶⁷⁸College of Arts and Sciences, Ohio University, Zanesville, OH, USA; ⁶⁷⁹School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran; ⁶⁸⁰Department of Neurosurgery, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ⁶⁸¹Department of Public Health, Jordan University of Science and Technology, Irbid, Jordan; ⁶⁸²Department of Molecular Biology and Genetics, Liaquat University Of Medical and Health Sciences, Jamshoro, Pakistan; ⁶⁸³Department of Cognition and Neuroscience, University of Texas, Dallas, TX, USA; ⁶⁸⁴Department of Pharmacology, University of Gondar, Gondar, Ethiopia; ⁶⁸⁵Department of Nutrition, Simmons University, Boston, MA, USA; ⁶⁸⁶School of Health Sciences, Kristiania University College, Oslo, Norway; ⁶⁸⁷Department of International Health and Sustainable Development, Tulane University, New Orleans, LA, USA; ⁶⁸⁸Department of Nursing and Health Promotion, Oslo Metropolitan University, Oslo, Norway; ⁶⁸⁹Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; ⁶⁹⁰Copernicus Institute of Sustainable Development, Utrecht University, Utrecht, Netherlands; ⁶⁹¹Department of Biochemistry, All India Institute of Medical Sciences, Bhopal, India; ⁶⁹²Department of Internal and Pulmonary Medicine, Sheri Kashmir Institute of Medical Sciences, Srinagar, India; ⁶⁹³San Juan de Dios Sanitary Park, Barcelona, Spain; ⁶⁹⁴Department of Anthropology, Panjab University, Chandigarh, India; ⁶⁹⁵Department of Anesthesiology, Duke University, Durham, NC, USA; ⁶⁹⁶Department of Community Medicine, Employees' State Insurance Model Hospital, Chennai, India; ⁶⁹⁷Department of Mathematics, University of Rajshahi, Rajshahi, Bangladesh; ⁶⁹⁸Department of Biochemistry, University of Hail, Hail, Saudi Arabia; ⁶⁹⁹Department of Health Research, Kazakh National Medical University, Almaty, Kazakhstan; ⁷⁰⁰Atchabarov Scientific Research Institute of Fundamental and Applied Medicine, Kazakh National Medical University, Almaty, Kazakhstan; ⁷⁰¹Department of Medicine, Queensland Health, Brisbane, QLD, Australia; ⁷⁰²Department of Cardiothoracic Surgery, UN Mehta Institute of Cardiology and Research Center, Ahmedabad, India; ⁷⁰³Department of Cardiothoracic Surgery, Medanta Hospital, Gurugram, India; ⁷⁰⁴Department of Internal Medicine, Cabrini Institute, Akron, OH, USA; ⁷⁰⁵Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, India; ⁷⁰⁶Department of Chemistry, Indian Institute of Technology Madras, Chennai, India; ⁷⁰⁷Biodesign Center for Environmental Health Engineering, Arizona State University, Tempe, AZ, USA; ⁷⁰⁸Department of Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia; ⁷⁰⁹Department of Public Health, Malaria Consortium, Abuja, Nigeria; ⁷¹⁰Public Health Pharmacy, West African Postgraduate College of Pharmacists, Lagos, Nigeria; ⁷¹¹Department of Health Services Research and Management, City University of London, London, UK; ⁷¹²Faculty of Public Health, University of Indonesia, Depok, Indonesia; ⁷¹³Department of Health Policy, London School of Economics and Political Science, London, UK; ⁷¹⁴Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; ⁷¹⁵National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, UK; ⁷¹⁶Department of Nursing Science, Bayero University Kano, Kano, Nigeria; ⁷¹⁷Department of Global Public Health, Karolinska Institute, Stockholm, Sweden; ⁷¹⁸Institute for Social and Health Sciences, University of South Africa, Pretoria, South Africa; ⁷¹⁹Department of Health Policy and Strategy, Foundation for People-centric Health Systems, New Delhi, India; ⁷²⁰SD Gupta School of

Public Health, Indian Institute of Health Management Research University, Jaipur, India; ⁷²¹Dr. B. C. Roy Multi Specialty Medical Research Centre, Indian Institute of Technology Kharagpur, Kharagpur, India; ⁷²²School of Digital Science, Universiti Brunei Darussalam, Gadong, Brunei; ⁷²³Institute of Applied Data Analytics, Universiti Brunei Darussalam, Gadong, Brunei; ⁷²⁴Department of Public Health, University of Helsinki, Helsinki, Finland; ⁷²⁵Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA; ⁷²⁶Unit of Genetics and Public Health, Institute of Medical Sciences, Las Tablas, Panama; ⁷²⁷Ministry of Health, Herrera, Panama; ⁷²⁸Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy; ⁷²⁹Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran; ⁷³⁰Department of Medical Sciences, Uppsala University, Uppsala, Sweden; ⁷³¹Department of Clinical Chemistry and Pharmacology, Uppsala University Hospital, Uppsala, Sweden; ⁷³²Department of Otorhinolaryngology, Father Muller Medical College, Mangalore, India; ⁷³³Centre for Family Welfare, University of Indonesia, Depok, Indonesia; ⁷³⁴Department of Global Health and Health Security, Taipei Medical University, Taipei, Taiwan; ⁷³⁵Department of Anesthesiology, Iran University of Medical Sciences, Tehran, Iran; ⁷³⁶Department of Surgery, National University of Singapore, Singapore, Singapore; ⁷³⁷International Society Doctors for the Environment, Arezzo, Italy; ⁷³⁸Department of Psychology, National Yang-Ming University, Ho Chi Minh city, Viet Nam; ⁷³⁹Health Economics Division, Monash University, Burwood, VIC, Australia; ⁷⁴⁰Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam; ⁷⁴¹Cardiovascular Research Department, Methodist Hospital, Merrillville, IN, USA; ⁷⁴²University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam; ⁷⁴³Independent Consultant, Ho Chi Minh City, Viet Nam; ⁷⁴⁴Internal Medicine Department, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam; ⁷⁴⁵Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; ⁷⁴⁶Department of Medical Science, Ajou University School of Medicine, Suwon, South Korea; ⁷⁴⁷Department of Health Sciences, University of Leicester, Leicester, UK; ⁷⁴⁸Department of Precision Medicine, Sungkyunkwan University, Suwon-si, South Korea; ⁷⁴⁹Department of Internal Medicine, University of Texas, Galveston, TX, USA; ⁷⁵⁰Department of Preventive Medicine, Korea University, Seoul, South Korea; ⁷⁵¹School of Social Sciences, Södertörn University, Huddinge, Sweden; ⁷⁵²Department of Epidemiology and Biostatistics, National Institute for Health Development, Tallinn, Estonia; ⁷⁵³UO Neurologia, Salute Pubblica e Disabilità (Neurology, Public Health and Disability Unit), Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; ⁷⁵⁴School of Public Health, Dilla University, Dilla, Ethiopia; ⁷⁵⁵Center for Dentistry and Oral Hygiene, University of Groningen, Groningen, Netherlands; ⁷⁵⁶Stomatological Hospital, Southern Medical University, Guangzhou, China; ⁷⁵⁷Department of Health Promotion and Health Education, National Taiwan Normal University, Taipei, Taiwan; ⁷⁵⁸Department of Psychiatry, Yale University, New Haven, CT, USA; ⁷⁵⁹Department of Health Management Center, Fudan University, Shanghai, China; ⁷⁶⁰National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Shenzhen, China; ⁷⁶¹Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia; ⁷⁶²Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, China; ⁷⁶³College of Public Health, China Medical University, Taichung, Taiwan; ⁷⁶⁴Asbestos Diseases Research Institute, Concord, NSW, Australia; ⁷⁶⁵School of Public Health, University of Haifa, Haifa, Israel; ⁷⁶⁶School of Life Sciences, University of Technology Sydney, Ultimo, NSW, Australia; ⁷⁶⁷Centre for Inflammation, Centenary Institute, Camperdown, NSW, Australia; ⁷⁶⁸Department of Radiology and Data Science, Harvard University, Boston, MA, USA; ⁷⁶⁹Department of Radiology, Massachusetts General Hospital, Boston, MA, USA; ⁷⁷⁰Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; ⁷⁷¹Department of Quantitative Health Science, Case Western Reserve University, Cleveland, OH, USA; ⁷⁷²Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrücke, Potsdam, Germany; ⁷⁷³German Center for Diabetes Research (DZD), München-Neuherberg, Germany; ⁷⁷⁴Department of Epidemiology and Evidence-Based Medicine, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; ⁷⁷⁵National Institutes of Health, University of

the Philippines Manila, Manila, Philippines; ⁷⁷⁶Department of Health Economics, Syreon Research Romania, Targu Mures, Romania; ⁷⁷⁷Department of Doctoral Studies, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Târgu-Mureș, Romania; ⁷⁷⁸Institute of Nutritional Sciences, Friedrich Schiller University Jena, Jena, Germany; ⁷⁷⁹Competence Cluster for Nutrition and Cardiovascular Health (nutriCARD), Jena, Germany; ⁷⁸⁰Department of Medicine, University of Sao Paulo, São Paulo, Brazil; ⁷⁸¹School of Medicine, Federal University of Juiz de Fora, Juiz de Fora, Brazil; ⁷⁸²Centre for Public Health and Wellbeing, University of the West of England, Bristol, UK; ⁷⁸³Department of Biostatistics and Epidemiology, Yazd University of Medical Sciences, Yazd, Iran; ⁷⁸⁴Institute for Physical Activity and Nutrition, Deakin University, Melbourne, VIC, Australia; ⁷⁸⁵Department of Human Nutrition Research, Autonomous University of Sinaloa, Culiacán, Mexico; ⁷⁸⁶Faculty of Medicine, University of Limoges, Limoges, France; ⁷⁸⁷Department of Forensic Medicine & Toxicology, Mysore Medical College & Research Institute, Mysooru, India; ⁷⁸⁸Department of Health and Family Welfare, Government of Karnataka, Bangalore, India; ⁷⁸⁹Department of Clinical and Hospital Pharmacy, Taibah University, Al-Madinah Al-Munawwarah, Saudi Arabia; ⁷⁹⁰Student Research Committee, Iran University of Medical Sciences, Tehran, Iran; ⁷⁹¹Center for Health & Nature, Houston Methodist Hospital, Houston, Texas, USA; ⁷⁹²Department of Cardiology, October 6 University, Cairo, Egypt; ⁷⁹³Department of Pediatric Cardiology, Tehran University of Medical Sciences, Tehran, Iran; ⁷⁹⁴Non-communicable Disease Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; ⁷⁹⁵Department of Internal Medicine, Dayanand Medical College and Hospital, Ludhiana, India; ⁷⁹⁶Electrical Engineering Department, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia; ⁷⁹⁷Department of Pharmacy, The University of Lahore, Lahore, Pakistan; ⁷⁹⁸Department of Maternal and Child Nursing and Public Health, Federal University of Minas Gerais, Belo Horizonte, Brazil; ⁷⁹⁹Department of Medical Laboratory Sciences, Arba Minch University, Arba Minch, Ethiopia; ⁸⁰⁰Shiraz University of Medical Sciences, Shiraz, Iran; ⁸⁰¹Substance Abuse Prevention Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran; ⁸⁰²Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran; ⁸⁰³Biomedical Engineering Research Center (CREB), Universitat Politècnica de Catalunya, Barcelona, Spain; ⁸⁰⁴Department of Biomedical Engineering, University of Isfahan, Isfahan, Iran; ⁸⁰⁵Department of Food, Environmental and Nutritional Sciences (DEFENS), University of Milan, Milano, Italy; ⁸⁰⁶Department of Food, Environmental and Nutritional Sciences (DEFENS), University of Milan, Milan, Italy; ⁸⁰⁷Faculty of Public Health, Universitas Airlangga (Airlangga University), Surabaya, Indonesia; ⁸⁰⁸Indonesian Public Health Association, Surabaya, Indonesia; ⁸⁰⁹Department of Pharmacy, Bahauddin Zakariya university, Multan, Pakistan; ⁸¹⁰Department of Public Health, Management and Science University, Shah Alam, Malaysia; ⁸¹¹Jeffrey Cheah School of Medicine and Health Sciences, Monash University, Subang Jaya, Malaysia; ⁸¹²Department of Pharmacology, Shahroud University of Medical Sciences, Shahroud, Iran; ⁸¹³Department of Dermatology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; ⁸¹⁴Board Director, Association of Resident Physicians, Bucharest, Romania; ⁸¹⁵Department of Anatomy, Genetics and Biomedical Informatics, University of Colombo, Colombo, Sri Lanka; ⁸¹⁶Australian Regenerative Medicine Institute, Monash University, Clayton, VIC, Australia; ⁸¹⁷Department of Public Health and Community Medicine, Central University of Kerala, Kasaragod, India; ⁸¹⁸Health Policy Research, Public Health Foundation of India, Gurugram, India; ⁸¹⁹Institute of Population Health Sciences, University of Liverpool, Liverpool, UK; ⁸²⁰Department of Medicine, University of Louisville, Louisville, KY, USA; ⁸²¹Epidemiology Department, Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand; ⁸²²Nuffield Department of Medicine, University of Oxford, Oxford, UK; ⁸²³Department GF Ingrassia, University of Catania, Catania, Italy; ⁸²⁴Department of Twin Research and Genetic Epidemiology, King's College London, London, UK; ⁸²⁵Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia; ⁸²⁶National Centre for Register-based Research, Aarhus University, Aarhus, Denmark; ⁸²⁷Australian Centre for Health Services Innovation, Queensland University of Technology, Kelvin Grove, QLD, Australia; ⁸²⁸Digital Health

and Informatics Directorate, Queensland Health, Brisbane, QLD, Australia; ⁸²⁹Department of Healthcare, University of Vlora, Vlora City, Albania; ⁸³⁰Clinic of Social and Family Medicine, University of Crete, Heraklion, Greece; ⁸³¹Department of Global Health, University of the Ryukyus, Nishihara, Japan; ⁸³²Department of Preventive Oncology, All India Institute of Medical Sciences, New Delhi, India; ⁸³³Cardiac Rehabilitation Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; ⁸³⁴Department of Medical Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland; ⁸³⁵Peru Country Office, United Nations Population Fund (UNFPA), Lima, Peru; ⁸³⁶Forensic Medicine Division, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; ⁸³⁷Department of Public Health, Debre Markos University, Debre Markos, Ethiopia; ⁸³⁸Department of Physiology, King Saud University, Riyadh, Saudi Arabia; ⁸³⁹Department of Medical Laboratory Sciences, Haramaya University, Harar, Ethiopia; ⁸⁴⁰Neurology Unit, Helsinki University Hospital, Helsinki, Finland; ⁸⁴¹School of Health Sciences, University of Melbourne, Melbourne, VIC, Australia; ⁸⁴²Breast Surgery Unit, Helsinki University Hospital, Helsinki, Finland; ⁸⁴³University of Helsinki, Helsinki, Finland; ⁸⁴⁴University Centre Varazdin, University North, Varazdin, Croatia; ⁸⁴⁵Department of Pharmacology, University of Kelaniya, Ragama, Sri Lanka; ⁸⁴⁶Department of Clinical Medicine, Colombo North Teaching Hospital, Ragama, Sri Lanka; ⁸⁴⁷Department of Paediatrics, University of Kelaniya, Ragama, Sri Lanka; ⁸⁴⁸University Paediatrics Unit, Colombo North Teaching Hospital, Ragama, Sri Lanka; ⁸⁴⁹Department of Preventive Medicine, Northwestern University, Chicago, IL, USA; ⁸⁵⁰South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Cape Town, South Africa; ⁸⁵¹Department of Health Promotion, Education, and Behavior, University of South Carolina, Columbia, SC, USA; ⁸⁵²School of Public Health and Community Medicine, University of Gothenburg, Gothenburg, Sweden; ⁸⁵³Department of Propedeutics of Internal Diseases & Arterial Hypertension, Pomeranian Medical University, Szczecin, Poland; ⁸⁵⁴Department of Epidemiology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; ⁸⁵⁵National Cancer Registry, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; ⁸⁵⁶Pacific Institute for Research & Evaluation, Calverton, MD, USA; ⁸⁵⁷International Ph.D. Program in Medicine, Taipei Medical University, Taipei, Taiwan; ⁸⁵⁸Research Center for Artificial Intelligence in Medicine, Taipei Medical University, Taipei, Taiwan; ⁸⁵⁹Department of Global Health, University of Washington, Seattle, WA, USA; ⁸⁶⁰Department of Clinical Research, Kilimanjaro Clinical Research Centre (KCRI), Moshi, Tanzania; ⁸⁶¹Department of General Surgery, Isfahan University of Medical Sciences, Isfahan, Iran; ⁸⁶²Sports and Exercise Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran; ⁸⁶³Internal Medicine Programme, Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan; ⁸⁶⁴Department of Atherosclerosis and Coronary Heart Disease, National Center of Cardiology and Internal Disease, Bishkek, Kyrgyzstan; ⁸⁶⁵Department of Hospital Administration, All India Institute of Medical Sciences, Bathinda, India; ⁸⁶⁶Social Determinants of Health Center, Urmia University of Medical Sciences, Urmia, Iran; ⁸⁶⁷Bloomberg school of public health, Johns Hopkins University, Baltimore, MD, USA; ⁸⁶⁸College of Applied and Natural Science, University of Hargeisa, Hargeisa, Somalia; ⁸⁶⁹Internal Medicine, Brown University, Providence, RI, USA; ⁸⁷⁰Molecular Biology Unit, Sirius Training and Research Centre, Khartoum, Sudan; ⁸⁷¹Bio-Statistical and Molecular Biology Department, Sirius Training and Research Centre, Khartoum, Sudan; ⁸⁷²Department of Public Health, Dire Dawa University, Dire Dawa, Ethiopia; ⁸⁷³Department of Clinical Pharmacy and Pharmacy Practice, Ahmadu Bello University, Zaria, Nigeria; ⁸⁷⁴School of Pharmaceutical Sciences, University of Science Malaysia, Penang, Malaysia; ⁸⁷⁵Department of Pharmaceutical Sciences, Notre Dame of Maryland University, Baltimore, MD, USA; ⁸⁷⁶Department of Pharmacy, Mizan-Tepi University, Mizan, Ethiopia; ⁸⁷⁷Health Systems and Policy Research Unit, Ahmadu Bello University, Zaria, Nigeria; ⁸⁷⁸Department of Health Care Management, Technical University of Berlin, Berlin, Germany; ⁸⁷⁹Oncology Department, Appalachian Regional Healthcare, Hazard, KY, USA; ⁸⁸⁰Department of Internal Medicine, University of Kentucky, Lexington, KY, USA; ⁸⁸¹Department of Biostatistics, Shiraz University of Medical Sciences, Shiraz, Iran; ⁸⁸²Clinical Epidemiology and Public Health Research Unit, Burlo Garofolo Institute

for Maternal and Child Health, Trieste, Italy; ⁸⁸³School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ⁸⁸⁴Medicine, Birjand University of Medical Sciences, Birjand, Iran; ⁸⁸⁵Department of Epidemiology and Biostatistics, Kurdistan University of Medical Sciences, Sanandaj, Iran; ⁸⁸⁶Computer, Electrical, and Mathematical Sciences and Engineering Division, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia; ⁸⁸⁷International Laboratory for Air Quality and Health, Queensland University of Technology, Brisbane, QLD, Australia; ⁸⁸⁸Clinical Research Development Unit, Mashhad University of Medical Sciences, Mashhad, Iran; ⁸⁸⁹Division of Plastic and Reconstructive Surgery, University of Washington, Seattle, WA, USA; ⁸⁹⁰Department of Cardiology and Cardiac Surgery, University of Warmia and Mazury, Olsztyn, Poland; ⁸⁹¹Stanford Cardiovascular Institute, Stanford University, Palo Alto, CA, USA; ⁸⁹²Mechanical and Industrial Engineering, University of Toronto, Toronto, ON, Canada; ⁸⁹³Non-communicable Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran; ⁸⁹⁴Department of Community Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; ⁸⁹⁵Epidemiology Department, Aging Research Institute, Tabriz, Iran; ⁸⁹⁶Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA; ⁸⁹⁷Department of Radiology, University of Tripoli, Tripoli, Libya; ⁸⁹⁸Federal Institute for Population Research, Wiesbaden, Germany; ⁸⁹⁹Center for Population and Health, Wiesbaden, Germany; ⁹⁰⁰Knowledge Management, Prahlad Omkarwati Foundation (POF), Mumbai, India; ⁹⁰¹Independent Consultant, New Delhi, India; ⁹⁰²Amity Institute of Pharmacy, Amity University, Noida, India; ⁹⁰³Clinical Epidemiology Research Unit, Mexican Institute of Social Security, Villa de Alvarez, Mexico; ⁹⁰⁴Postgraduate in Medical Sciences, Universidad de Colima, Colima, Mexico; ⁹⁰⁵Department of Pediatrics, Shaqra University, Shaqra, Saudi Arabia; ⁹⁰⁶Department of Pediatrics & Pediatric Pulmonology, Institute of Mother & Child Care, Multan, Pakistan; ⁹⁰⁷Department of Research Methodology, Orthopaedic Research Group, Coimbatore, India; ⁹⁰⁸Department of Biotechnology, Karpagam Academy of Higher Education, Coimbatore, India; ⁹⁰⁹Internal Medicine, University of Botswana, Gaborone, Botswana; ⁹¹⁰Neuropsychiatry, Seoul National University, Seongnam-si, South Korea; ⁹¹¹Research and Analytics Department, Initiative for Financing Health and Human Development, Chennai, India; ⁹¹²Department of Research and Analytics, Bioinsilico Technologies, Chennai, India; ⁹¹³Department of Nephrology, Manipal Academy of Higher Education, Manipal, India; ⁹¹⁴College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia; ⁹¹⁵Department of Engineering, Western Sydney University, Sydney, NSW, Australia; ⁹¹⁶Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA; ⁹¹⁷Department of Community Medicine, MOSC Medical College, Kolenchery, India; ⁹¹⁸Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran; ⁹¹⁹Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran University of Medical Sciences, Tehran, Iran; ⁹²⁰Department of Physiotherapy, Tehran University of Medical Sciences, Tehran, Iran; ⁹²¹Research Center for War-affected People, Tehran University of Medical Sciences, Tehran, Iran; ⁹²²Suraj Eye Institute, Nagpur, India; ⁹²³Mysore Medical College and Research Institute, Government Medical College, Mysore, India; ⁹²⁴Department of Clinical Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil; ⁹²⁵Clinical Hospital, Federal University of Minas Gerais, Belo Horizonte, Brazil; ⁹²⁶National Dental Research Institute Singapore, Duke-NUS Medical School, Singapore, Singapore; ⁹²⁷Department of Pharmacology and Toxicology, Islamic Azad University, Tehran, Iran; ⁹²⁸Department of Dental Public Health, King Abdulaziz University, Jeddah, Saudi Arabia; ⁹²⁹Department of Health Policy and Oral Epidemiology, Harvard University, Boston, MA, USA; ⁹³⁰College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates; ⁹³¹Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway; ⁹³²Department of Biotechnology, University of Central Punjab, Lahore, Pakistan; ⁹³³Department of Medical Laboratory Sciences, Adigrat University, Adigrat, Ethiopia; ⁹³⁴Department of General Surgery, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; ⁹³⁵Department of General Surgery, Emergency Hospital of Bucharest, Bucharest, Romania; ⁹³⁶Department of Anatomy and Embryology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; ⁹³⁷Department

of Cardiology, Cardio-Aid, Bucharest, Romania; ⁹³⁸Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; ⁹³⁹Faculty of Medicine, Euromed University of Fes, Fez, Morocco; ⁹⁴⁰Faculty of Medicine, University Sidi Mohammed Ben Abdellah, Fez, Morocco; ⁹⁴¹Department of Clinical Biochemistry, Kerman University of Medical Sciences, Kerman, Iran; ⁹⁴²Department of Community Medicine, Kathmandu University, Palpa, Nepal; ⁹⁴³Department of Epidemiology and Global Health, Umeå University, Umeå, Sweden; ⁹⁴⁴Department of Medical Engineering, University of South Florida, Tampa, FL, USA; ⁹⁴⁵Department of Surgery, Danang Family Hospital, Danang, Viet Nam; ⁹⁴⁶Department of General Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam; ⁹⁴⁷International Islamic University Islamabad, Islamabad, Pakistan; ⁹⁴⁸School of Medicine, Harvard University, Cambridge, MA, USA; ⁹⁴⁹School of Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA; ⁹⁵⁰Internal Medicine, Ziauddin University, Karachi, Pakistan; ⁹⁵¹Department of Applied Microbiology, Taiz University, Taiz, Yemen; ⁹⁵²Faculty of Applied Sciences and Technology, Universiti Tun Hussein Onn Malaysia, Johor, Malaysia; ⁹⁵³Department of Health Policy and Management, Keio University, Tokyo, Japan; ⁹⁵⁴Department of Global Health Policy, University of Tokyo, Tokyo, Japan; ⁹⁵⁵Microbiology and Molecular Genetics, The Women University Multan, Multan, Pakistan; ⁹⁵⁶Department of Clinical Sciences, Lund University, Lund, Sweden; ⁹⁵⁷Centre for Heart Rhythm Disorders, University of Adelaide, Adelaide, SA, Australia; ⁹⁵⁸Department of Paediatrics, Nnamdi Azikiwe University, Awka, Nigeria; ⁹⁵⁹Division of Cardiology, University of Cape Town, Cape Town, South Africa; ⁹⁶⁰The Cardiac Clinic, Groote Schuur Hospital, Cape Town, South Africa; ⁹⁶¹Public Health Department, Banten School of Health Science, South Tangerang, Indonesia; ⁹⁶²Ministry of Research, Technology and Higher Education, Higher Education Service Institutions (LL-DIKTI) Region IV, Bandung, Indonesia; ⁹⁶³Center of Excellence in Reproductive Health Innovation (CERHI), University of Benin, Benin City, Nigeria; ⁹⁶⁴Department of Physiology, University of Benin, Edo, Nigeria; ⁹⁶⁵Department of Physiology, Benson Idahosa University, Benin City, Nigeria; ⁹⁶⁶James Cook University, Townsville, QLD, Australia; ⁹⁶⁷Department of Medicine, National University of Ireland Galway, Galway, Ireland; ⁹⁶⁸Department of Obstetrics and Gynecology, University of Ibadan, Ibadan, Nigeria; ⁹⁶⁹Department of Medicine, University College Hospital, Ibadan, Ibadan, Nigeria; ⁹⁷⁰Institute of Cardiovascular Science, University College London, London, UK; ⁹⁷¹School of Health and Related Research, University of Sheffield, Sheffield, UK; ⁹⁷²Centre for Social Research in Health, University of New South Wales, Sydney, NSW, Australia; ⁹⁷³Independent Consultant, Sydney, NSW, Australia; ⁹⁷⁴Department of Food and Nutrition, Seoul National University, Seoul, South Korea; ⁹⁷⁵College of Medicine, University of Ibadan, Ibadan, Nigeria; ⁹⁷⁶Department of Food Science and Postharvest Technology, Gulu University, Gulu, Uganda; ⁹⁷⁷School of Pharmacy, University of the Western Cape, Cape Town, South Africa; ⁹⁷⁸Department of Medical Physiology, Babcock University, Ilisan-Remo, Nigeria; ⁹⁷⁹Department of Medical Physiology, University of Lagos, Lagos, Nigeria; ⁹⁸⁰Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada; ⁹⁸¹Department of Psychiatry, University of Lagos, Lagos, Nigeria; ⁹⁸²Department of Microbiology, Immunology and Parasitology, Addis Ababa University, Addis Ababa, Ethiopia; ⁹⁸³Medical Laboratory Sciences, Ambo University, Ambo, Ethiopia; ⁹⁸⁴Department of Nursing Science, Bowen University, Iwo, Nigeria; ⁹⁸⁵Cardiology Department, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; ⁹⁸⁶Department of Community Medicine, Ahmadu Bello University, Zaria, Nigeria; ⁹⁸⁷Slum and Rural Health Initiative Research Academy, Slum and Rural Health Initiative, Ibadan, Nigeria; ⁹⁸⁸Department of Microbiology, University of Medical Sciences, Ondo, Ondo City, Nigeria; ⁹⁸⁹Department of Anatomy, University of Medical Sciences, Ondo, Ondo City, Nigeria; ⁹⁹⁰Department of Anatomy, Olabisi Onabanjo University, Sagamu, Nigeria; ⁹⁹¹Surgery Department, Sulaimani University, Sulaimani, Iraq; ⁹⁹²ENT Department, Tor Vergata University of Rome, Rome, Italy; ⁹⁹³College of Animal Science and Technology, Henan University of Science and Technology, Henan, China; ⁹⁹⁴Non-communicable Disease Prevention Unit, Ministry of Health, Bandar Seri Begawan, Brunei; ⁹⁹⁵Early Detection & Cancer Prevention Services, Pantai Jerudong Specialist Centre, Bandar Seri Begawan, Brunei; ⁹⁹⁶Department of

Biomedical Sciences, Mercer University School of Medicine, Macon, GA, USA; ⁹⁹⁷Department of Pharmacotherapy and Pharmaceutical Care, Medical University of Warsaw, Warsaw, Poland; ⁹⁹⁸Health Systems Research Center, National Institute of Public Health, Cuernavaca, Mexico; ⁹⁹⁹Department of Medicine, Autonomous University of Madrid, Madrid, Spain; ¹⁰⁰⁰Department of Nephrology and Hypertension, The Institute for Health Research Foundation Jiménez Díaz University Hospital, Madrid, Spain; ¹⁰⁰¹One Health Global Research Group, Universidad de las Americas, Quito, Ecuador; ¹⁰⁰²Department of Biology, Khalifa University, Abu Dhabi, United Arab Emirates; ¹⁰⁰³School of Medicine, Western Sydney University, Campbelltown, NSW, Australia; ¹⁰⁰⁴Department of Optometry and Vision Science, University of KwaZulu-Natal, KwaZulu-Natal, South Africa; ¹⁰⁰⁵Laboratory of Public Health Indicators Analysis and Health Digitalization, Moscow Institute of Physics and Technology, Dolgoprudny, Russia; ¹⁰⁰⁶Department of Project Management, National Research University Higher School of Economics, Moscow, Russia; ¹⁰⁰⁷Department of Medicine, University of Ibadan, Ibadan, Nigeria; ¹⁰⁰⁸Department of Respiratory Medicine, Jagadguru Sri Shivarathreeswara University, Mysore, India; ¹⁰⁰⁹National School of Public Health, Institute of Health Carlos III, Madrid, Spain; ¹⁰¹⁰Department of Forensic Medicine and Toxicology, Kasturba Medical College, Mangalore, Mangalore, India; ¹⁰¹¹Systems and Information Engineering, University of Virginia, Charlottesville, VA, USA; ¹⁰¹²Hungarian Health Management Association, Hungarian Health Management Association, Budapest, Hungary; ¹⁰¹³Department of Public Health, University of Naples Federico II, Naples, Italy; ¹⁰¹⁴Department of Primary Care and Public Health, Imperial College London, London, UK; ¹⁰¹⁵Epidemiology and Biostatistics, Anhui Medical University, Hefei, China; ¹⁰¹⁶Saveetha Medical College and Hospitals, Saveetha University, Chennai, India; ¹⁰¹⁷Division of Research and Development, Lovely Professional University, Phagwara, India; ¹⁰¹⁸Department of Science and Mathematics, Deree-The American College of Greece, Athens, Greece; ¹⁰¹⁹Department of Biophysics, University of Athens, Athens, Greece; ¹⁰²⁰Yonsei University College of Medicine, Seodaemun-gu, South Korea; ¹⁰²¹Department of Medical Sciences, University of Torino, Torino, Italy; ¹⁰²²Department of Imaging, AOU Città della Salute e della Scienza di Torino, Torino, Italy; ¹⁰²³Global Health Governance Programme, University of Edinburgh, Edinburgh, UK; ¹⁰²⁴School of Dentistry, University of Leeds, Leeds, UK; ¹⁰²⁵College of Dental Medicine, Roseman University of Health Sciences, South Jordan, UT, USA; ¹⁰²⁶Centre of Molecular Medicine and Diagnostics (COMMANd), Saveetha University, Chennai, India; ¹⁰²⁷Second Department of Internal Medicine, European Interbalkan Medical Center, Thessaloniki, Greece; ¹⁰²⁸Second Department of Cardiology, Aristotle University of Thessaloniki, Thessaloniki, Greece; ¹⁰²⁹Department of Internal Medicine, Advent Health, Palm Coast, FL, USA; ¹⁰³⁰Hospital Medicine, Sound Physicians, Palm Coast, FL, USA; ¹⁰³¹Department of Genetics, Yale University, New Haven, CT, USA; ¹⁰³²School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia; ¹⁰³³College of Public Health, Medical, and Veterinary Sciences, James Cook University, Townsville, QLD, Australia; ¹⁰³⁴Clinical Research Department, IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy; ¹⁰³⁵Department of Infection Control, Taihe Hospital, Shiyan, China; ¹⁰³⁶The First Clinical College, Hubei University of Medicine, Shiyan, China; ¹⁰³⁷Center for Research and Innovation, Ateneo De Manila University, Pasig City, Philippines; ¹⁰³⁸Institute of Collective Health, Federal University of Bahia, Salvador, Brazil; ¹⁰³⁹Department of Applied Nursing, Federal University of Minas Gerais, Belo Horizonte, Brazil; ¹⁰⁴⁰Department of Psychiatry, University of São Paulo, São Paulo, Brazil; ¹⁰⁴¹International Institute for Educational Planning (IIEP), Albert Einstein Hospital, São Paulo, Brazil; ¹⁰⁴²Department of Development Studies, International Institute for Population Sciences, Mumbai, India; ¹⁰⁴³Mario Negri Institute for Pharmacological Research, Bergamo, Italy; ¹⁰⁴⁴Facultad de Medicina, Universidad Diego Portales (Faculty of Medicine, Diego Portales University), Santiago, Chile; ¹⁰⁴⁵School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK; ¹⁰⁴⁶Medical School, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Viet Nam; ¹⁰⁴⁷School of Pharmacy, University of Nizwa, Nizwa, Oman; ¹⁰⁴⁸Department of Cardiology, University of Bern, Bern, Switzerland; ¹⁰⁴⁹Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, Russia;

¹⁰⁵⁰Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia; ¹⁰⁵¹Department of Medicine, Nazarbayev University, Astana, Kazakhstan; ¹⁰⁵²Clinical Academic Department of Pediatrics, University Medical Center (UMC), Astana, Kazakhstan; ¹⁰⁵³Department of Data Management and Analysis, The INCLEN Trust International, New Delhi, India; ¹⁰⁵⁴Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; ¹⁰⁵⁵International UNESCO Center for Health-related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran; ¹⁰⁵⁶Department of Community Medicine, Tribhuvan University, Kathmandu, Nepal; ¹⁰⁵⁷Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA; ¹⁰⁵⁸Department of Clinical Research and Epidemiology, Institute of Liver and Biliary Sciences, New Delhi, New Delhi, India; ¹⁰⁵⁹Centre for Dental Education and Research, All India Institute of Medical Sciences, New Delhi, India; ¹⁰⁶⁰Department of Biostatistics Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, USA; ¹⁰⁶¹Department of Neonatology, Case Western Reserve University, Cleveland, OH, USA; ¹⁰⁶²Department of Cardiology, Third Military Medical University, Chongqing, China; ¹⁰⁶³Medical Sciences Education Department, Western University of Health Sciences, Pomona, CA, USA; ¹⁰⁶⁴Cardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan, Iran; ¹⁰⁶⁵College of Medicine, University of Central Florida, Orlando, FL, USA; ¹⁰⁶⁶Department of Radiology, University of California Irvine, Irvine, CA, USA; ¹⁰⁶⁷Research and Development Coordination, Health Research Institute National Institutes of Health, Islamabad, Pakistan; ¹⁰⁶⁸UO Neurologia, Salute Pubblica e Disabilità, Fondazione IRCCS Istituto Neurologico Carlo Besta (Neurology, Public Health and Disability Unit, Carlo Besta Neurological Institute), Milan, Italy; ¹⁰⁶⁹Department of Health Sciences, Cihan University Sulaimaniya, Sulaymaniyah, Iraq; ¹⁰⁷⁰Cihan University Sulaimaniya Research Center (CUSRC), Sulaymaniyah, Iraq; ¹⁰⁷¹Department of Health Policy & Organization, University of Alabama at Birmingham, Birmingham, AL, USA; ¹⁰⁷²Department of Health Services Administration, University of Alabama at Birmingham, Birmingham, AL, USA; ¹⁰⁷³Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; ¹⁰⁷⁴Department of Population Science and Human Resource Development, University of Rajshahi, Rajshahi, Bangladesh; ¹⁰⁷⁵Institute of Health and Wellbeing, Federation University Australia, Berwick, VIC, Australia; ¹⁰⁷⁶School of Nursing and Midwifery, La Trobe University, Melbourne, VIC, Australia; ¹⁰⁷⁷Future Technology Research Center, National Yunlin University of Science and Technology, Yunlin, Taiwan; ¹⁰⁷⁸Department of Nutrition, Qazvin University of Medical Sciences, Qazvin, Iran; ¹⁰⁷⁹Department of Public Health, Torbat Jam Faculty of Medical Sciences, Torbat Jam, Iran; ¹⁰⁸⁰School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; ¹⁰⁸¹Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran; ¹⁰⁸²Institute of Environment and Sustainable Development, Banaras Hindu University, Varanasi, India; ¹⁰⁸³Department of Cardiology, Emory University, Atlanta, GA, USA; ¹⁰⁸⁴Department of Urology, All India Institute of Medical Sciences, Bhubaneswar, India; ¹⁰⁸⁵Department of Community Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, India; ¹⁰⁸⁶Department of Radiology, Stanford University, Stanford, CA, USA; ¹⁰⁸⁷Leadership Institute for Global Health Transformation (LIGHT), National University of Singapore, Singapore, Singapore; ¹⁰⁸⁸Department of Biochemistry, JSS Academy of Higher Education & Research, Mysore, India; ¹⁰⁸⁹Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada; ¹⁰⁹⁰Research and Innovation Division, South Asian Institute for Social Transformation (SAIST), Dhaka, Bangladesh; ¹⁰⁹¹Translation Health Research Institute, Western Sydney University, Campbelltown, NSW, Australia; ¹⁰⁹²Research Department, Policy Research Institute, Kathmandu, Nepal; ¹⁰⁹³Health and Public Policy Department, Global Center for Research and Development, Kathmandu, Nepal; ¹⁰⁹⁴Centre for Clinical Pharmacology, University of Defence in Belgrade, Belgrade, Serbia; ¹⁰⁹⁵Centre for Clinical Pharmacology, Medical College of Georgia at Augusta University, Belgrade, Serbia; ¹⁰⁹⁶Health Economics and Outcomes Research, Agios Pharmaceuticals, Cambridge, MA, USA; ¹⁰⁹⁷Department of Pharmaceutical Economics and Policy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA; ¹⁰⁹⁸School of Humanities and Social Sciences, Indian

Institute of Technology Mandi, Mandi, India; ¹⁰⁹⁹Department of Medicine, University of Otago, Wellington, New Zealand; ¹¹⁰⁰Department of Neurology, Capital & Coast District Health Board, Wellington, New Zealand; ¹¹⁰¹Community Medicine, Manipal Academy of Higher Education, Mangalore, India; ¹¹⁰²Department of Oral Pathology, Sharavathi Dental College and Hospital, Shimogga, India; ¹¹⁰³University of Social Welfare and Rehabilitation Sciences, Tehran, Iran; ¹¹⁰⁴Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan; ¹¹⁰⁵Department of Geography, Soran University, Soran, Iraq; ¹¹⁰⁶Department of Biomedical Engineering, Khulna University of Engineering and Technology, Khulna, Bangladesh; ¹¹⁰⁷Department of Population Medicine, Qatar University, Doha, Qatar; ¹¹⁰⁸Pulmonary Critical Care, University of Chicago, Chicago, IL, USA; ¹¹⁰⁹Academic Public Health England, Public Health England, London, UK; ¹¹¹⁰Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; ¹¹¹¹Department Biological Sciences, King Abdulaziz University, Jeddah, Egypt; ¹¹¹²Department of Protein Research, Research and Academic Institution, Alexandria, Egypt; ¹¹¹³Unisabana Center for Translational Science, Universidad de La Sabana, Chia, Colombia; ¹¹¹⁴Critical Care Department, Clinica Universidad De La Sabana, Chia, Colombia; ¹¹¹⁵Department of Epidemiology and Biostatistics, Rafsanjan University of Medical Sciences, Rafsanjan, Iran; ¹¹¹⁶Centre of Telehealth, Federal University of Minas Gerais, Belo Horizonte, Brazil; ¹¹¹⁷Associated Laboratory for Green Chemistry (LAQV), University of Porto, Porto, Portugal; ¹¹¹⁸Faculty of Agrarian Sciences and Environment, University of the Azores, Angra do Heroísmo, Portugal; ¹¹¹⁹Institute of Diagnostic and Interventional Radiology and Neuroradiology, Essen University Hospital, Essen, Germany; ¹¹²⁰Department of Clinical Research, Federal University of Uberlândia, Uberlândia, Brazil; ¹¹²¹Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Beirut, Lebanon; ¹¹²²Faculty of Nursing, Chulalongkorn University, Bangkok, Thailand; ¹¹²³Analytical and Applied Economics, Utkal University, Bhubaneswar, India; ¹¹²⁴Department of Biochemistry and Food Analysis, Patuakhali Science and Technology University, Patuakhali, Bangladesh; ¹¹²⁵Department of Labour, Directorate of Factories, Government of West Bengal, Kolkata, India; ¹¹²⁶Department of Cardiology and Internal Medicine, University of Warmia and Mazury, Olsztyn, Poland; ¹¹²⁷Cardiovascular Department, Zagazig University, Zagazig, Egypt; ¹¹²⁸Faculty of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran; ¹¹²⁹Infectious Diseases Research Center, Gonabad University of Medical Sciences, Gonabad, Iran; ¹¹³⁰Department of Epidemiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ¹¹³¹Department of Neurology, University of L'Aquila, L'Aquila, Italy; ¹¹³²Department of Cardiology, Department of Veterans Affairs, Decatur, GA, USA; ¹¹³³Department of Cardiology, Medical College of Georgia at Augusta University, Augusta, GA, USA; ¹¹³⁴Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates; ¹¹³⁵Multidisciplinary Laboratory Foundation University School of Health Sciences (FUSH), Foundation University, Islamabad, Pakistan; ¹¹³⁶International Center of Medical Sciences Research (ICMSR), Islamabad, Pakistan; ¹¹³⁷Traditional Medicine and Materia Medica Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ¹¹³⁸Sharjah Institute of Medical Sciences, University of Sharjah, Sharjah, United Arab Emirates; ¹¹³⁹Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; ¹¹⁴⁰Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; ¹¹⁴¹Department of Community and Family Medicine, All India Institute of Medical Sciences, Bathinda, India; ¹¹⁴²Neurology Department, Golestan University of Medical Sciences, Gorgan, Iran; ¹¹⁴³Department of Statistics, University of Gujrat, Pakistan, Gujrat, Pakistan; ¹¹⁴⁴Ludwig Maximilian University of Munich, Munich, Germany; ¹¹⁴⁵Institute for Employment Research, Nuremberg, Germany; ¹¹⁴⁶Department of Oral and Maxillofacial Surgery, University College Hospital, Ibadan, Ibadan, Nigeria; ¹¹⁴⁷Campaign for Health and Neck Cancer Education (CHANCE) Programme, Cephas Health Research Initiative Inc, Ibadan, Nigeria; ¹¹⁴⁸Faculty of Pharmacy, Mansoura University, Mansoura, Egypt; ¹¹⁴⁹Mark and Mary Stevens Neuroimaging and Informatics Institute, University of Southern California, Los Angeles, CA, USA; ¹¹⁵⁰Public Health and Community Medicine Department, Cairo University, Giza, Egypt; ¹¹⁵¹Technology Management Department, University College of Applied Sciences, Gaza, Palestine;

¹¹⁵²Department of Neurology, Charité University Medical Center Berlin, Berlin, Germany; ¹¹⁵³Department of Neurology, University of Southern Denmark, Odense, Denmark; ¹¹⁵⁴Department of Anatomy, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates; ¹¹⁵⁵Department of Entomology, Ain Shams University, Cairo, Egypt; ¹¹⁵⁶Medical Ain Shams Research Institute (MASRI), Ain Shams University, Cairo, Egypt; ¹¹⁵⁷Department of Surgery, Marshall University, Huntington, WV, USA; ¹¹⁵⁸Department of Nutrition and Preventive Medicine, Case Western Reserve University, Cleveland, OH, USA; ¹¹⁵⁹Department of Pediatrics, Pravara Institute of Medical Sciences, Loni, India; ¹¹⁶⁰School of Public Health and Health Management, University of Belgrade, Belgrade, Serbia; ¹¹⁶¹Research Development Coordination Section, Pakistan Health Research Council, Islamabad, Pakistan; ¹¹⁶²School of Sciences, University of Management and Technology, Lahore, Pakistan; ¹¹⁶³Pharmacy Study Program, Udayana University, Badung, Indonesia; ¹¹⁶⁴Department of Clinical Pharmacy, Taipei Medical University, Taipei, Taiwan; ¹¹⁶⁵Department of Pharmacology and Research, All India Institute of Medical Sciences, Jodhpur, India; ¹¹⁶⁶Indira Gandhi Medical College and Research Institute, Puducherry, India; ¹¹⁶⁷Department of Public Health, Jahrom University of Medical Sciences, Jahrom, Iran; ¹¹⁶⁸Department of Food Processing Technology, West Bengal State Council of Technical Education, Malda, India; ¹¹⁶⁹Department of Health and Society, University of Applied and Environmental Sciences, Bogota, Colombia; ¹¹⁷⁰National School of Public Health, Carlos III Health Institute, Madrid, Spain; ¹¹⁷¹Department of Oral Pathology and Microbiology, Dr. D.Y. Patil University, Pune, India; ¹¹⁷²Department of Oral Pathology and Microbiology, Dr. D.Y. Patil Dental College and Hospital, Pune, India; ¹¹⁷³Department of Family and Preventive Medicine, Emory University, Atlanta, GA, USA; ¹¹⁷⁴Department of Medicine, Bangalore Medical College and Research Institute, Bangalore, India; ¹¹⁷⁵Department of Public Health Sciences, University of North Carolina at Charlotte, Charlotte, NC, USA; ¹¹⁷⁶Education Development Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; ¹¹⁷⁷Department of Neurology, National and Kapodistrian University of Athens, Athens, Greece; ¹¹⁷⁸Department of Neurology, Columbia University, New York, NY, USA; ¹¹⁷⁹Cardiovascular Research Center, Massachusetts General Hospital, Cambridge, MA, USA; ¹¹⁸⁰Department of Cardiovascular Sciences, Katholieke Universiteit Leuven, Leuven, Belgium; ¹¹⁸¹The George Institute for Global Health, Sydney, NSW, Australia; ¹¹⁸²Department of Psychology, University of Alabama at Birmingham, Birmingham, AL, USA; ¹¹⁸³Department of Microbiology, Kurdistan University of Medical Sciences, Sanandaj, Iran; ¹¹⁸⁴Department of Population and Health, University of Cape Coast, Cape Coast, Ghana; ¹¹⁸⁵College of Public Health, Medical and Veterinary Sciences, James Cook University, Townsville, QLD, Australia; ¹¹⁸⁶Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran; ¹¹⁸⁷Faculty of Medicine, Bioscience and Nursing, MAHSA University, Jenjarom, Malaysia; ¹¹⁸⁸Department of Medical Sciences, Bharath Institute of Higher Education and Learning (BIHER), Chennai, India; ¹¹⁸⁹Emergency Department, Manian Medical Centre, Erode, India; ¹¹⁹⁰Department of Medicine and Surgery, Government Doon Medical College, Dehradun, India; ¹¹⁹¹Endocrinology and Metabolism Research Center (EMRC), Tehran University of Medical Sciences, Tehran, Iran; ¹¹⁹²National Heart, Lung, and Blood Institute, National Institute of Health, Rockville, MD, USA; ¹¹⁹³Department of Community Health, Aja University of Medical Sciences, Tehran, Iran; ¹¹⁹⁴Sina Trauma Research Center, Tehran University of Medical Sciences, Tehran, Iran; ¹¹⁹⁵Department of Infectious Diseases and Microbiology, Rajiv Gandhi University of Health Sciences, Bangalore, India; ¹¹⁹⁶HepatoPancreatoBiliary Surgery and Liver Transplant Department, Healthcare Global Limited Cancer Care Hospital, Bangalore, India; ¹¹⁹⁷Department of Medicine, Tehran University of Medical Sciences, Tehran, Iran; ¹¹⁹⁸Division of Preventive Cardiology, Houston Methodist Academic Institute, Houston, TX, USA; ¹¹⁹⁹Institute of Molecular Biology and Biotechnology (IMBB), The University of Lahore, Lahore, Pakistan; ¹²⁰⁰Research Centre for Health Sciences (RCHS), The University of Lahore, Lahore, Pakistan; ¹²⁰¹Department of Physics, The University of Lahore, Lahore, Pakistan; ¹²⁰²Department of Clinical Sciences, Al-Quds University, Ajman, United Arab Emirates; ¹²⁰³Independent Consultant, Karachi, Pakistan; ¹²⁰⁴Department of Pathology and Laboratory Medicine, Northwell Health, New York

City, NY, USA; ¹²⁰⁵Department of Health Education and Promotion, Jazan University, Jazan, Saudi Arabia; ¹²⁰⁶Department of Clinical Review and Safety, Baim Institute for Clinical Research, Boston, MA, USA; ¹²⁰⁷Beth Israel Deaconess Medical Center, Harvard University, Boston, MA, USA; ¹²⁰⁸Department of Pharmaceutical Care, Tehran University of Medical Sciences, Tehran, Iran; ¹²⁰⁹Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran; ¹²¹⁰Facultad de Medicina, Universidad del Azuay (Faculty of Medicine, University of Azuay), Cuenca, Ecuador; ¹²¹¹Department of Medical Oncology, Kent Hospital, Warwick, RI, USA; ¹²¹²Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia; ¹²¹³Department of Physiotherapy, Kathmandu University, Dhulikhel, Nepal; ¹²¹⁴Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, India; ¹²¹⁵Institute of Forensic Science & Criminology, Panjab University, Chandigarh, India; ¹²¹⁶Centre for Medical Informatics, University of Edinburgh, Edinburgh, UK; ¹²¹⁷Division of General Internal Medicine, Harvard University, Boston, MA, USA; ¹²¹⁸Department of Public Health, Dambi Dollo University, Dembi Dollo, Ethiopia; ¹²¹⁹National Institute of Infectious Diseases, Tokyo, Japan; ¹²²⁰Korea University, Seoul, South Korea; ¹²²¹Finnish Institute of Occupational Health, Helsinki, Finland; ¹²²²Washington State University, Pullman, WA, USA; ¹²²³Department of Veterinary Public Health and Preventive Medicine, Usmanu Danfodiyo University, Sokoto, Sokoto, Nigeria; ¹²²⁴Center for Environmental and Respiratory Health Research, University of Oulu, Oulu, Finland; ¹²²⁵National Institute of Environmental Health Sciences, National Health Research Institutes, Miaoli, Taiwan; ¹²²⁶Department of Public Health Dentistry, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, India; ¹²²⁷School of Pharmacy, Monash University, Selangor Darul Ehsan, Malaysia; ¹²²⁸The Cooper Institute, Dallas, TX, USA; ¹²²⁹Department of Pediatrics and Child Health Nursing, Dilla University, Dilla, Ethiopia; ¹²³⁰Department of Psychology, Reykjavik University, Reykjavik, Iceland; ¹²³¹Department of Health and Behavior Studies, Columbia University, New York, NY, USA; ¹²³²School of Health, Victoria University of Wellington, Wellington, New Zealand; ¹²³³Usher Institute, University of Edinburgh, Edinburgh, UK; ¹²³⁴Department of Dentistry, All India Institute of Medical Sciences, Bhopal, India; ¹²³⁵Department of Geography, Banaras Hindu University, Varanasi, India; ¹²³⁶School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; ¹²³⁷Medicine Service, US Department of Veterans Affairs (VA), Birmingham, AL, USA; ¹²³⁸Department of Radiodiagnosis, All India Institute of Medical Sciences, Bathinda, India; ¹²³⁹Department of Food Science and Technology, Dr YSP College of Horticulture and Forestry, Solan, India; ¹²⁴⁰Maternal and Child Health Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh; ¹²⁴¹Clinical Branch, Moscow Research and Practical Centre on Addictions, Moscow, Russia; ¹²⁴²Addiction Psychiatry Department, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; ¹²⁴³Department of Infectious Diseases and Epidemiology, Pirogov Russian National Research Medical University, Moscow, Russia; ¹²⁴⁴Division of Injury Prevention, The Bizzell Group, Atlanta, GA, USA; ¹²⁴⁵Rollins School of Public Health, Emory University, Atlanta, GA, USA; ¹²⁴⁶Faculty of Public Health, Universitas Ahmad Dahlan, Yogyakarta, Indonesia; ¹²⁴⁷Department of Medicinal Chemistry, University of Sharjah, Sharjah, United Arab Emirates; ¹²⁴⁸Sociology Department, University of Wisconsin Oshkosh, Oshkosh, WI, USA; ¹²⁴⁹Department of Health Policy and Management, University of Georgia College of Public Health, Athens, GA, USA; ¹²⁵⁰Institute of Child and Adolescent Health, Peking University, Beijing, China; ¹²⁵¹Hospital Universitario de La Princesa (Princess University Hospital), Autonomous University of Madrid, Madrid, Spain; ¹²⁵²Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES) (Center for Biomedical Research in Respiratory Diseases Network), Madrid, Spain; ¹²⁵³3rd Department of Cardiology, University of Athens, Athens, Greece; ¹²⁵⁴Division of Community Medicine, International Medical University, Kuala Lumpur, Malaysia; ¹²⁵⁵Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece; ¹²⁵⁶National Institute of Epidemiology, Indian Council of Medical Research, Chennai, India; ¹²⁵⁷Mental Health Research, Independent Consultant, Khulna, Bangladesh; ¹²⁵⁸Division of Global Mental Health, EviSyn Health, Khulna, Bangladesh; ¹²⁵⁹Analytical and Applied Economics Department, Utkal University,

Bhubaneswar, India; ¹²⁶⁰Department of Neurology, Università degli Studi di Milano Bicocca, Monza, Italy; ¹²⁶¹Department of Medical Informatics, Mashhad University of Medical Sciences, Mashhad, Iran; ¹²⁶²Clinical Research Development Unit, Mashhad University of Medical Sciences, Mashhad, Iran; ¹²⁶³Department of Basic Medical Sciences, Islamic Azad University, Mashhad, Iran; ¹²⁶⁴Department of Internal Medicine, Islamic Azad University, Mashhad, Iran; ¹²⁶⁵Department of Medical Education, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ¹²⁶⁶School of Social Work, University of Illinois, Urbana, IL, USA; ¹²⁶⁷Department of Pharmacology, Shaqra University, Shaqra, Saudi Arabia; ¹²⁶⁸Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan; ¹²⁶⁹Department of Epidemiology and Biostatistics, Wollo University, Dessie, Ethiopia; ¹²⁷⁰Living Systems Institute, University of Exeter, Exeter, UK; ¹²⁷¹Department of Environmental, Agricultural and Occupational Health, University of Nebraska Medical Center, Omaha, NE, USA; ¹²⁷²Pathology Department, Alexandria University, Alexandria, Egypt; ¹²⁷³Department of Dermato-Venereology, Dr. Victor Babes Clinical Hospital of Infectious Diseases and Tropical Diseases, Bucharest, Romania; ¹²⁷⁴Department of Epidemiology, Stellenbosch University, Cape Town, South Africa; ¹²⁷⁵Department of Medicine, Northlands Medical Group, Omuthiya, Namibia; ¹²⁷⁶State Key Laboratory of Numerical Modeling for Atmospheric Sciences and Geophysical Fluid Dynamics (LASG), Chinese Academy of Sciences, Beijing, China; ¹²⁷⁷Department of Population and Behavioural Sciences, University of Health and Allied Sciences, Ho, Ghana; ¹²⁷⁸Department of Economics, Rice University, Houston, TX, USA; ¹²⁷⁹Department of Research and Innovation, Enventure Medical Innovation, Houston, TX, USA; ¹²⁸⁰Department of Pathology, Tehran University of Medical Sciences, Tehran, Iran; ¹²⁸¹Department of health Education & Health Promotion, Mashhad University of Medical Sciences, Mashhad, Iran; ¹²⁸²Department of Urology, Sabzevar University of Medical Sciences, Sabzevar, Iran; ¹²⁸³Pediatric Intensive Care Unit, King Saud University, Riyadh, Saudi Arabia; ¹²⁸⁴College of Pharmacy, Alfaisal University, Riyadh, Saudi Arabia; ¹²⁸⁵Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA; ¹²⁸⁶Department of Pharmacology, All India Institute of Medical Sciences, Raipur, India; ¹²⁸⁷Public Health Department, Amrita Institute of Medical Sciences, Kochi, India; ¹²⁸⁸Department of Medicine, Monash Health, Melbourne, VIC, Australia; ¹²⁸⁹Monitoring and Evaluation, Nepal Development Society, Kathmandu, Nepal; ¹²⁹⁰Department of Pediatrics, University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH, USA; ¹²⁹¹Division of Pediatric Gastroenterology, Case Western Reserve University, Cleveland, OH, USA; ¹²⁹²Institute of Applied Health Research, University of Birmingham, Birmingham, UK, UK; ¹²⁹³Faculty of Medicine, University of Southampton, Southampton, UK; ¹²⁹⁴Department of Gastroenterology, PSG Institute of Medical Sciences and Research, Coimbatore, India; ¹²⁹⁵Faculty of Biomedical Engineering, Czech Technical University, Prague, Czech Republic; ¹²⁹⁶Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, UK; ¹²⁹⁷Department of Medicine, University of Calgary, Calgary, AB, Canada; ¹²⁹⁸Institute of Public Health, Jagiellonian University Medical College, Kraków, Poland; ¹²⁹⁹Agency for Health Technology Assessment and Tariff System, Warsaw, Poland; ¹³⁰⁰Nutritional Epidemiology Research Team EREN, National Institute for Health and Medical Research INSERM, Paris, France; ¹³⁰¹Department of Health, Medicine and Human Biology, Sorbonne Paris Nord University, Bobigny, France; ¹³⁰²Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, India; ¹³⁰³SRM College of Pharmacy, SRM Institute of Science and Technology (SRMIST), Chennai, India; ¹³⁰⁴School of Medicine, Indiana University, Indianapolis, IN, USA; ¹³⁰⁵Department of Health, Children's Hospital 1, Ho Chi Minh City, Viet Nam; ¹³⁰⁶Department of Medicine, Tra Vinh University, Tra Vinh City, Viet Nam; ¹³⁰⁷Division of Cardiovascular Medicine, University of Louisville, Louisville, KY, USA; ¹³⁰⁸Adult Learning Disability Service, Leicestershire Partnership National Health Service Trust, Leicester, UK; ¹³⁰⁹Internal Medicine Department, Nazareth Hospital, Philadelphia, PA, USA; ¹³¹⁰School of Medicine, Nam Can Tho University, Can Tho, Viet Nam; ¹³¹¹Department of Medicine, University of Crete, Heraklion, Greece; ¹³¹²Department of Nursing, Aksum University, Aksum, Ethiopia; ¹³¹³Department of Psychiatry, Dalhousie University, Halifax, NS, Canada;

¹³¹⁴Department of Physiology, East Carolina University, Greenville, NC, USA; ¹³¹⁵Diabetes & Obesity Institute and physiology, East Carolina University, Greenville, NC, USA; ¹³¹⁶Department of Public Health, East Carolina University, Greenville, NC, USA; ¹³¹⁷College of Public Health, Temple University, Philadelphia, PA, USA; ¹³¹⁸Department of Biosciences and Biotechnology, University of Medical Sciences, Ondo, Ondo, Nigeria; ¹³¹⁹Department of Health and Community Sciences, University of Exeter, Exeter, UK; ¹³²⁰Natural and Medical Sciences Research Center, University of Nizwa Oman, Nizwa, Oman, Oman; ¹³²¹Department of Zoology, University of Education, Lahore, Lahore, Pakistan; ¹³²²Division of Science and Technology, University of Education, Lahore, Lahore, Pakistan; ¹³²³Medical Genomics Research Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; ¹³²⁴Department of Life Sciences, University of Management and Technology, Lahore, Pakistan; ¹³²⁵Division of Surgery and Interventional Science, University College London, London, UK; ¹³²⁶Department of Cardiovascular, Endocrine-metabolic Diseases and Aging, National Institute of Health, Rome, Italy; ¹³²⁷Kasturba Medical College, Manipal Academy of Higher Education, Mangalore, India; ¹³²⁸Department of Physiotherapy, Bayero University, Kano, Kano, Nigeria; ¹³²⁹College of Health and Sport Sciences, University of Bahrain, Salmayya, Bahrain; ¹³³⁰Urmia University of Medical Sciences, Urmia, Iran; ¹³³¹Department. of Public Health and Epidemiology, University of Debrecen, Debrecen, Hungary; ¹³³²Department of Periodontology, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, India; ¹³³³Department of Internal Medicine, University of Groningen, Groningen, Netherlands; ¹³³⁴UKK Institute, Tampere, Finland; ¹³³⁵Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; ¹³³⁶Department of Zoology, Central University of Punjab, Bathinda, India; ¹³³⁷Department of Human Genetics & Molecular Biology, Bharathiar University, Coimbatore, India; ¹³³⁸Department of Health Policy and Management, Johns Hopkins University, Baltimore, MD, USA; ¹³³⁹Occupational Health Unit, Sant'Orsola Malpighi Hospital, Bologna, Italy; ¹³⁴⁰Division of Cardiology, Johns Hopkins University, Baltimore, MD, USA; ¹³⁴¹Department of Medical Oncology, University of Medicine and Pharmacy "Grigore T Popa" Iasi, Iași, Romania; ¹³⁴²Department of Medical Oncology, Regional Institute of Oncology, Iași, Romania; ¹³⁴³Faculty of Medicine Institute of Epidemiology, University of Belgrade, Belgrade, Serbia; ¹³⁴⁴School of Population Health and Environmental Sciences, King's College London, London, UK; ¹³⁴⁵Brown School, Washington University in St. Louis, St. Louis, MO, USA; ¹³⁴⁶Department of Surgery, Washington University in St. Louis, St. Louis, MO, USA; ¹³⁴⁷School of Public Health, Xuzhou Medical University, Xuzhou, China; ¹³⁴⁸Cardiovascular Department, The George Institute for Global Health, Sydney, NSW, Australia; ¹³⁴⁹Cardiology Department, University of Sydney, Sydney, NSW, Australia; ¹³⁵⁰Department of Neurosurgery, Capital Medical University, Beijing, China; ¹³⁵¹General Internal Medicine and Health Services Research, University of California Los Angeles, Los Angeles, CA, USA; ¹³⁵²Department of Medicine, Greater Los Angeles VA Healthcare System, Los Angeles, CA, USA; ¹³⁵³Demographic Change and Aging Research Area, Federal Institute for Population Research, Wiesbaden, Germany; ¹³⁵⁴Department of Community Medicine, Rajarata University of Sri Lanka, Anuradhapura, Sri Lanka; ¹³⁵⁵Department of Neurology, University of Melbourne, Melbourne, VIC, Australia; ¹³⁵⁶Department of Medicine, University of Rajarata, Saliyapura Anuradhapuraya, Sri Lanka; ¹³⁵⁷Department of Nursing, Universitas Aisyiyah Bandung, Bandung, Indonesia; ¹³⁵⁸NIHR Biomedical Research Centre, Guy's and St. Thomas' Hospital and Kings College London, London, UK; ¹³⁵⁹Global Health and Health Security department, Taipei Medical University, Taipei, Taiwan; ¹³⁶⁰Division of Gastroenterology, Huazhong University of Science and Technology, Wuhan, China; ¹³⁶¹School of Public Health, Zhejiang University, Zhejiang, China; ¹³⁶²Department of Public Health Science, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ¹³⁶³Department of Endocrinology, University of Science and Technology of China, Hefei, China; ¹³⁶⁴School of Medicine, University of Rochester, Rochester, NY, USA; ¹³⁶⁵Cardiovascular Program, The George Institute for Global Health, Sydney, NSW, Australia; ¹³⁶⁶Australian Institute of Health Innovation, Macquarie University, Macquarie Park, NSW, Australia; ¹³⁶⁷Department of Family Medicine and Community Health, Duke University, Durham, IL, USA; ¹³⁶⁸Research Center of Physiology,

Semnan University of Medical Sciences, Semnan, Iran; ¹³⁶⁹Department of Social Preventive Medical Sciences, Chiba University, Chiba, Japan; ¹³⁷⁰Department of Gerontological Evaluation, National Center for Geriatrics and Gerontology, Obu, Japan; ¹³⁷¹The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA; ¹³⁷²National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China; ¹³⁷³The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia; ¹³⁷⁴Department of Family Medicine, St. Peter's Specialized Hospital, Addis Ababa, Ethiopia; ¹³⁷⁵Independent Consultant, Addis Ababa, Ethiopia; ¹³⁷⁶Biostatistics, Epidemiology, and Science Computing Department, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia; ¹³⁷⁷Department of Health Management, Süleyman Demirel Üniversitesi (Süleyman Demirel University), Isparta, Türkiye; ¹³⁷⁸Department of Public Health, Wollega University, Nekemte, Ethiopia; ¹³⁷⁹Department of Pediatrics, Kyung Hee University, Seoul, South Korea; ¹³⁸⁰Department of Neuropsychopharmacology, National Center of Neurology and Psychiatry, Kodaira, Japan; ¹³⁸¹Department of Public Health, Juntendo University, Tokyo, Japan; ¹³⁸²Department of Environmental Health, Mazandaran University of Medical Sciences, Sari, Iran; ¹³⁸³Department of Neurology, University Hospital Antwerp, Antwerp, Belgium; ¹³⁸⁴Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; ¹³⁸⁵Department of Epidemiology and Biostatistics, Wuhan University, Wuhan, China; ¹³⁸⁶Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina, Columbia, SC, USA; ¹³⁸⁷Department of Medical Genetics, Mashhad University of Medical Sciences, Mashhad, Iran; ¹³⁸⁸Department of Pulmonary and Critical Care Medicine, Tehran University of Medical Sciences, Baltimore, MD, USA; ¹³⁸⁹Faculty of Medicine and Health Sciences, Hodeidah University, Hodeidah, Yemen; ¹³⁹⁰Department of Virology, University of Helsinki, Helsinki, Finland; ¹³⁹¹Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA; ¹³⁹²Addictology Department, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; ¹³⁹³Department of GI Medical Oncology, University of Texas, Houston, FL, USA; ¹³⁹⁴School of Population and Global Health, University of Western Australia, Perth, WA, Australia; ¹³⁹⁵Department of Anesthesiology, Central South University, Changsha, China; ¹³⁹⁶Department of Epidemiology and Biostatistics, Ministry of Public Health, Hefei, China; ¹³⁹⁷Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China; ¹³⁹⁸Department of Neurology, Capital Medical University, Beijing, China; ¹³⁹⁹National Center for Neurological Diseases, Capital Medical University, Beijing, China; ¹⁴⁰⁰School of Public Health, Peking University, Beijing, China; ¹⁴⁰¹Department of International Health, Johns Hopkins University, Baltimore, MD, USA; ¹⁴⁰²Cardiovascular Diseases Centre, China Academy of Chinese Medical Sciences, Beijing, China; ¹⁴⁰³Medical Oncology Department of Gastrointestinal Cancer, Cancer Hospital of Dalian University of Technology, Shenyang, China; ¹⁴⁰⁴School of Biomedical Engineering, Faculty of Medicine, Dalian University of Technology, Dalian, China; ¹⁴⁰⁵School of Public Policy and Administration, Xi'an Jiaotong University, Xi'an, China; ¹⁴⁰⁶School of Public Health, Wuhan University of Science and Technology, Wuhan, China; ¹⁴⁰⁷Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Wuhan University of Science and Technology, Wuhan, China; ¹⁴⁰⁸College of Traditional Chinese Medicine, Hebei University, Baoding, China; ¹⁴⁰⁹School of Public Health and Emergency Management, Southern University of Science and Technology, Shenzhen, China; ¹⁴¹⁰School of Life Sciences, Yunnan University, Kunming, China; ¹⁴¹¹Department of Biochemistry and Pharmacogenomics, Medical University of Warsaw, Warsaw, Poland; ¹⁴¹²Department of Anatomy, Addis Ababa University, Addis Ababa, Ethiopia; ¹⁴¹³Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA; ¹⁴¹⁴Department of Infection, University College London, London, UK; ¹⁴¹⁵NIHR-Biomedical Research Centre (NIHR-BRC), University College London Hospitals, London, UK; ¹⁴¹⁶Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital Duesseldorf, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany; ¹⁴¹⁷Center of Medical and Bio-Allied Health Sciences Research (CMBHSR), Ajman University, Ajman, United Arab Emirates; ¹⁴¹⁸School of Physics, Universiti Sains Malaysia, Penang,

Malaysia; ¹⁴¹⁹Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA; ¹⁴²⁰Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; ¹⁴²¹Division of Cardiology, University of Washington, Seattle, WA, USA.

Authors' Contributions

Providing data or critical feedback on data sources

Yohannes Habtegiorgis Abate, Ashkan Abdollahi, Auwal Abdullahi, Aidin Abedi, Armita Abedi, Hiwa Abubaker Ali, Niveen M.E. Abu-Rmeileh, Abdelrahman I. Abushouk, Ahmed Abu-Zaid, Oladimeji M. Adebayo, Qorinah Estiningtyas Sakilah Adnani, Saira Afzal, Pradyumna Agasthi, Antonella Agodi, Constanza Elizabeth Aguilera Arriagada, Bright Opoku Ahinkorah, Muayyad M. Ahmad, Ayman Ahmed, Haroon Ahmed, Muktar Beshir Ahmed, Alaa Alashi, Mohammed Albashtawy, Mohammad T AlBataineh, Haileselesie Berhane Alema, Yihun Mulugeta Alemu, Rafat Ali, Syed Shujait Shujait Ali, Gianfranco Alicandro, Syed Mohamed Aljunid, François Alla, Farrukh Jawad Alvi, Nelson Alvis-Guzman, Nelson J. Alvis-Zakzuk, Hassan Alwafi, Hany Aly, Golnoosh Ansari, Geminn Louis Carace Apostol, Jalal Arabloo, Olatunde Aremu, Johan Ärnlöv, Anton A. Artamonov, Kurnia Dwi Artanti, Judie Arulappan, Alok Atreya, Amdehiwot A. Aynalem, Zahra Azizi, Ahmed Y. Azzam, Ashish D. Badiye, Arvind Bagga, Sara Bagherieh, Abdulaziz T. Bako, Ovidiu Constantin Baltatu, Maciej Banach, Biswajit Banik, Palash Chandra Banik, Martina Barchitta, Mainak Bardhan, Till Winfried Bärnighausen, Nebiyu Simegnew Bayileyeegn, Emad Behboudi, Yannick Béjot, Sefealem Assefa Belay, Melaku Ashagrie Belete, Uzma Iqbal Belgaumi, Michelle L. Bell, Salaheddine Bendak, Derrick A. Bennett, Catherine P. Benziger, Adam E. Berman, Habtamu B. Beyene, Akshaya Srikanth Srikanth Bhagavathula, Vivek Bhat, Gurjit Kaur Bhatti, Jasvinder Singh Bhatti, Boris Bikbov, Bijit Biswas, Aadam Olalekan Bodunrin, Archith Boloor, Milad Bonakdar Hashemi, Hamed Borhany, Dejana Braithwaite, Luisa C. Brant, Michael Brauer, Lemma N. Bulto, Juan J. Carrero, Joao Mauricio Castaldelli-Maia, Carlos A. Castañeda-Orjuela, Vijay Kumar Chattu, Abdulaal Chitheer, William C. S. Cho, Bryan Chong, Hitesh Chopra, Rajiv Chowdhury, Dinh-Toi Chu, Alyssa Columbus, Paolo Angelo Cortesi, Rosa A. S. Couto, Michael H. Criqui, Xiaochen Dai, Albertino Antonio Moura Damasceno, Giovanni Damiani, Saswati Das, Maedeh Dastmardi, Aklilu Tamire Debele, Andreas K. Demetriades, Nebiyu Dereje Dereje, Awoke Masrie Asrat Derese, Hardik Dineshbhai Desai, Rupak Desai, Vishal R. Dhulipala, Michael J. Diaz, Thanh Chi Do, Thao Huynh Phuong Do, Wendel Mombaqué dos Santos, Abdel Douiri, Ashel Chelsea Dsouza, Haneil Larson Dsouza, Mi Du, Andre Rodrigues Duraes, Sulagna Dutta, Ebrahim Eini, Michael Ekholuenetale, Temitope Cyrus Ekundayo, Iman El Sayed, Islam Y. Elgendy, Ryenchindorj Erkhembayar, Tesfahun C. Eshetie, Adeniyi Francis Fagbamigbe, Carla Sofia e Sá Farinha, Andre Faro, Abidemi Omolara Fasanmi, Ali Fatehizadeh, Valery L. Feigin, Seyed-Mohammad Fereshtehnejad, Abdullah Hamid Feroze, David Flood, Artem Alekseevich Fomenkov, Richard Charles Franklin, Takeshi Fukumoto, Peter Andras Gaal, Muktar A. Gadanya, Shilpa Gaidhane, Emmanuela Gakidou, Yaseen Galali, Kahsu Gebrekirstos Gebrekidan, Johanna M. Geleijnse, Ramy Mohamed Ghazy, Arun Digambarrao Ghuge, Ali Golchin, Pouya Goleij, Kashish Goyal, Mesay Dechasa Gudeta, Avirup Guha, Bhawna Gupta, Rajat Das Gupta, Renu Gupta, Sapna Gupta, Veer Bala Gupta, Vijai Kumar Gupta, Vivek Kumar Gupta, Lami Gurmessa, Aram Halimi, Rabih Halwani, Nadia M Hamdy, Chieh Han, Arief Hargono, Josep Maria Haro, Faizul Hasan, Maryam Hashemian, Simon I. Hay, Claudiu Herteliu, Hamed Hesami, Kamran Hessami, Nguyen Quoc Hoan, Md Mahbub Hossain, Mehdi Hosseinzadeh, Hong-Han Huynh, Khalid S. Ibrahim, Sheikh Mohammed Shariful Islam, Nahlah Elkudssiah Ismail, Gaetano Isola, Linda Merin J, Jalil Jaafari, Khusheen Jaggi, Haitham Jahrami, Nityanand Jain, Mihajlo Jakovljevic, Sathish Kumar Jayapal, Shubha Jayaram, Yinzi Jin, Yash B. Jobanputra, Catherine Owens Johnson, Tamas Joo, Abel Joseph, Nitin Joseph, Charity Ehimwenma Joshua, Jacek Jerzy Jozwiak, Mikk Jürisson, Zubair Kabir, Vidya Kadashetti, Laleh R. Kalankesh, Himal Kandel, Prabin Karki, Faizan Zaffar Kashoo, Eskeziaw Abebe Kassahun, Nicholas J. Kassebaum, Patrick D. M. C. Katoto, Neda Kaydi, Morteza Abdullatif Khafaie, Himanshu Khajuria, Nauman Khalid, Rovshan Khalilov, Asaduzzaman Khan, Ejaz Ahmad Khan, Maseer

Khan, Mohammad Jobair Khan, Yusra H. Khan, Mahammed Ziauddin Khan suheb, Khaled Khatab, Sorour Khateri, Feriha Fatima Khidri, Saeid Kian, Adnan Kisa, Sezer Kisa, Gerbrand Koren, Kewal Krishan, Hare Krishna, Vijay Krishnamoorthy, Yuvaraj Krishnamoorthy, Mohammed Kuddus, Akshay Kumar, Kunle Rotimi Kunle, Dian Kusuma, Ilias Kyriopoulos, Muhammad Awwal Ladan, Chandrakant Lahariya, Tea Lallukka, Anders O. Larsson, Savita Lasrado, Kamaluddin Latief, Kaveh Latifinaibin, Nhi Huu Hanh Le, Thao Thi Thu Le, Trang Diep Thanh Le, Trang Thi Bich Le, Caterina Ledda, Munjae Lee, Seung Won Lee, Kate E. LeGrand, Mall Leinsalu, Xiaopan Li, Yichong Li, Lee-Ling Lim, Stephen S. Lim, Megan Lindstrom, Gang Liu, Simin Liu, Xuefeng Liu, Erand Llanaj, László Lorenzovici, Stefan Lorkowski, Zheng Feei Ma, Omar Mohamed Makram, Elaheh Malakan Rad, Kashish Malhotra, Muhammad Sajeel Ahmed Malik, Tauqeer Hussain Mallhi, Deborah Carvalho Malta, Aseer Manilal, Borhan Mansouri, Mohammad Ali Mansournia, Sharmeen Maryam, Roy Rillera Marzo, Clara N Matei, Jishanth Mattumpuram, Andrea Maugeri, Mohsen Mazidi, Enkeleint A. Mechili, Jitendra Kumar Meena, Walter Mendoza, Ritesh G. Menezes, Haftu Asmerom Meresa, Atte Meretoja, Irmina Maria Michalek, Le Huu Nhat Minh, Erkin M. Mirrakhimov, Moonis Mirza, Mohammad Mirza-Aghazadeh-Attari, Soheil Mohammadi, Mustapha Mohammed, Salahuddin Mohammed, Shafiu Mohammed, Nagabhishek Moka, Ali H. Mokdad, Sara Momtazmanesh, Lorenzo Monasta, Yousef Moradi, Jakub Morze, Ebrahim Mostafavi, Vincent Mougine, Ahmed Msherghi, Ulrich Otto Mueller, Sumoni Mukherjee, Kavita Munjal, Christopher J. L. Murray, Ghulam Mustafa, Julius C. Mwita, Ahamarshan Jayaraman Nagarajan, Shankar Prasad Nagaraju, Sreenivas Narasimha Swamy, Shumaila Nargus, Bruno Ramos Nascimento, Hadis Nasoori, Zuhair S. Natto, Muhammad Naveed, Biswa Prakash Nayak, Ionut Negoj, Ruxandra Irina Negoj, Reza Nejad Shahrokh Abadi, Dang H Nguyen, Phat Tuan Nguyen, Van Thanh Nguyen, Robina Khan Niazi, Muhammad A. Nizam, Shuhei Nomura, Bo Norrving, Jean Jacques Noubiap, Mpiko Ntsekhe, Dieta Nurrika, Chimezie Igwegbe Nzopotam, Ogochukwu Janet Nzopotam, Kehinde O. Obamiro, Martin James O'Donnell, Onome Bright Oghenetega, Ayodipupo Sikiru Oguntade, James Odhiambo Oguta, Osaretin Christabel Okonji, Patrick Godwin Okwute, Andrew T. Olagunju, Matthew Idowu Olatubi, Yinka Doris Oluwafemi, Mohammad Mehdi Ommati, Kanyin Liane Ong, Sokking Ong, Alberto Ortiz, Stanislav S. Otstavnov, Mayowa O. Owolabi, Mahesh Padukudru P A, Jagadish Rao Padubidri, Tamás Palicz, Raffaele Palladino, Seithikurippu R. Pandi-Perumal, Jay Patel, Shankargouda Patil, Venkata Suresh Patthipati, Shrikant Pawar, Amy E. Peden, Veincent Christian Filipino Pepito, Arokiasamy Perianayagam, Hoang Tran Pham, Anil K. Philip, David M. Pigott, Ramesh Poluru, Ghazaleh Pourali, Pranil Man Singh Pradhan, Elton Junio Sady Prates, Bharathi M. Purohit, Gangzhen Qian, Ibrar Rafique, Fakher Rahim, Md Jillur Rahim, Amir Masoud Rahmani, Sathish Rajaa, Ali Rajabpour-Sanati, Pradhun Ram, Prasanna Ram, Sudha Ramalingam, Shakthi Kumaran Ramasamy, Sheena Ramazan, Pushkal Sinduvadi Ramesh, Jewel Rana, Chhabi Lal Ranabhat, Nemanja Rancic, Amey Rane, Sowmya J. Rao, Sina Rashedi, Vahid Rashedi, Ahmed Mustafa Rashid, Zubair Ahmed Ratan, Nakul Ravikumar, Salman Rawaf, Christian Razo, Luis Felipe Reyes, Antonio Luiz P Ribeiro, Leonardo Roever, Luca Ronfani, Himanshu Sehar Sekhar Rout, Aly M. A. Saad, Siamak Sabour, Basema Saddik, Umar Saeed, Narjes Saheb Sharif-Askari, Mirza Rizwan Sajid, Marwa Rashad Salem, Sara Samadzadeh, Abdallah M. Samy, Juan Sanabria, Milena M. Santric-Milicevic, Gargi Sachin Sarode, Anudeep Sathyanarayan, Monika Sawhney, Mehdi Sayyah, David C. Schwebel, Pallav Sengupta, Subramanian Senthilkumaran, Yashendra Sethi, Allen Seylani, Masood Ali Shaikh, Sunder Sham, Javad Sharifi-Rad, Purva Sharma, Vishal Sharma, Aminu Shittu, K M Shivakumar, Sunil Shrestha, Kerem Shuval, Inga Dora Sigfusdottir, Abhinav Singh, Ambrish Singh, Jasvinder A. Singh, Paramdeep Singh, Rajat Singh, Valentin Yurievich Skryabin, Anna Aleksandrovna Skryabina, Solikhah Solikhah, Sameh S. M. Soliman, Michael Spartalis, Chandrashekhar T. Sreeramareddy, Lauryn K. Stafford, Benjamin A. Stark, Rizwan

Suliankatchi Abdulkader, Abida Sultana, Johan Sundström, Chandan Kumar Swain, Shima Tabatabai, Karen M. Tabb, Takahiro Tabuchi, Yasaman Taheri Abkenar, Mircea Tampa, Ker-Kan Tan, Elvis Enowbeyang Tarkang, Hadi Tehrani, Pugazhenthana Thangaraju, Nikhil Kenny Thomas, Ales Tichopad, Tala Tillawi, Roman Topor-Madry, Mathilde Touvier, Marcos Roberto Tovani-Palone, Jasmine T. Tran, Phu Van Tran, Avnish Tripathi, Aristidis Tsatsakis, Munkhtuya Tumurkhuu, Sana Ullah, Muhammad Umair, Tungki Pratama Umar, Bhaskaran Unnikrishnan, Era Upadhyay, Jibrin Sammani Usman, Asokan Govindaraj Vaithinathan, Jef Van den Eynde, Shoban Babu Varthya, Tommi Juhani Vasankari, Balachandar Vellingiri, Maria Viskadourou, Simona Ruxandra Volovat, Theo Vos, Nelson Wang, Shu Wang, Andrea Werdecker, Tissa Wijeratne, Charles D. A. Wolfe, Zenghong Wu, Hong Xiao, Suowen Xu, Dong Keon Yon, Naohiro Yonemoto, Zabihollah Yousefi, Chuanhua Yu, Ismaeel Yunusa, Farbod Zahedi Tajrishi, Mikhail Sergeevich Zastrozhin, Magdalena Zielińska, Yossef Teshome Zikarg, Mohammad Zmaili, and Alimuuddin Zumla

Developing methods or computational machinery

Ashkan Abdollahi, Armita Abedi, Hiwa Abubaker Ali, Qorinah Estiningtyas Sakilah Adnani, Saira Afzal, Bright Opoku Ahinkorah, Muktar Beshir Ahmed, Mohammed Albashtawy, Farrukh Jawad Alvi, Aleksandr Y. Aravkin, Judie Arulappan, Zahra Aryan, Ahmed Y Azzam, Gregory J. Bertolacci, Aadam Olalekan Bodunrin, Michael Brauer, Fan Cao, Sinclair Carr, Catherine S Chen, Kaleb Coberly, Rosa A. S. Couto, Emma Johnson Cowart, Jessica A. Cruz, Xiaochen Dai, Maedeh Dastmardi, Aklilu Tamire Debele, Awoke Masrie Asrat Derese, Hardik Dineshbhai Desai, Thanh Chi Do, Mi Du, Mehdi Emamverdi, Ali Fatehizadeh, Shilpa Gaidhane, Emmanuela Gakidou, Shi-Yang Guan, Chieh Han, Faizul Hasan, Simon I. Hay, Mohammad Heidari, Kamran Hessami, Mehdi Hosseinzadeh, Hong-Han Huynh, Khalid S. Ibrahim, Gaetano Isola, Linda Merin J, Haitham Jahrami, Sathish Kumar Jayapal, Catherine Owens Johnson, Daniel John Kapner, Faizan Zaffar Kashoo, Nicholas J. Kassebaum, Alireza Khalilian, Rovshan Khalilov, M Nuruzzaman Khan, Sorour Khateri, Feriha Fatima Khidri, Saeid Kian, Adnan Kisa, Chandrakant Lahariya, Nhi Huu Hanh Le, Thao Thi Thu Le, An Li, Megan Lindstrom, Erand Llanaj, Borhan Mansouri, Le Huu Nhat Minh, Moonis Mirza, Mustapha Mohammed, Salahuddin Mohammed, Ali H. Mokdad, Yousef Moradi, Dariush Mozaffarian, Ahmed Msherghi, Kavita Munjal, Phat Tuan Nguyen, Van Thanh Nguyen, Mohammad Mehdi Ommati, Michal Ordak, Hoang Tran Pham, Amir Masoud Rahmani, Chhabi Lal Ranabhat, Christian Razo, Gregory A. Roth, Himanshu Sehar Sekhar Rout, Umar Saeed, Abdallah M. Samy, Mehdi Sayyah, Austin E Schumacher, Mansour Sedighi, Javad Sharifi-Rad, Rajat Singh, Yi Song, Michael Spartalis, Lauryn K Stafford, Benjamin A. Stark, Chandan Kumar Swain, Mohammad Tabish, Tala Tillawi, Muhammad Umair, Shoban Babu Varthya, Theo Vos, Shu Wang, Shadrach Wilson, Zenghong Wu, Hanqing Zhao, Peng Zheng, Yossef Teshome Zikarg, and Leo Zucker Zoeckler

Providing critical feedback on methods or results

Yohannes Habtegiorgis Abate, Mohammadreza Abbasian, Foad Abd-Allah, Ashkan Abdollahi, Mohammad Abdollahi, Deldar Morad Abdulah, Auwal Abdullahi, Ayele Mamo Abebe, Aidin Abedi, Armita Abedi, Olugbenga Olusola Abiodun, Hiwa Abubaker Ali, Eman Abu-Gharbieh, Niveen ME Abu-Rmeileh, Salahdein Aburuz, Ahmed Abu-Zaid, Tigist Demssew Adane, Nicola J Adderley, Oladimeji M. Adebayo, Bashir Aden, Temitayo Esther Adeyeoluwa, Olorunsola Israel Adeyomoye, Qorinah Estiningtyas Sakilah Adnani, Fatemeh Afrashteh, Saira Afzal, Pradyumna Agasthi, Antonella Agodi, Constanza Elizabeth Aguilera Arriagada, Williams Agyemang-Duah, Bright Opoku Ahinkorah, Aqeel Ahmad, Danish Ahmad, Firdos Ahmad, Muayyad M Ahmad, Ayman Ahmed, Haroon Ahmed, Muktar Beshir Ahmed, Syed Anees Ahmed, Karolina Akinosoglou, Moein Ala, Tareq Mohammed Ali AL-Ahdal, Samer O. Alalalmeh, Ziyad Al-Aly, Nazmul Alam, Rasmieh Mustafa Al-amer, Alaa Alashi, Mohammed Albashtawy, Mohammad T.

AlBataineh, Haileselesie Berhane Alema, Sharifullah Alemi, Yihun Mulugeta Alemu, Adel Ali Saeed Al-Gheethi, Khalid F. Alhabib, Mohammed Usman Ali, Rafat Ali, Syed Shujait Shujait Ali, Gianfranco Alicandro, Reyhaneh Alikhani, Syed Mohamed Aljunid, Wael Almahmeed, Sabah Al-Marwani, Rajaa M. Al-Raddadi, Farrukh Jawad Alvi, Nelson Alvis-Guzman, Nelson J. Alvis-Zakzuk, Hassan Alwafi, Hany Aly, Prince M. Amegbor, Tarek Tawfik Amin, Alireza Amindarolzari, Mostafa Amini-Rarani, Sohrab Amiri, Enrico Ammirati, Tanu Anand, Robert Ancuceanu, Deanna Anderlini, Golnoosh Ansari, Anayochukwu Edward Anyasodor, Geminn Louis Carace Apostol, Jalal Arabloo, Mosab Arafat, Olatunde Aremu, Benedetta Armocida, Johan Ärnlov, Anton A. Artamonov, Kurnia Dwi Artanti, Judie Arulappan, Idowu Thomas Aruleba, Ashokan Arumugam, Mohammad Asghari-Jafarabadi, Thomas Astell-Burt, Mahshid Ataei, Mohammad Athar, Alok Atreya, Avinash Aujayeb, Adedapo Wasu Awotidebe, Amdehiwot A. Aynalem, Zahra Azizi, Ahmed Y. Azzam, Abraham Samuel Babu, Muhammad Badar, Feras Bader, Ashish D. Badiye, Arvind Bagga, Sara Bagherieh, Farshad Bahrami Asl, Ruhai Bai, Jennifer L. Baker, Shankar M. Bakkannavar, Abdulaziz T. Bako, Ravleen Kaur Bakshi, Saliu A. Balogun, Ovidiu Constantin Baltatu, Maciej Banach, Soham Bandyopadhyay, Palash Chandra Banik, Hamid Reza Baradaran, Franca Barbic, Martina Barchitta, Mainak Bardhan, Till Winfried Bärnighausen, Sandra Barteit, Lingkan Barua, Mohsen Bayati, Nebiyu Simegnew Bayileyegn, Emad Behboudi, Amir Hossein Behnoush, Sefaelem Assefa Belay, Melaku Ashagrie Belete, Uzma Iqbal Belgaumi, Michelle L. Bell, Bright Benfor, Derrick A. Bennett, Isabela M. Bensenor, Catherine P. Benziger, Azizullah Beran, Adam E. Berman, Amiel Nazer C. Bermudez, Habtamu B. Beyene, Akshaya Srikanth Srikanth Bhagavathula, Nikha Bhardwaj, Pankaj Bhardwaj, Prarthna V. Bhardwaj, Vivek Bhat, Gurjit Kaur Bhatti, Jasvinder Singh Bhatti, Boris Bikbov, Andras Bikov, Marina G. Birck, Bijit Biswas, Aadam Olalekan Bodunrin, Eyob Ketema Bogale, Kassawmar Angaw Bogale, Archith Bloor, Milad Bonakdar Hashemi, Hamed Borhany, Dejana Braithwaite, Luisa C Brant, Lemma N. Bulto, Yasser Bustanji, Zahid A. Butt, Fan Cao, Rosario Cárdenas, Sinclair Carr, Giulia Carreras, Márcia Carvalho, Joao Mauricio Castaldelli-Maia, Luca Cegolon, Ester Cerin, Yaacoub Chahine, Mei Yen Chan, Raymond N. C. Chan, Periklis Charalampous, Jaykaran Charan, Vijay Kumar Chattu, An-Tian Chen, Haowei Chen, Suma Sri Chennapragada, Derek S. Chew, So Mi Jemma Cho, William C. S. Cho, Bryan Chong, Hitesh Chopra, Rahul Choudhary, Enayet Karim Chowdhury, Rajiv Chowdhury, Dinh-Toi Chu, Isaac Sunday Chukwu, Arrigo Francesco Giuseppe Cicero, Zinle Cindi, Sean Coffey, Alyssa Columbus, Joao Conde, Sara Conti, Barbara Corso, Sandra Cortés, Paolo Angelo Cortesi, Rosa A. S. Couto, Michael H. Criqui, Omid Dadras, Xiaochen Dai, Zhaoli Dai, Maxwell Ayindenaba Dalaba, Giovanni Damiani, Emanuele D'Amico, Saswati Das, Subasish Das, Mohsen Dashti, Mohammad Dashtkoohi, Maedeh Dastmardi, Kairat Davletov, Aklilu Tamire Debele, Shayom Debopadhaya, Ivan Delgado-Enciso, Juana Maria Delgado-Saborit, Berecha Hundessa Demessa, Andreas K. Demetriades, Xinlei Deng, Nebiyu Dereje Dereje, Awoke Masrie Asrat Derese, Hardik Dineshbhai Desai, Rupak Desai, Vinoth Gnana Chellaiyan Devanbu, Syed Masudur Rahman Dewan, Sourav Dey, Vishal R. Dhulipala, Daniel Diaz, Michael J. Diaz, Delaney D. Ding, Ricardo Jorge Dinis-Oliveira, Thanh Chi Do, Thao Huynh Phuong Do, Saeid Doaei, Wanyue Dong, Mario D'Oria, Wendel Mombaqué dos Santos, Abdel Douiri, Robert Kokou Dowou, Haneil Larson Dsouza, Viola Dsouza, Mi Du, Oyewole Christopher Durojaiye, Sulagna Dutta, Arkadiusz Marian Dziedzic, Alireza Ebrahimi, Defi Efendi, Diyan Ermawan Effendi, Ebrahim Eini, Michael Ekholuenetale, Temitope Cyrus Ekundayo, Iman El Sayed, Frank J Elgar, Muhammed Elhadi, Waseem El-Huneidi, Mehdi Emamverdi, Theophilus I. Emeto, Ryenchindorj Erkhembayar, Tesfahun C. Eshetie, Juan Espinosa-Montero, Farshid Etaee, Natalia Fabin, Ibtihal Fadhil, Adeniyi Francis Fagbamigbe, Luca Falzone, Carla Sofia e Sá Farinha, MoezAllIslam Ezzat Mahmoud Faris, Andre Faro, Mithila Faruque, Medhat Farwati, Ali Fatehizadeh, Pooria Fazeli, Valery L. Feigin, Xiaoqi Feng, Seyed-Mohammad Fereshtehnejad, Abdullah Hamid Feroze, Irina Filip, David Flood,

Morenike Oluwatoyin Folayan, Artem Alekseevich Fomenkov, Matteo Foschi, Richard Charles Franklin, Takeshi Fukumoto, Blima Fux, Peter Andras Gaal, Muktar A. Gadanya, Shilpa Gaidhane, Abduzhappar Gaipov, Emmanuela Gakidou, Yaseen Galali, Aravind P. Gandhi, Balasankar Ganesan, Rupesh K. Gautam, Miglas W. W. Gebregergis, Johanna M. Geleijnse, Urge Gerema, Alireza Ghajar, Afsaneh Ghasemzadeh, Maryam Gholamalizadeh, Arun Digambarrao Ghuge, Paramjit Singh Gill, Tiffany K. Gill, Ali Golchin, Alessandra C. Goulart, Mesay Dechasa Gudeta, Avirup Guha, Stefano Guicciardi, David Gulisashvili, Damitha Asanga Gunawardane, Cui Guo, Anish Kumar Gupta, Bhawna Gupta, Indarchand Ratanlal Gupta, Kartik Gupta, Mohak Gupta, Rajat Das Gupta, Rajeev Gupta, Sapna Gupta, Veer Bala Gupta, Vijai Kumar Gupta, Vivek Kumar Gupta, Lami Gurmessa, Reyna Alma Gutiérrez, Farrokh Habibzadeh, Mostafa Hadei, Helia Sadat Haeri Boroojeni, Aram Halimi, Sebastian Haller, Rabih Halwani, Randah R. Hamadeh, Nadia M. Hamdy, Samer Hamidi, Chieh Han, Qixia Han, Arief Hargono, Faizul Hasan, Ikramul Hasan, Hamidreza Hasani, Md Saquib Hasnain, Ikrama Hassan, Johannes Haubold, Rasmus J. Havmoeller, Simon I. Hay, Khezhar Hayat, Youssef Hbid, Omar E. Hegazi, Tadele Yohannes Hegena, Mohammad Heidari, Bartosz Helfer, Brenda Yuliana Herrera-Serna, Claudiu Herteliu, Hamed Hesami, Kamran Hessami, Keyvan Heydari, Kamal Hezam, Yuta Hiraike, Nguyen Quoc Hoan, Ramesh Holla, Md Mahbub Hossain, Md. Belal Hossain, Hassan Hosseinzadeh, Mehdi Hosseinzadeh, Mohamed Hsairi, Michael Hultström, Hong-Han Huynh, Bing-Fang Hwang, Khalid S. Ibrahim, Olayinka Stephen Ilesanmi, Irena M. Ilic, Milena D. Ilic, Mustapha Immurana, Leebek Raja Inbaraj, Muhammad Iqhrammullah, Sheikh Mohammed Shariful Islam, Nahlah Elkudssiah Ismail, Gaetano Isola, Masao Iwagami, Linda Merin J, Jalil Jaafari, Louis Jacob, Khushleen Jaggi, Haitham Jahrami, Akhil Jain, Nityanand Jain, Ammar Abdulrahman Jairoun, Mihajlo Jakovljevic, Roland Dominic G Jamora, Nilofer Javadi, Sathish Kumar Jayapal, Shubha Jayaram, Rime Jebai, Rebuma Sorsa Jeben, Sun Ha Jee, Anil K Jha, Ravi Prakash Jha, Vivekanand Jha, Heng Jiang, Yinzi Jin, Yash B. Jobanputra, Catherine Owens Johnson, Mohammad Jokar, Tamas Joo, Abel Joseph, Nitin Joseph, Charity Ehimwenma Joshua, Mikk Jürisson, Ali Kabir, Zubair Kabir, Vidya Kadashetti, Farima Kahe, Farnaz Kalantar, Yogeshwar Kalkonde, Sanjay Kalra, Ashwin Kamath, Sagarika Kamath, Tanuj Kanchan, Himal Kandel, Arun R. Kanmanthareddy, Kehinde Kazeem Kanmodi, Sushil Kumar Kansal, Sitanshu Sekhar Kar, Paschalis Karakasis, Prabin Karki, Faizan Zaffar Kashoo, Eskeziaw Abebe Kassahun, Nicholas J. Kassebaum, Patrick D. M. C. Katoto, Neda Kaydi, Foad Kazemi, Sina Kazemian, Jessica A. Kerr, Emmanuelle Kesse-Guyot, Mohammad Keykhaei, Morteza Abdullatif Khafaie, Himanshu Khajuria, Amirmohammad Khalaji, Nauman Khalid, Alireza Khalilian, Rovshan Khalilov, Asaduzzaman Khan, Ejaz Ahmad Khan, Junaid Khan, M Nuruzzaman Khan, Maseer Khan, Mohammad Jobair Khan, Muhammad Shahzeb Khan, Yusra H. Khan, Mahammed Ziauddin Khan suheb, Shaghayegh Khanmohammadi, Khaled Khatab, Sorour Khateri, Khalid A. Kheirallah, Feriha Fatima Khidri, Saeid Kian, Zemene Demelash Kifle, Ruth W. Kimokoti, Adnan Kisa, Sezer Kisa, Ali-Asghar Kolahi, Farzad Kompani, Gerbrand Koren, Ashwin Laxmikant Kotnis, Ai Koyanagi, Kewal Krishan, Hare Krishna, Vijay Krishnamoorthy, Yuvaraj Krishnamoorthy, Md Abdul Kuddus, Mohammed Kuddus, Mukhtar Kulimbet, Akshay Kumar, Ashish Kumar, Naveen Kumar, Nithin Kumar, Rahul Kumar, Netsanet Bogale Kumsa, Kunle Rotimi Kunle, Dian Kusuma, Ilias Kyriopoulos, Carlo La Vecchia, Muhammad Awwal Ladan, Chandrakant Lahariya, Arista Lahiri, Tea Lallukka, Qing Lan, Francesco Lanfranchi, Bagher Larijani, Anders O. Larsson, Savita Lasrado, Kamaluddin Latief, Kaveh Latifinaibin, Jerrald Lau, Paolo Lauriola, Khuong Le, Long Khanh Dao Le, Nhi Huu Hanh Le, Thao Thi Thu Le, Trang Diep Thanh Le, Trang Thi Bich Le, Caterina Ledda, Munjae Lee, Seung Won Lee, Wei-Chen Lee, Yo Han Lee, Kate E. LeGrand, Mall Leinsalu, Matilde Leonardi, Temesgen L. Lerango, An Li, Ming-Chieh Li, Wei Li, Xiaopan Li, Yichong Li, Lee-Ling Lim, Stephen S Lim, Ro-Ting Lin, Megan Lindstrom, Shai Linn, Gang Liu, Simin Liu, Xiaofeng Liu, Xuefeng Liu, Katherine M. Livingstone,

Erand Llanaj, Arianna Maever Loreche, László Lorenzovici, Stefan Lorkowski, Paulo A. Lotufo, Giancarlo Lucchetti, Alessandra Lugo, Zheng Feei Ma, Farzan Madadzadeh, Ralph Maddison, Javier A. Magaña Gómez, D. R. Mahadeshwara Prasad, Mansour Adam Mahmoud, Elham Mahmoudi, Omar Mohamed Makram, Elaheh Malakan Rad, Reza Malekzadeh, Kashish Malhotra, Iram Malik, Muhammad Sajeel Ahmed Malik, Tauqeer Hussain Mallhi, Deborah Carvalho Malta, Aseer Manilal, Yosef Manla, Yasaman Mansoori, Borhan Mansouri, Pejman Mansouri, Mohammad Ali Mansournia, Hamid Reza Marateb, Mirko Marino, Daniela Martini, Santi Martini, Sharmeen Maryam, Roy Rillera Marzo, Sahar Masoudi, Clara N. Matei, Yasith Mathangasinghe, Manu Raj Mathur, Jishanth Mattumpuram, Richard James Maude, Andrea Maugeri, Mahsa Mayeli, Mohsen Mazidi, John J. McGrath, Steven M. McPhail, Enkeleint A. Mechili, John Robert Carabeo Medina, Jitendra Kumar Meena, Kamran Mehrabani-Zeinabad, Max Alberto Mendez Mendez-Lopez, Walter Mendoza, Ritesh G. Menezes, George A. Mensah, Sultan Ayoub Meo, Haftu Asmerom Meresa, Atte Meretoja, Tuomo J. Meretoja, Tomislav Mestrovic, Kukulege Chamila Dinushi Mettananda, Sachith Mettananda, Laurette Mhlanga, Junmei Miao Jonasson, Tomasz Miazgowski, Irmina Maria Michalek, Ted R. Miller, Le Huu Nhat Minh, Neema W. Minja, Pouya Mir Mohammad Sadeghi, Andreea Mirica, Erkin M. Mirrakhimov, Moonis Mirza, Mohammad Mirza-Aghazadeh-Attari, Prasanna Mithra, Zahra Moghimi, Jama Mohamed, Mouhand F. H. Mohamed, Nouh Saad Mohamed, Soheil Mohammadi, Mustapha Mohammed, Salahuddin Mohammed, Shafiu Mohammed, Nagabhishek Moka, Ali H. Mokdad, Hossein Molavi Vardanjani, Sara Momtazmanesh, Fateme Montazeri, Yousef Moradi, Lidia Morawska, Negar Morovatdar, Shane Douglas Morrison, Jakub Morze, Ebrahim Mostafavi, Amirmahdi Mostofinejad, Seyed Ehsan Mousavi, Dariush Mozaffarian, Ahmed Msherghi, Lorenzo Muccioli, Ulrich Otto Mueller, Sumoni Mukherjee, Kavita Munjal, Efrén Murillo-Zamora, Christopher J. L. Murray, Ghulam Mustafa, Sathish Muthu, Julius C. Mwita, Woojae Myung, Ahamarshan Jayaraman Nagarajan, Shankar Prasad Nagaraju, Ganesh R. Naik, Gurudatta Naik, Tapas Sadasivan Nair, Mohammad Sadeq Najafi, Vinay Nangia, Sreenivas Narasimha Swamy, Shumaila Nargus, Bruno Ramos Nascimento, Gustavo G. Nascimento, Zuhair S. Natto, Javaid Nauman, Muhammad Naveed, Biswa Prakash Nayak, Vinod C. Nayak, Hadush Negash, Ionut Negoii, Ruxandra Irina Negoii, Seyed Aria Nejadghaderi, Chakib Nejjari, Samata Nepal, Nawi Ng, Dang H. Nguyen, Phat Tuan Nguyen, Van Thanh Nguyen, Robina Khan Niazi, Shawn S. Nijjar, Muhammad A. Nizam, Efaq Ali Noman, Shuhei Nomura, Mamoona Noreen, Bo Norrving, Jean Jacques Noubiap, Chisom Adaobi Nri-Ezedi, Dieta Nurrika, Chimezie Igwegbe Nzoputam, Ogochukwu Janet Nzoputam, Kehinde O. Obamiro, Martin James O'Donnell, Onome Bright Oghenetega, Ayodipupo Sikiru Oguntade, James Odhiambo Oguta, Akinkunmi Paul Okekunle, Lawrence Okidi, Osaretin Christabel Okonji, Patrick Godwin Okwute, Andrew T. Olagunju, Muideen Tunbosun Olaiya, Matthew Idowu Olatubi, Abdulhakeem Abayomi Olorukooba, Isaac Iyinoluwa Olufadewa, Yinka Doris Oluwafemi, Gideon Olamilekan Oluwatunase, Goran Latif Omer, Mohammad Mehdi Ommati, Kanyin Liane Ong, Kenneth Ikenna Onyedibe, Michal Ordak, Doris V. Ortega-Altamirano, Alberto Ortiz, Wael M. S. Osman, Uchechukwu Levi Osuagwu, Adrian Otoi, Stanislav S. Otstavnov, Mayowa O. Owolabi, Mahesh Padukudru P A, Alicia Padron-Monedero, Jagadish Rao Padubidri, Mahsa Pahlavikah Varnosfaderani, Tamás Palicz, Raffaele Palladino, Feng Pan, Hai-Feng Pan, Seithikurippu R. Pandi-Perumal, Paraskevi Papadopoulou, Seoyeon Park, Roberto Passera, Jay Patel, Shankargouda Patil, Dimitrios Patoulias, Shrikant Pawar, Amy E. Peden, Paolo Pedersini, Veincent Christian Filipino Pepito, Emmanuel K. Peprah, Marcos Pereira, Maria Odete Pereira, Mario F. P. Peres, Arokiasamy Perianayagam, Fanny Emily Petermann-Rocha, Hoang Tran Pham, Anil K. Philip, David M. Pigott, Evgenii Plotnikov, Dimitri Poddighe, Roman V. Polibin, Ramesh Poluru, Ghazaleh Pournali, Akram Pourshams, Pranil Man Singh Pradhan, Manya Prasad, Elton Junio Sady Prates, Bharathi M. Purohit, Jagadeesh Puvvula, Ibrahim

Qattee, Gangzhen Qian, Maryam Faiz Qureshi, Mehrdad Rabiee rad, Amir Radfar, Seyedeh Niloufar Rafiei Alavi, Ibrar Rafique, Alberto Raggi, Fakher Rahim, Md Jillur Rahim, Mehran Rahimi, Mosiur Rahman, Muhammad Aziz Rahman, Amir Masoud Rahmani, Bitra Rahmani, Shayan Rahmani, Vahid Rahmanian, Sathish Rajaa, Ali Rajabpour-Sanati, Prashant Rajput, Pradhun Ram, Prasanna Ram, Sudha Ramalingam, Shakthi Kumaran Ramasamy, Sheena Ramazanu, Pushkal Sinduvadi Ramesh, Juwel Rana, Kritika Rana, Chhabi Lal Ranabhat, Nemanja Rancic, Amey Rane, Shubham Ranjan, Annemarei Ranta, Indu Ramachandra Rao, Sowmya J. Rao, Sina Rashedi, Vahid Rashedi, Ahmed Mustafa Rashid, Azad Rasul, Zubair Ahmed Ratan, Giridhara Rathnaiah Babu, Nakul Ravikumar, Salman Rawaf, Iman Razeghian-Jahromi, Christian Razo, Murali Mohan Rama Krishna Reddy, Elrashdy Moustafa Mohamed Redwan, Luis Felipe Reyes, Nazila Rezaei, Mohsen Rezaeian, Antonio Luiz P. Ribeiro, Daniela Ribeiro, Reza Rikhtegar, Leonardo Roever, Debby Syahru Romadlon, Himanshu Sehar Sekhar Rout, Nitai Roy, Priyanka Roy, Aly M. A. Saad, Zahra Saadatian, Siamak Sabour, Rajesh Sachdeva, Basema Saddik, Erfan Sadeghi, Umar Saeed, Fatemeh Saheb Sharif-Askari, Narjes Saheb Sharif-Askari, Soumya Swaroop Sahoo, Seyed Aidin Sajedi, Mirza Rizwan Sajid, Joseph W. Sakshaug, Mohamed A. Saleh, Sana Salehi, Marwa Rashad Salem, Sara Samadzadeh, Saad Samargandy, Vijaya Paul Samuel, Abdallah M. Samy, Juan Sanabria, Rama Krishna Sanjeev, Milena M. Santric-Milicevic, Muhammad Arif Nadeem Saqib, Made Ary Sarasmita, Yaser Sarikhani, Tanmay Sarkar, Rodrigo Sarmiento-Suárez, Gargi Sachin Sarode, Sachin C. Sarode, Thirunavukkarasu Sathish, Anudeep Sathyanarayan, Monika Sawhney, Mehdi Sayyah, Nikolaos Scarmeas, Benedikt Michael Schaarschmidt, Art Schuermans, Aletta Elisabeth Schutte, David C. Schwebel, Mansour Sedighi, Abdul-Aziz Seidu, Farbod Semnani, Sabyasachi Senapati, Pallav Sengupta, Subramanian Senthilkumaran, Sadaf G. Sepanlou, Yashendra Sethi, Seyed Arsalan Seyedi, Maryam Shabany, Melika Shafeghat, Mahan Shafie, Pritik A. Shah, Ataollah Shahbandi, Izza Shahid, Samiah Shahid, Wajeehah Shahid, Moyad Jamal Shahwan, Masood Ali Shaikh, Muhammad Aaqib Shamim, Mohd Shanawaz, Sadaf Sharfaei, Amin Sharifan, Javad Sharifi-Rad, Purva Sharma, Saurab Sharma, Ujjawal Sharma, Vishal Sharma, Aziz Sheikh, Desalegn Shiferaw Shiferaw, Mika Shigematsu, Min-Jeong Shin, Rahman Shiri, Kawkab Shishani, Aminu Shittu, Ivy Shiue, K M Shivakumar, Sunil Shrestha, Kerem Shuval, Migbar Mekonnen Sibhat, Inga Dora Sigfusdottir, Colin R. Simpson, Abhinav Singh, Aditya Singh, Ambrish Singh, Jasvinder A. Singh, Paramdeep Singh, Rajat Singh, Md Shahjahan Siraj, Valentin Yurievich Skryabin, Anna Aleksandrovna Skryabina, David A. Sleet, Hamidreza Soleimani, Solikhah Solikhah, Sameh S. M. Soliman, Juyeon Son, Suhang Song, Yi Song, Joan B. Soriano, Michael Spartalis, Chandrashekhar T. Sreeramareddy, Lauryn K. Stafford, Benjamin A. Stark, Paschalis Steiropoulos, Stefan Stortecky, Rizwan Suliankatchi Abdulkader, Abida Sultana, Johan Sundström, Chandan Kumar Swain, Payam Tabaei Damavandi, Seyyed Mohammad Tabatabaei, Ozra Tabatabaei Malazy, Seyed-Amir Tabatabaeizadeh, Shima Tabatabai, Karen M. Tabb, Mohammad Tabish, Fentaw Tadese, Yasaman Taheri Abkenar, Jabeen Taiba, Iman M. Talaat, Mircea Tampa, Jacques J.L. Lukenze Tamuzi, Ker-Kan Tan, Haosu Tang, Elvis Enowbeyang Tarkang, Seyed Mohammad Tavangar, Hadi Tehrani, Mojtaba Teimoori, Mohamad-Hani Temsah, Reem Mohamad Hani Temsah, Masayuki Teramoto, Pugazhenthan Thangaraju, Kavumpurathu Raman Thankappan, Rajshree Thapa, Rekha Thapar, Rasiah Thayakaran, Nikhil Kenny Thomas, Jing Tian, Ales Tichopad, Tala Tillawi, Roman Topor-Madry, Mathilde Touvier, Marcos Roberto Tovani-Palone, Jasmine T. Tran, Nghia Minh Tran, Phu Van Tran, Indang Trihandini, Avnish Tripathi, Samuel Joseph Tromans, Guesh Mebrahtom Tsegay, Munkhtuya Tumurkhuu, Kang Tung, Chukwudi S. Ubah, Aniefiok John Udoakang, Arit Udoh, Sana Ullah, Muhammad Umair, Bhaskaran Unnikrishnan, Era Upadhyay, Jibrin Sammani Usman, Seyed Mohammad Vahabi, Asokan Govindaraj Vaithinathan, Rohollah Valizadeh, Jef Van den Eynde, Orsolya Varga, Siddhartha Alluri Varma, Priya Vart, Shoban Babu Varthya, Balachandar Vellingiri, Dominique Vervoort,

Jorge Hugo Villafañe, Maria Viskadourou, Simona Ruxandra Volovat, Theo Vos, Isidora S. Vujcic, Feras Wahab, Cong Wang, Fang Wang, Nelson Wang, Shu Wang, Yanzhong Wang, Yuan-Pang Wang, Melissa Y. Wei, Andrea Werdecker, Nuwan Darshana Wickramasinghe, Tissa Wijeratne, Angga Wilandika, Charles D. A. Wolfe, Utoomporn Wongsin, Zenghong Wu, Hong Xiao, Suowen Xu, Xiaoyue Xu, Yuichiro Yano, Habib Yaribeygi, Iman Yazdani Nia, Pengpeng Ye, Subah Abderehim Yesuf, Saber Yezli, Arzu Yiğit, Vahit Yiğit, Mekdes Tigistu Yilma, Dong Keon Yon, Naohiro Yonemoto, Laetitia Yperzeele, Chuanhua Yu, Ismaeel Yunusa, Nima Zafari, Farbod Zahedi Tajrishi, Fathiah Zakham, Mikhail Sergeevich Zastrozhin, Mohammad A. Zeineddine, Dawit T. Zemedikun, Youjie Zeng, chunxia Zhai, Chen Zhang, Haijun Zhang, Hongwei Zhang, Ning Zhang, Yunquan Zhang, Hanqing Zhao, Chenwen Zhong, Shuduo Zhou, Bin Zhu, Lei Zhu, Magdalena Zielińska, Yossef Teshome Zikarg, Mohammad Zmaili, Zhiyong Zou, Alimuddin Zumla, Elric Zweck, and Samer H Zyoud

Drafting the work or revising it critically for important intellectual content

Yohannes Habtegiorgis Abate, Foad Abd-Allah, Ashkan Abdollahi, Auwal Abdullahi, Ayele Mamo Abebe, Aidin Abedi, Armita Abedi, Olugbenga Olusola Abiodun, Eman Abu-Gharbieh, Salahdein Aburuz, Abdelrahman I. Abushouk, Ahmed Abu-Zaid, Nicola J. Adderley, Oladimeji M. Adebayo, Olorunsola Israel Adeyomoye, Qorinah Estiningtyas Sakilah Adnani, Shadi Afyouni, Saira Afzal, Pradyumna Agasthi, Antonella Agodi, Constanza Elizabeth Aguilera Arriagada, Bright Opoku Ahinkorah, Danish Ahmad, Firdos Ahmad, Muayyad M. Ahmad, Ayman Ahmed, Haroon Ahmed, Muktar Beshir Ahmed, Syed Anees Ahmed, Marjan Ajami, Karolina Akinosoglou, Samer O. Alalalmeh, Rasmieh Mustafa Al-amer, Alaa Alashi, Mohammed Albashtawy, Mohammad T. AlBataineh, Yihun Mulugeta Alemu, Khalid F. Alhabib, Fadwa Alhalaiqa Naji Alhalaiqa, Mohammed Usman Ali, Rafat Ali, Wael Almahmeed, Sabah Al-Marwani, Jordi Alonso, Farrukh Jawad Alvi, Nelson Alvis-Guzman, Nelson J. Alvis-Zakzuk, Hassan Alwafi, Prince M. Amegbor, Tarek Tawfik Amin, Alireza Amindarolzari, Sohrab Amiri, Tanu Anand, Robert Ancuceanu, Deanna Anderlini, Abhishek Anil, Philip Emeka Anyanwu, Anayochukwu Edward Anyasodor, Geminn Louis Carace Apostol, Jalal Arabloo, Olatunde Aremu, Benedetta Armocida, Johan Ärnlov, Oluwaseyi Olalekan Arowosegbe, Kurnia Dwi Artanti, Judie Arulappan, Idowu Thomas Aruleba, Ashokan Arumugam, Zahra Aryan, Alok Atreya, Avinash Aujayeb, Adedapo Wasiru Awotidebe, Zahra Azizi, Ahmed Y. Azzam, Abraham Samuel Babu, Muhammad Badar, Ashish D. Badiye, Sara Bagherieh, Jennifer L. Baker, Shankar M. Bakkannavar, Abdulaziz T. Bako, Ravleen Kaur Bakshi, Saliu A. Balogun, Ovidiu Constantin Baltatu, Kiran Bam, Maciej Banach, Soham Bandyopadhyay, Kannu Bansal, Hamid Reza Baradaran, Martina Barchitta, Mainak Bardhan, Suzanne Lyn Barker-Collo, Till Winfried Bärnighausen, Francesco Barone-Adesi, Sandra Barteit, Azadeh Bashiri, Amir Hossein Behnoush, Yannick Béjot, Sefaelem Assefa Belay, Uzma Iqbal Belgaumi, Michelle L. Bell, Luis Belo, Salaheddine Bendak, Bright Benfor, Isabela M. Bensor, Catherine P. Benziger, Azizullah Beran, Habtamu B. Beyene, Kebede A. Beyene, Akshaya Srikanth Bhagavathula, Prarthna V. Bhardwaj, Vivek Bhat, Gurjit Kaur Bhatti, Jasvinder Singh Bhatti, Marina G. Birck, Bijit Biswas, Saeid Bitaraf, Aadam Olalekan Bodunrin, Milad Bonakdar Hashemi, Hamed Borhany, Edward J. Boyko, Dejana Braithwaite, Luisa C. Brant, Susanne Breitner, Andrey Briko, Yasser Bustanji, Daniela Calina, Sinclair Carr, Juan J. Carrero, Joao Mauricio Castaldelli-Maia, Carlos A. Castañeda-Orjuela, Maria Sofia Cattaruzza, Luca Cegolon, Ester Cerin, Yaacoub Chahine, Jeffrey Shi Kai Chan, Mei Yen Chan, Vijay Kumar Chattu, An-Tian Chen, Haowei Chen, Gerald Chi, Patrick R. Ching, William C. S. Cho, Bryan Chong, Hitesh Chopra, Rajiv Chowdhury, Dinh-Toi Chu, Arrigo Francesco Giuseppe Cicero, Iolanda Cioffi, Sean Coffey, Alyssa Columbus, Joao Conde, Sara Conti, Sandra Cortés, Paolo Angelo Cortesi, Vera Marisa Costa, Rosa A. S. Couto, Michael H. Criqui, Sriharsha Dadana, Zhaoli Dai, Maxwell Ayindenaba Dalaba, Albertino Antonio Moura Damasceno, Giovanni Damiani, Emanuele

D'Amico, Saswati Das, Mohsen Dashti, Maedeh Dastmardi, Aklilu Tamire Debele, Shayom Debopadhaya, Nicole K. DeCleene, Ivan Delgado-Enciso, Juana Maria Delgado-Saborit, Berecha Hundessa Demessa, Andreas K. Demetriades, Edgar Denova-Gutiérrez, Awoke Masrie Asrat Derese, Hardik Dineshbhai Desai, Rupak Desai, Vinoth Gnana Chellaiyan Devanbu, Syed Masudur Rahman Dewan, Vishal R. Dhulipala, Michael J. Diaz, Delaney D. Ding, Ricardo Jorge Dinis-Oliveira, Thanh Chi Do, Sushil Dohare, Mario D'Oria, Wendel Mombaqué dos Santos, Abdel Douiri, Robert Kokou Dowou, Ashel Chelsea Dsouza, Haneil Larson Dsouza, Mi Du, Oyewole Christopher Durojaiye, Sulagna Dutta, Arkadiusz Marian Dziejczak, Defi Efendi, Ferry Efendi, Ebrahim Eini, Iman El Sayed, Maha El Tantawi, Iffat Elbarazi, Frank J. Elgar, Islam Y. Elgendy, Muhammed Elhadi, Mehdi Emamverdi, Theophilus I. Emeto, Juan Espinosa-Montero, Farshid Etaee, Natalia Fabin, Adeniyi Francis Fagbamigbe, Luca Falzone, MoezAllIslam Ezzat Mahmoud Faris, Andre Faro, Medhat Farwati, Abidemi Omolara Fasanmi, Ali Fatehizadeh, Seyed-Mohammad Fereshtehnejad, Pietro Ferrara, Nuno Ferreira, Irina Filip, Laura Fleszar, David Flood, Morenike Oluwatoyin Folayan, Diogo A. Fonseca, Carla Fornari, Matteo Foschi, Takeshi Fukumoto, Valentin Fuster, Peter Andras Gaal, Muktar A. Gadanya, Shilpa Gaidhane, Emmanuela Gakidou, Yaseen Galali, Silvano Gallus, Balasankar Ganesan, Rupesh K. Gautam, Miglas W. W. Gebregergis, Johanna M. Geleijnse, Alireza Ghajar, Seyyed-Hadi Ghamari, MohammadReza Ghasemi, Ghazal Ghasempour Dabaghi, Afsaneh Ghasemzadeh, Arun Digambarrao Ghuge, Paramjit Singh Gill, Tiffany K. Gill, Richard F. Gillum, Elena V. Gnedovskaya, Ali Golchin, Giuseppe Gorini, Alessandra C. Goulart, Anmol Goyal, Kashish Goyal, Shi-Yang Guan, Giovanni Guarducci, Mesay Dechasa Gudeta, Avirup Guha, Stefano Guicciardi, David Gulisashvili, Damitha Asanga Gunawardane, Cui Guo, Bhawna Gupta, Kartik Gupta, Mohak Gupta, Rajat Das Gupta, Rajeev Gupta, Sapna Gupta, Veer Bala Gupta, Vivek Kumar Gupta, Reyna Alma Gutiérrez, Farrokh Habibzadeh, Mostafa Hadei, Helia Sadat Haeri Boroojeni, Aram Halimi, Rabih Halwani, Randah R. Hamadeh, Nadia M. Hamdy, Graeme J. Hankey, Md. Abdul Hannan, Josep Maria Haro, Faizul Hasan, Ikramul Hasan, Hamidreza Hasani, Md Saquib Hasnain, Amr Hassan, Johannes Haubold, Rasmus J. Havmoeller, Khezhar Hayat, Omar E. Hegazi, Tadele Yohannes Hegena, Bartosz Helfer, Claudiu Herteliu, Hamed Hesami, Kamran Hessami, Kamal Hezam, Yuta Hiraike, Ramesh Holla, Md Mahbub Hossain, Mihaela Hostiuc, Sorin Hostiuc, Junjie Huang, Michael Hultström, Hong-Han Huynh, Khalid S. Ibrahim, Oluwatope Olaniyi Idowu, Olayinka Stephen Ilesanmi, Irena M. Ilic, Milena D. Ilic, Mustapha Immurana, Muhammad Iqhrammullah, Sheikh Mohammed Shariful Islam, Faisal Ismail, Nahlah Elkudssiah Ismail, Gaetano Isola, Linda Merin J, Louis Jacob, Abdollah Jafarzadeh, Khushleen Jaggi, Haitham Jahrami, Akhil Jain, Ammar Abdulrahman Jairoun, Mihajlo Jakovljevic, Roland Dominic G. Jamora, Nilofer Javadi, Sathish Kumar Jayapal, Shubha Jayaram, Rime Jebai, Rebuma Sorsa Jeben, Anil K. Jha, Ravi Prakash Jha, Vivekanand Jha, Yash B. Jobanputra, Catherine Owens Johnson, Tamas Joo, Abel Joseph, Nitin Joseph, Mikk Jürisson, Ali Kabir, Vidya Kadashetti, Farima Kahe, Rizwan Kalani, Laleh R. Kalankesh, Sanjay Kalra, Sagarika Kamath, Arun Kamireddy, Himal Kandel, Kehinde Kazeem Kanmodi, Sushil Kumar Kansal, Paschalis Karakasis, Prabin Karki, Faizan Zaffar Kashoo, Hengameh Kasraei, Nicholas J. Kassebaum, Patrick D. M. C. Katoto, Foad Kazemi, Sina Kazemian, Sara Kazemina, Jessica A. Kerr, Emmanuelle Kesse-Guyot, Mohamad Mehdi Khadembashiri, Mohammad Amin Khadembashiri, Himanshu Khajuria, Amirmohammad Khalaji, Nauman Khalid, Rovshan Khalilov, Ejaz Ahmad Khan, Junaid Khan, M Nuruzzaman Khan, Maseer Khan, Mohammad Jobair Khan, Yusra H Khan, Mahammed Ziauddin Khan suheb, Khaled Khatab, Hamid Reza Khayat Kashani, Khalid A. Kheirallah, Saeid Kian, Adnan Kisa, Sezer Kisa, Farzad Kompani, Ashwin Laxmikant Kotnis, Parvaiz A. Koul, Ai Koyanagi, Kewal Krishan, Hare Krishna, Mohammed Kuddus, Vishnutheertha Kulkarni, Ashish Kumar, Kunle Rotimi Kunle, Dian Kusuma, Ilias Kyriopoulos, Carlo La Vecchia, Ben Lacey, Muhammad Awwal Ladan, Lucie Laflamme, Chandrakant Lahariya, Arista Lahiri, Tea

Lallukka, Iván Landires, Bagher Larijani, Anders O. Larsson, Savita Lasrado, Kamaluddin Latief, Kaveh Latifinaibin, Jerrald Lau, Long Khanh Dao Le, Nhi Huu Hanh Le, Thao Thi Thu Le, Trang Thi Bich Le, Caterina Ledda, Paul H. Lee, Kate E. LeGrand, Matilde Leonardi, An Li, Wei Li, Lee-Ling Lim, Megan Lindstrom, Simin Liu, Xuefeng Liu, Katherine M. Livingstone, Erand Llanaj, Platon D. Lopukhov, László Lorenzovici, Stefan Lorkowski, Paulo A. Lotufo, Giancarlo Lucchetti, Zheng Feei Ma, Farzan Madadzadeh, Javier A. Magaña Gómez, Julien Magne, D. R. Mahadeshwara Prasad, Mehrdad Mahalleh, Mansour Adam Mahmoud, Elham Mahmoudi, Omar Mohamed Makram, Elaheh Malakan Rad, Reza Malekzadeh, Tauqeer Hussain Mallhi, Deborah Carvalho Malta, Aseer Manilal, Yasaman Mansoori, Borhan Mansouri, Hamid Reza Marateb, Mirko Marino, Daniela Martini, Sharmeen Maryam, Roy Rillera Marzo, Alireza Masoudi, Clara N. Matei, Yasith Mathangasinghe, Elezebeth Mathews, Jishanth Mattumpuram, Andrea Maugeri, Mahsa Mayeli, John J McGrath, Steven M. McPhail, Enkeleint A Mechili, Jitendra Kumar Meena, Kamran Mehrabani-Zeinabad, Max Alberto Mendez Mendez-Lopez, Walter Mendoza, Ritesh G. Menezes, Belayneh Mengist, George A. Mensah, Sultan Ayoub Meo, Haftu Asmerom Meresa, Atte Meretoja, Tuomo J. Meretoja, Tomislav Mestrovic, Kukulege Chamila Dinushi Mettananda, Sachith Mettananda, Laurette Mhlanga, Tianyue Mi, Tomasz Miazgowski, Ted R. Miller, Le Huu Nhat Minh, Neema W. Minja, Pouya Mir Mohammad Sadeghi, Niloofar Mirdamadi, Moonis Mirza, Prasanna Mithra, Mouhand F. H. Mohamed, Nouh Saad Mohamed, Hussen Mohammed, Mustapha Mohammed, Salahuddin Mohammed, Shafiu Mohammed, Ali H. Mokdad, Sara Momtazmanesh, Lorenzo Monasta, Fateme Montazeri, AmirAli Moodi Ghalibaf, Yousef Moradi, Paula Moraga, Shane Douglas Morrison, Jakub Morze, Ebrahim Mostafavi, Amirmahdi Mostofinejad, Parsa Mousavi, Seyed Ehsan Mousavi, Dariush Mozaffarian, Ahmed Msherghi, Ulrich Otto Mueller, Sumoni Mukherjee, Kavita Munjal, Efrén Murillo-Zamora, Christopher J. L. Murray, Ghulam Mustafa, Sathish Muthu, Julius C. Mwita, Woojae Myung, Ahamarshan Jayaraman Nagarajan, Shankar Prasad Nagaraju, Mohammad Sadeq Najafi, Nouredin Nakhostin Ansari, Sreenivas Narasimha Swamy, Shumaila Nargus, Bruno Ramos Nascimento, Gustavo G. Nascimento, Zuhair S. Natto, Javaid Nauman, Biswa Prakash Nayak, Vinod C. Nayak, Hadush Negash, Ionut Negoj, Ruxandra Irina Negoj, Seyed Aria Nejadghaderi, Mohammad Hadi Nematollahi, Samata Nepal, Nawi Ng, Dang H. Nguyen, Phat Tuan Nguyen, Van Thanh Nguyen, Robina Khan Niazi, Shawn S Nijjar, Muhammad A. Nizam, Mamoon Noreen, Bo Norrving, Jean Jacques Noubiap, Chisom Adaobi Nri-Ezedi, Mpiko Ntsekhe, Dieta Nurrika, Chimezie Igwegbe Nzopotam, Ogochukwu Janet Nzopotam, Kehinde O. Obamiro, Onome Bright Oghenetega, Ayodipupo Sikiru Oguntade, Sylvester Reuben Okeke, Akinkunmi Paul Okekunle, Osaretin Christabel Okonji, Patrick Godwin Okwute, Andrew T. Olagunju, Matifan Dereje Olana, Matthew Idowu Olatubi, Gláucia Maria Moraes Oliveira, Abdulhakeem Abayomi Olorukooba, Yinka Doris Oluwafemi, Gideon Olamilekan Oluwatunase, Mohammad Mehdi Ommati, Kenneth Ikenna Onyedibe, Michal Ordak, Doris V. Ortega-Altamirano, Alberto Ortiz, Esteban Ortiz-Prado, Wael M. S. Osman, Uchechukwu Levi Osuagwu, Adrian Otoiu, Mayowa O. Owolabi, Mahesh Padukudru P A, Alicia Padron-Monedero, Jagadish Rao Padubidri, Mahsa Pahlavikhah Varnosfaderani, Feng Pan, Seithikurippu R. Pandi-Perumal, Paraskevi Papadopoulou, Roberto Passera, Jay Patel, Shankargouda Patil, Dimitrios Patoulas, Venkata Suresh Patthipati, Shrikant Pawar, Amy E. Peden, Paolo Pedersini, Veincent Christian Filipino Pepito, Marcos Pereira, Mario F. P. Peres, Norberto Perico, Fanny Emily Petermann-Rocha, Hoang Tran Pham, Anil K. Philip, Thomas Pilgrim, Michael A. Piradov, Dimitri Poddighe, Pranil Man Singh Pradhan, Manya Prasad, Elton Junio Sady Prates, Bharathi M. Purohit, Ibrahim Qattee, Mehrdad Rabiee rad, Amir Radfar, Seyedeh Niloufar Rafiei Alavi, Alberto Raggi, Fakher Rahim, Mehran Rahimi, Bitra Rahmani, Shayan Rahmani, Pramila Rai, Sathish Rajaa, Ali Rajabpour-Sanati, Prashant Rajput, Pradhun Ram, Sudha Ramalingam, Shakthi Kumaran Ramasamy, Sheena Ramazanu, Pushkal Sinduvadi Ramesh, Kritika Rana, Chhabi Lal

Ranabhat, Nemanja Rancic, Shubham Ranjan, Annemarei Ranta, Mithun Rao, Sowmya J. Rao, Vahid Rashedi, Ahmed Mustafa Rashid, Giridhara Rathnaiah Babu, Nakul Ravikumar, Salman Rawaf, Iman Razeghian-Jahromi, Christian Razo, Elrashdy Moustafa Mohamed Redwan, Giuseppe Remuzzi, Luis Felipe Reyes, Nazila Rezaei, Antonio Luiz P. Ribeiro, Daniela Ribeiro, Reza Rikhtegar, Leonardo Roever, Debby Syahru Romadlon, Luca Ronfani, Gregory A. Roth, Himanshu Sehar Sekhar Rout, Nitai Roy, Priyanka Roy, Andrzej Rynkiewicz, Aly M. A. Saad, Simona Sacco, Rajesh Sachdeva, Basema Saddik, Umar Saeed, Fahimeh Safaeinejad, Fatemeh Saheb Sharif-Askari, Narjes Saheb Sharif-Askari, Amirhossein Sahebkar, Soumya Swaroop Sahoo, Seyed Aidin Sajedi, Mirza Rizwan Sajid, Nasir Salam, Afeez Abolarinwa Salami, Marwa Rashad Salem, Mohammed Z. Y. Salem, Sara Samadzadeh, Saad Samargandy, Vijaya Paul Samuel, Abdallah M. Samy, Juan Sanabria, Milena M. Santric-Milicevic, Aswini Saravanan, Yaser Sarikhani, Tanmay Sarkar, Rodrigo Sarmiento-Suárez, Gargi Sachin Sarode, Sachin C. Sarode, Thirunavukkarasu Sathish, Anudeep Sathyanarayan, Mehdi Sayyah, Nikolaos Scarneas, Benedikt Michael Schaarschmidt, Art Schuermans, Aletta Elisabeth Schutte, David C. Schwebel, Sabyasachi Senapati, Pallav Sengupta, Sadaf G. Sepanlou, Yashendra Sethi, Allen Seylani, Maryam Shabany, Melika Shafeghat, Mahan Shafie, Pritik A. Shah, Izza Shahid, Samiah Shahid, Wajeehah Shahid, Moyad Jamal Shahwan, Muhammad Aaqib Shamim, Mohd Shanawaz, Amin Sharifan, Javad Sharifi-Rad, Purva Sharma, Saurab Sharma, Ujjawal Sharma, Vishal Sharma, Mika Shigematsu, Min-Jeong Shin, Aminu Shittu, K M Shivakumar, Sunil Shrestha, Migbar Mekonnen Sibhat, Colin R. Simpson, Abhinav Singh, Aditya Singh, Jasvinder A. Singh, Paramdeep Singh, Rajat Singh, Surjit Singh, Valentin Yurievich Skryabin, Anna Aleksandrovna Skryabina, Solikhah Solikhah, Sameh S. M. Soliman, Suhang Song, Yi Song, Joan B. Soriano, Michael Spartalis, Chandrashekhar T. Sreeramareddy, Benjamin A. Stark, Paschalis Steiropoulos, Stefan Stortecky, Abida Sultana, Johan Sundström, Chandan Kumar Swain, Payam Tabae Damavandi, Ozra Tabatabaei Malazy, Seyed-Amir Tabatabaeizadeh, Karen M. Tabb, Takahiro Tabuchi, Iman M. Talaat, Mircea Tampa, Jacques J.L. Lukenze Tamuzi, Ker-Kan Tan, Nathan Y. Tat, Seyed Mohammad Tavangar, Mohamad-Hani Temsah, Reem Mohamad Hani Temsah, Masayuki Teramoto, Pugazhenthan Thangaraju, Aravind Thavamani, Jing Tian, Tala Tillawi, Marcello Tonelli, Roman Topor-Madry, Mathilde Touvier, Marcos Roberto Tovani-Palone, Jasmine T. Tran, Nghia Minh Tran, Phu Van Tran, Indang Trihandini, Avnish Tripathi, Samuel Joseph Tromans, Vien T. Truong, Thien Tan Tri Tai Truyen, Evangelia Eirini Tsermpini, Munkhtuya Tumurkhuu, Chukwudi S. Ubah, Aniefiok John Udoakang, Arit Udoh, Atta Ullah, Muhammad Umair, Tungki Pratama Umar, Brigid Unim, Bhaskaran Unnikrishnan, Era Upadhyay, Jibrin Sammani Usman, Asokan Govindaraj Vaithinathan, Jef Van den Eynde, Orsolya Varga, Siddhartha Alluri Varma, Priya Vart, Shoban Babu Varthya, Tommi Juhani Vasankari, Balachandar Vellingiri, Dominique Vervoort, Jorge Hugo Villafañe, Francesco S. Violante, Simona Ruxandra Volovat, Hatem A. Wafa, Feras Wahab, Cong Wang, Fang Wang, Shu Wang, Yanzhong Wang, Yuan-Pang Wang, Melissa Y. Wei, Andrea Werdecker, Nuwan Darshana Wickramasinghe, Charles D. A. Wolfe, Lalit Yadav, Yuichiro Yano, Yuichi Yasufuku, Subah Abderehim Yesuf, Arzu Yiğit, Vahit Yiğit, Dong Keon Yon, Naohiro Yonemoto, Nima Zafari, Farbod Zahedi Tajrishi, Mikhail Sergeevich Zastrozhin, Mohammad A. Zeineddine, Dawit T. Zemedikun, Chunxia Zhai, Haijun Zhang, Ning Zhang, Chenwen Zhong, Bin Zhu, Magdalena Zielińska, Yossef Teshome Zikarg, Mohammad Zmaili, Alimuddin Zumla, and Samer H. Zyoud

[Managing the estimation or publications process](#)

Armita Abedi, Mohammed Albashtawy, Wael Almahmeed, Farrukh Jawad Alvi, Judie Arulappan, Ahmed Y. Azzam, Aadam Olalekan Bodunrin, Luisa C. Brant, Yaacoub Chahine, Catherine S. Chen, Rosa A. S. Couto, Giovanni Damiani, Maedeh Dastmardi, Vishal R. Dhulipala, Thanh Chi Do, Mi Du, Ali Fatehizadeh, Shilpa Gaidhane, Faizul Hasan, Simon I. Hay, Hong-Han Huynh, Khalid S. Ibrahim, Gaetano Isola, Linda

Merin J, Sathish Kumar Jayapal, Yash B. Jobanputra, Catherine Owens Johnson, Faizan Zaffar Kashoo, Nicholas J. Kassebaum, Rovshan Khalilov, Nhi Huu Hanh Le, Thao Thi Thu Le, Kate E. LeGrand, Megan Lindstrom, Borhan Mansouri, George A. Mensah, Le Huu Nhat Minh, Moonis Mirza, Salahuddin Mohammed, Ali H. Mokdad, Ahmed Msherghi, Kavita Munjal, Phat Tuan Nguyen, Van Thanh Nguyen, Mohammad Mehdi Ommati, Mahesh Padukudru P A, Hoang Tran Pham, Nemanja Rancic, Giridhara Rathnaiah Babu, Gregory A. Roth, Aly M. A. Saad, Abdallah M. Samy, Mehdi Sayyah, Javad Sharifi-Rad, Purva Sharma, Rajat Singh, Michael Spartalis, Pugazhenthan Thangaraju, Muhammad Umair, Shoban Babu Varthya, Mikhail Sergeevich Zastrozhin, and Liqun Zhang

Declarations

O.O. Abiodun reports honoraria from AstraZeneca, Servier, and Pfizer; support for attending scientific meetings from Boehringer Ingelheim, Megalifesciences, and MSN; all outside the submitted work. N.J. Adderlay reports grants or contracts from National Institute for Health and Care Research, UKRI Medical Research Council, Clinical Research Network West Midlands, and Action Against AMD (charity), all as payments to their institution; all outside the submitted work. O.M. Adebayo reports grants or contracts from Teesside University, Sevier, and Viatrix/Pfizer; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Novartis; all outside the submitted work. S. Afzal reports support for the present manuscript from King Edward Medical University, Department of Community Medicine, which provided study materials, research article, supporting staff and office for working on the manuscript; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from King Edward Medical University; participation on a Data Safety Monitoring Board or Advisory Board with the National Bioethics Committee Pakistan, King Edward Medical University Institutional Ethical Review Board and Ethical Review Committee in Board of Faculty, and Ethical Review Board Fatima Jinnah Medical University and Sir Ganga Ram Hospital; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, Pakistan Association of Medical Editors, Fellow of Faculty of Public Health Royal Colleges UK (FFPH), Society of Prevention, Advocacy And Research, King Edward Medical University (SPARK), Member Pakistan Society of Infectious Diseases, Member Pakistan Society of Internal Medicine, Member Pakistan Society of Community Medicine and Public Health; other financial or nonfinancial interests in the Higher Education Commission of Pakistan as a member Research and Publications Committee, and Pakistan Medical and Dental Council as a member Journal Research Evaluation Committee; all outside the submitted work. A. Alashi reports grants or contracts from NIH-NRSA T32:HL098069, outside the submitted work. E. Ammirati reports grants or contracts from Italian Ministry of Health (GR-2019-12368506), the European Union, NextGenerationEU (M6C2/2.1 PNRR-MAD-2022-12376225-CUP H43C21000140006); consulting fees from Kiniksa, Cytokinetics, AstraZeneca; all outside the submitted work. R. Ancuceanu reports consulting fees from Abbvie; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Abbvie, Sandoz, B. Braun, Laropharm, and MagnaPharm; all outside the submitted work. J. Ärnlöv reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca; participation on an Advisory Board with Astella, and AstraZeneca; all outside the submitted work. T. Astell-Burt reports grants or contracts from NHMRC-UKRI Built Environment and Prevention, MRFF PANDA Trial, and the Australian Research Council Future Fellowship, all outside the submitted work. J.L. Baker reports grants from Novo Nordisk Foundation, World Cancer Research Fund, Independent Research Council Denmark, European Union Horizon, all as payments to their institution; consulting fees from Novo Nordisk Denmark A/S; support for attending meetings and/or travel from European Association for the Study of Obesity; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, with European Association for the Study of Obesity; all outside the submitted work. O.C. Baltatu reports support for the present manuscript from National Council for Scientific and Technological Development (CNPq, 304224/2022-7), and Anima Institute-AI research professor fellowship; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, with the Health and Biotechnology Board at São José dos Campos Technology Park, and Afya-UNINOVAFAPI as Academic Ambassador; all outside the submitted work. S. Bandyopadhyay reports grants or contracts from National Institute of Health Research; support for attending meetings and/or travel from Royal Society of Medicine, and the Association of Surgeons in Training; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, with British Medical Association; all outside the submitted work. F. Barbic reports leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, with ICOH SC Occupational Cardiology, outside the submitted work. T.W. Bärnighausen reports support for the present

manuscript from the Horizon Europe program through the project IDAlert (<https://idalertproject.eu>) with grant no. 101057554; grants from the European Union (Horizon 2020 and EIT Health), German Research Foundation (DFG), US National Institutes of Health, German Ministry of Education and Research, Alexander von Humboldt Foundation, Else-Kröner-Fresenius - Foundation, Wellcome Trust, Bill & Melinda Gates Foundation, KfW, UNAIDS, and WHO; consulting fees from KfW on the OSCAR initiative in Vietnam; participation on a Data Safety Monitoring Board or Advisory Board with the NIH-funded study "Healthy Options," Chair, Data Safety and Monitoring Board (DSMB), German National Committee on the "Future of Public Health Research and Education," Chair of the scientific advisory board to the EDCTP Evaluation, Member of the UNAIDS Evaluation Expert Advisory Committee, National Institutes of Health Study Section Member on Population and Public Health Approaches to HIV/AIDS, US National Academies of Sciences, Engineering, and Medicine's Committee for the "Evaluation of Human Resources for Health in the Republic of Rwanda under the President's Emergency Plan for AIDS Relief," and University of Pennsylvania Population Aging Research Center External Advisory Board Member; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, with the Global Health Hub Germany; all outside the submitted work. Y. Béjot reports consulting fees from Medtronic, NovoNordisk, and Novartis; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from BMS, Pfizer, Servier, Amgen, and Medtronic; support for attending meetings and/or travel from Medtronic; leadership or fiduciary role in other board, society, committee, or advocacy group, unpaid, with Société Française Neurovasculaire; all outside the submitted work. M.L. Bell reports grants or contracts from US EPA, NIH, High Tide Foundation, Health Effects Institute, Yale Women Faculty Forum, Environmental Defense Fund, Wellcome Trust Foundation, Yale Climate Change and Health Center, and Robert Wood Johnson Foundation as payments to their institution; consulting fees from Clinique; honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Colorado School of Public Health, Duke University, University of Texas, Data4Justice, Korea University, Organization of Teratology Information Specialists, UPenn, Boston University, IOP Publishing, NIH, Health Canada, PAC-10, UKRI, AXA Research Fund Fellowship, FRNS, UAE, Harvard University, and the University of Montana; support for attending meetings and/or travel from Colorado School of Public Health, University of Texas, Duke University, Boston University, UPenn, Harvard University, and APHA; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, with Fifth National Climate Assessment, Lancet Countdown, US EPA Clean Air Scientific Advisory Committee (CASAC), Johns Hopkins EHE Advisory Board, Harvard external advisory committee for training grant, WHO Global Air Pollution and Health Technical Advisory group, and National Academies Panels and Committees; all outside the submitted work. L. Belo reports other financial or nonfinancial interests in FCT in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of UCIBIO and the project LA/P/0140/2020 of i4HB, all outside the submitted work. C. Benzinger reports grants or contracts from AHRQ R18HS27402-01A1, NIH/NIA U19AG065188, DOD W81XWH-17-2-0030, NIH/NHLBI 1R01HL155396-01A1, PCORI PLACER-2020C3-21005, and PCORI PLACER-2020C3-21005; participation on a Data Safety Monitoring Board or Advisory Board as DSMB chair, *A Team-Based and Technology Driven Adherence Intervention to Improve Chronic Disease Outcomes* (5R01HL136937-02); leadership or fiduciary role in other board, society, committee, or advocacy group, unpaid, with American Heart Association Epidemiology Leadership council, American College of Cardiology Prevention Committee, Minnesota Chapter of American College of Cardiology board of directors; all outside the submitted work. P.V. Bhardwaj reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Doximity; stock or stock options in Doximity; all outside the submitted work. B. Bikbov reports grants or contracts from the European Commission; support for attending meetings and/or travel from the European Renal Association; leadership or fiduciary role in an advocacy group, unpaid, with International Society of Nephrology; other financial or nonfinancial interests in Scientific-Tools.org; all outside the submitted work. E.J. Boyko reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from the Korean Diabetes

Association, International Society for the Diabetic Foot, Diabetes Association of the R.O.C. (Taiwan), and the American Diabetes Association; support for attending meetings and/or travel from Korean Diabetes Association, Diabetes Association of the R.O.C. (Taiwan), and the International Society for the Diabetic Foot; all outside the submitted work. M. Brauer reports support for the present manuscript from the Bill and Melinda Gates Foundation as payments to their institution; leadership or fiduciary roles in other board, society, committee, or advocacy group, unpaid, with the World Heart Federation Air Pollution Expert Group (2019-2023) as Chair, outside the submitted work. M. Carvalho reports other financial or nonfinancial interests in FCT in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of UCIBIO and the project LA/P/0140/2020 of i4HB, all outside the submitted work. J.M. Castaldelli-Maia reports grants or contracts from French National Institute for Cancer, Pfizer, and Sanofi; royalties or licenses from L'Oreal; all outside the submitted work. L. Cegolon reports grants or contracts from the University of Trieste, Department of Medical Surgical & Health Sciences; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from University of Pavia (Italy); support for attending meetings and/or travel from University of Trieste to attend annual MODERNET meetings, The Italian Society of Occupational Medicine (SIML) annual meetings, and the annual meeting of the Italian Public Health Society (Siti); all outside the submitted work. D.S. Chew reports grants or contracts from Canadian Institute of Health Research and Heart and Stroke Foundation of Canada, through payments to their institution; all outside the submitted work. G. Chi reports grants or contracts from Janssen Pharmaceuticals, Bayer, CSL Behring, all outside the submitted work. J. Conde reports a European Research Council Starting Grant (ERC-StG-2019-848325), outside the submitted work. S. Cortés reports grants or contracts from Advanced Center for Chronic Diseases (1513001) and Centro De Desarraollo Urbano Sustentable (1522A002); all outside the submitted work. X. Dai, N.K. DeCleene, E. Gakidou, C.O. Johnson, N.J. Kassebaum, Sh. Mohammed, C. Razo, L.K. Stafford, B.A. Stark, and F. Wahab report support for the present manuscript from the Bill and Melinda Gates Foundation as payments to IHME for the GBD Study. Sa. Das reports leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, as a Member and Indian section Char of Association for Diagnostics and Laboratory Medicine, and a Member of Women in Global Health India Chapter; all outside the submitted work. A.K. Demetriades reports leadership or fiduciary role in other board, society, committee, or advocacy group, unpaid, with AO Knowledge Forum Degen: Steering Committee, Global Neuro Foundation: Board, and EANS (European Association of Neurosurgical Societies): Board; all outside the submitted work. M. D'Oria reports consulting fees from Terumo Aortic, outside the submitted work. T.I. Emeto reports grants or contracts from the Emergency Medicine Foundation for Grant ID EMPJ-270R39-2023-BANKS and Grant ID EMTC-001R01-2021; all outside the submitted work. A. Faro reports support for the present manuscript from Coordination of Superior Level Staff Improvement (CNPq, Brazil), outside the submitted work. X. Feng reports grants or contracts from NHMRC-UKRI Built Environment and Prevention, MRFF PANDA Trial, and NHMRC Career Development Fellowship; all outside the submitted work. I. Filip and A. Radfar report support for the present manuscript from Avicenna Medical and Clinical Research Institute. D. Flood reports royalties or licenses from NHLBI (award number K23HL161271); consulting fees from WHO as payment to their institution; leadership or fiduciary role in other board, society, committee, or advocacy group, unpaid, with the Maya Health Alliance; all outside the submitted work. M. Foschi reports consulting fees from Roche Pharma as a Scientific Consultant; support for attending meetings and/or travel from Roche Pharma Support, Novartis, and Merck; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, with MSBase Foundation; all outside the submitted work. R.C. Franklin reports grants or contracts from the Queensland Government for Heatwaves in Queensland and Arc Flash–Human Factors, and Mobile Plant Safety-Agrifutures; honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from World Safety Conference 2022 as Conference Convener; support for attending meetings and/or travel from ACTM–Tropical Medicine and Travel Medicine Conference 2022, 2023, and ISTM–Travel Medicine Conference, Basel 2023; leadership or fiduciary role in other board, society,

committee, or advocacy group, paid or unpaid, as Director for Kidsafe, Director for Auschem, Governance Committee for ISASH, Director for Farmsafe, and PHAA Injury Prevention SIG Convenor; all outside the submitted work. J.M. Gelejinse reports grants or contracts from EU Horizon 2020 programme and Regio Deal Foodvalley Public funding, as payment to their institution; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, with the Health Council of the Netherlands as Vice President; all outside the submitted work. R.F. Gillum reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Annals of Epidemiology, outside the submitted work. A. Guha reports grants or contracts from the American Heart Association and the Department of Defense; consulting fees from Pfizer, Novartis, and Myovant; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, with the ZERO Prostate Cancer–health equity task force; all outside the submitted work. V.B. Gupta and V.K. Gupta report grants or contracts from National Health and Medical Research Council (NHMRC), Australia, as payments to their institutions, all outside the submitted work. G.J. Hankey reports consulting fees from Janssen and Bayer; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Medscape; participation on a Data Safety Monitoring Board or Advisory Board with AC Immune; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, with the American Heart Association; all outside the submitted work. A. Hassan reports consulting fees from Novartis, Sanofi Genzyme, Biologix, Merck, Hikma Pharma, Janssen, Inspire Pharma, Future Pharma, and Elixir pharma; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Novartis, Allergan, Merck, Biologix, Janssen, Roche, Sanofi Genzyme, Bayer, Hikma Pharma, Al Andalus, Chemipharm, Lundbeck, Inspire Pharma, Future Pharma and Habib Scientific Office, and Everpharma; support for attending meetings and/or travel from Novartis, Allergan, Merck, Biologix, Roche, Sanofi Genzyme, Bayer, Hikma Pharma, Chemipharm, and Al Andalus and Clavita pharm; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, as Member of educational, membership and regional committees of International Headache Societies; all outside the submitted work. C. Herteliu reports grants or contracts from the Romanian Ministry of Research Innovation and Digitalization, MCID, project number ID-585-CTR-42-PFE-2021, the European Commission Horizon 4P-CAN, and the European Union–NextgenerationEU and Romanian Government for projects no.760050/ 23.05.2023 and no.760034/ 23.05.2023, all outside the submitted work. M. Hultström reports grants or contracts from Knut och Alice Wallenberg Foundation, Hjärt-lungfonden, Läkarsällskapet; support for attending meetings and/or travel from American Physiological Society; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, with the American Physiological Society; all outside the submitted work. I.M. Ilic reports support for the present manuscript from Ministry of Education, Science and Technological Development, Republic of Serbia (project No 175042, 2011-2023). M.D. Ilic reports support for the present manuscript from Ministry of Science, Technological Development and Innovation of the Republic of Serbia (no. 451-03-47/2023-01/200111). S.M.S. Islam reports grants from NHMRC and the Heart Foundation, outside the submitted work. N.E. Ismail reports leadership or fiduciary role in other board, society, committee, or advocacy group, unpaid, with the Malaysian Academy of Pharmacy as Council Member and Bursar, outside the submitted work. R.D. Jamora reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Torrent Pharma Phil., HI-Eisai, and Medtronic Phil.; support for attending meetings and/or travel from Natrapharm Phil., Sun Pharma Phil., Torrent Pharma Phil.; and participation on a Data Safety Monitoring Board or Advisory Board with Torrent Pharma Phil. and HI-Eisai; all outside the submitted work. H. Jiang reports grants or contracts from the Australian Research Council (DP200101781), all outside the submitted work. T. Joo reports support for the present manuscript from the National Research, Development and Innovation Office in Hungary (RRF-2.3.1-21-2022-00006, Data-Driven Health Division of National Laboratory for Health Security), and the National Research, Development and Innovation Fund (TKP2021-NVA). A. Joseph reports grants or contracts from the American College of Gastroenterology, outside the submitted work. J.J. Jozwiak

reports payment for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Novartis, Adamed, and AMGEN; all outside the submitted work. S. Kalra reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk, and Sanofi; leadership or fiduciary role in other board, society, committee, or advocacy group, unpaid, with Executive post in International Society of Endocrinology, South Asian Federation of Endocrine Societies, Endocrine Society of India, Indian Professional Association of Transgender Health; all outside the submitted work. M.S. Khan reports support for attending meetings and/or travel from Bayer and Abbot; participation on a Data Safety Monitoring Board or Advisory Board with Bayer; all outside the submitted work. K. Krishan reports nonfinancial support from UGC Centre of Advanced Study, CAS II, Department of Anthropology, Panjab University, Chandigarh, India, outside the submitted work. B. Lacey reports support for the present manuscript from UK Biobank, funded largely by the UK Medical Research Council and Wellcome, through their employment at the University of Oxford. T. Lallukka reports support for the present manuscript from the Academy of Finland (Grant #330527). M. Lee reports support for the present manuscript from the Ministry of Education of the Republic of Korea and the National Research Foundation of Korea (NRF-2021R1I1A4A01057428) and Bio-convergence Technology Education Program through the Korea Institute for Advancement Technology (KIAT) funded by the Ministry of Trade, Industry and Energy (No. P0017805). K.E. LeGrand, M. Lindstrom, and G.A. Roth report support for the present manuscript from the Bill and Melinda Gates Foundation and the American College of Cardiology Foundation as payments to their institution. M. Leonardi reports support for attending meetings and/or travel from EAN, WFN, WFNR, and EFRR; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, with WFN, WFNR, EAN, EFRR, and SIN Italian Society of Neurology; all outside the submitted work. M.-C. Li reports grants or contracts from The National Science and Technology Council in Taiwan (NSTC 112-2410-H-003-031); leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, as Technical Editor with *Journal of the American Heart Association*; all outside the submitted work. Y. Li reports support for the present manuscript from Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen. L.-L. Lim reports grants or contracts from Novartis as payments to their institution, outside the submitted work. Xi Liu reports support for the present manuscript from National Institutes of Health (NIH) as payments to their institution; grants or contracts from Natural Science Foundation of Jiangsu Province (BK20200238); all outside the submitted work. E. Llanaj reports grants or contracts from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)–491394008 and a grant from the German Federal Ministry of Education and Research and the State of Brandenburg to the German Center for Diabetes Research (DZD)–82DZD03D03; all outside the submitted work. A.M. Loreche reports grants or contracts from Sanofi Consumer Healthcare; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Zuellig Family Foundation for a manuscript on local health systems strengthening; all outside the submitted work. S. Lorkowski reports grants or contracts from Akcea Therapeutics Germany and DSM Nutritional Products as payments to their institution; consulting fees from Danone, Novartis Pharma, and Swedish Orphan Biovitrum (SOBI); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Akcea Therapeutics Germany, AMARIN Germany, Amedes Holding, AMGEN, Berlin-Chemie, Boehringer Ingelheim Pharma, Daiichi-Sankyo Deutschland, Danone, Hubert Burda Media Holding, Janssen-Cilag, Lilly Deutschland, Novartis Pharma, Novo Nordisk Pharma, Roche Pharma, Sanofi-Aventis, and SYNLAB Holding Deutschland & SYNLAB Akademie; participation on a Data Safety Monitoring Board or Advisory Board with Akcea Therapeutics Germany, AMGEN, Daiichi-Sankyo Deutschland, Novartis Pharma, and Sanofi-Aventis; all outside the submitted work. M.A. Mahmoud reports grants or contracts from the Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia (project number 445-5-648), outside the submitted work. H.R. Marateb reports support for the present manuscript from the Biomedical Engineering Research Centre (CREB), Automatic Control Department (ESAI), and Universitat Politècnica de Catalunya-Barcelona Tech (UPC), 08028 Barcelona,

Spain; grants or contracts from The Beatriu de Pinós post-doctoral programme from the Office of the Secretary of Universities and Research from the Ministry of Business and Knowledge of the Government of Catalonia programme: 2020 BP 00261; all outside the submitted work. E. Mathews reports grants or contracts from the Wellcome DBT India Alliance, all outside the submitted work. R.J. Maude reports support for the present manuscript from the Wellcome Trust Grant number 220211 as it provides core funding for Mahidol Oxford Tropical Medicine Research, outside the submitted work. N. Moka reports leadership or fiduciary role in other board, society, committee, or advocacy group, unpaid, with the Kentucky Society of Clinical Oncology as Treasurer, outside the submitted work. L. Monasta reports support for the present manuscript from the Italian Ministry of Health (Ricerca Corrente 34/2017), payments made to the Institute for Maternal and Child Health IRCCS Burlo Garofolo. S.D. Morrison reports grants or contracts from Seattle Children's Hospital Academic Enrichment Fund paid to Seattle Children's Hospital, outside the submitted work. J. Morze reports honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Alab Laboratoria; all outside the submitted work. D. Mozaffarian reports grants or contracts from National Institutes of Health, the Bill and Melinda Gates Foundation, The Rockefeller Foundation, Vail Innovative Global Research, and Kaiser Permanente Fund; royalties or licenses from UpToDate; consulting fees from Acasti Pharma and Barilla; participation on a Data Safety Monitoring Board or Advisory Board with Beren Therapeutics, Brightseed, Calibrate, Elysium Health, Filtricine, HumanCo, Instacart Health, January Inc, Season Health, Validation Institute, Perfect Day, and Tiny Organics; stock or stock options in Calibrate and HumanCo; all outside the submitted work. U.O. Mueller reports support for the present manuscript from Grant #01ER2301C German Federal Ministry for Education and Research 2023-2028. S. Muthu reports leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, with AO Spine Knowledge Forum Degenerative, ICRS Next Gen Committee, and SICOT Grants Committee; all outside the submitted work. S. Nargus reports receipt of equipment, materials, drugs, medical writing, gifts, or other services for medical writing services, outside the submitted work. R. Nejad Shahrokh Abadi reports support for the present manuscript from Mashhad University of Medical Sciences. S. Nomura reports support for the present manuscript from Ministry of Education, Culture, Sports, Science and Technology of Japan (21H03203) and Precursory Research for Embryonic Science and Technology from the Japan Science and Technology Agency (JPMJPR22R8). B. Norrving reports participation on a Data Safety Monitoring Board or Advisory Board with Simbec-ORION HOVID trial as a member of DSMB, outside the submitted work. A.P. Okekunle reports support for the present manuscript from National Research Foundation of Korea funded by the Ministry of Science and ICT (2020H1D3A1A04081265); support for attending meetings and/or travel from National Research Foundation of Korea funded by the Ministry of Science and ICT (2020H1D3A1A04081265) outside the submitted work. A. Ortiz reports grants or contracts from Sanofi Institution: IIS-FJD; consultancy, speaker fees, and/or travel support from Advicciene, Astellas, Astrazeneca, Amicus, Amgen, Boehringer Ingelheim, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Menarini, Mundipharma, Kyowa Kirin, Lilly, Alexion, Freeline, Idorsia, Chiesi, Otsuka, Novo-Nordisk, Sysmex, and Vifor Fresenius Medical Care Renal Pharma; is Director of the Catedra Mundipharma-UAM of diabetic kidney disease and the Catedra Astrazeneca-UAM of chronic kidney disease and electrolytes; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, with the European Renal Association Council; stock or stock options in Telara Farma; all outside the submitted work. R. Palladino reports grants or contracts from the UK MS Society; consulting fees from Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from MSD; all outside the submitted work. F. Pan reports grants or contracts from the National Health and Medical Research Council (NHMRC) of Australia Early Career Fellowship, all outside the submitted work. R Passera reports participation on a Data Safety Monitoring Board or Advisory Board with DSMB for the trial "Consolidation with ADCT-402 (loncastuximab tesirine) after immunochemotherapy: a phase II study in BTKi-treated (or BTKi ineligible) Relapse/Refractory (R/R) Mantle Cell Lymphoma (MCL) patients," EudraCT number: 2021-000715-23, all

outside the submitted work. A.E. Peden reports support for the present manuscript from the Australian National Health and Medical Research Council (APP2009306). V.C.F. Pepito reports grants or contracts from International Initiative for Impact Evaluation (3ie), and Sanofi Consumer Healthcare, all outside the submitted work. T. Pilgrim reports grants or contracts from Biotronik and Boston Scientific as payments to their institution; consulting fees from for advisory board meetings for Medtronic and Biosensors paid to their institution; honoraria for lectures from Edwards Lifesciences, Biotronik, and Abbott, paid to their institution; participation on a Data Safety Monitoring Board or Advisory Board with DSMB for Empire trial (Biosensors), and Event Adjudication Committee for HighLife SAS, receipt of equipment, materials, drugs, medical writing, gifts, or other services from AT-Sens, Korea; all outside the submitted work. M.A. Piradov reports leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, as Editor-in-Chief of *Annals of Clinical and Experimental Neurology*, outside the submitted work. A. Rane reports stock or stock options in Agios Pharmaceuticals, outside the submitted work. L.F. Reyes reports grants or contracts from MSD, Pfizer, and GSK; consulting fees from GSK and Pfizer; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GSK, Pfizer, and MSD; payment for expert testimony from GSK; support for attending meetings and/or travel from GSK; all outside the submitted work. L. Ronfani reports support for the present manuscript from the Italian Ministry of Health (Ricerca Corrente 34/2017), payments made to the Institute for Maternal and Child Health IRCCS Burlo Garofolo. A. Rynkiewicz reports consulting fees from Boehringer Ingelheim, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Servier and Amgen; all outside the submitted work. S. Sacco reports grants or contracts from Novartis and Uriach; consulting fees from Novartis, Allergan-Abbvie, Teva, Lilly, Lundbeck, Pfizer, NovoNordisk, Abbott, and AstraZeneca; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Novartis, Allergan-Abbvie, Teva, Lilly, Lundbeck, Pfizer, NovoNordisk, Abbott, and AstraZeneca; support for attending meetings and/or travel from Lilly, Novartis, Teva, and Lundbeck; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, as President elect European Stroke Organization and Second vice-president European Headache Federation; receipt of equipment, materials, drugs, medical writing, gifts or other services from Allergan-Abbvie, and NovoNordisk; all outside the submitted work. J. Sanabria reports support for attending meetings and/or travel from Department CME fund; three patents planned, issued or pending; participation on a Data Safety Monitoring Board or Advisory Board with American Board of Surgery; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, with ASTS, AHPBA, IHBPA, CSA, SSAT, AASLD, and ACS; all outside the submitted work. N. Scarmeas reports grants or contracts from Novo Nordisk; participation on a Data Safety Monitoring Board or Advisory Board with NIH Albert Einstein College of Medicine as Chair of Data Safety Monitoring Board; all outside the submitted work. B.M. Schaarschmidt reports grants or contracts from Else Kröner-Fresenius Foundation, Deutsche Forschungsgemeinschaft, and PharmaCept GmbH; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca; support for attending meetings and/or travel from Bayer AG; all outside the submitted work. A.E. Schutte reports consulting fees from Abbott; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Servier, Abbott, Medtronic, Omron, and Sanofi; support for attending meetings and/or travel from Servier, Medtronic, and Omron; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, as Past President, International Society of Hypertension, Co-Chair: Hypertension Taskforce of Australia, Secretary: Australian Cardiovascular Alliance; all outside the submitted work. P.A. Shah reports grants or contracts from the Rajiv Gandhi University of Health Sciences, India, for a separate project on Neonatal Microbiome Studies; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, as President of Science and Research Club, BMCRI; all outside the submitted work. A. Sharifan reports leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, with Cochrane Early Career Professionals Network; receipt of equipment, materials, drugs, medical

writing, gifts or other services from Elsevier in the form of 30 days of complimentary access to ScienceDirect, Scopus, Reaxys, and Geofacets after reviewing a manuscript for the journal *Chest*; all outside the submitted work. S. Sharma reports grants or contracts from the John J. Bonica Postdoctoral Fellowship from the International Association for the Study of Pain (IASP) from November 2021–October 2023; support for attending meetings and/or travel to attend the IASP Congress in Toronto in 2022; all outside the submitted work. V. Sharma reports other financial or nonfinancial interests with DFSS (MHA)'s research project (DFSS28(1)2019/EMR/6) at Institute of Forensic Science & Criminology, Panjab University, Chandigarh, India, outside the submitted work. S. Shrestha reports other financial or nonfinancial interests in the School of Pharmacy, Monash University Malaysia through the Graduate Research Merit Scholarship to study in the PhD. C.R. Simpson reports grants or contracts from HRC (NZ), Ministry of Health (NZ), MBIE (NZ), Chief Scientist Office (UK), and MRC (UK); leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, as NZ Government Data Ethics Advisory Group Chair; all outside the submitted work. J.A. Singh reports consulting fees from AstraZeneca, Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc., Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam associates, Focus forward, Navigant consulting, Spherix, MedIQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, Practice Point communications, and the National Institutes of Health and the American College of Rheumatology; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from the speaker's bureau of Simply Speaking; support for attending meetings from OMERACT as a member of the steering committee; participation on an Advisory Committee with the FDA Arthritis Advisory Committee; leadership or fiduciary roles in board, society, committee, or advocacy groups, paid or unpaid as a past steering committee member of the OMERACT, an international organization that develops measures for clinical trials and receives arms-length funding from 12 pharmaceutical companies, Co-Chair of the Veterans Affairs Rheumatology Field Advisory Committee, and the editor and Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis; stock or stock options in Atai Life Sciences, Kintara Therapeutics, Intelligent Biosolutions, Acumen Pharmaceutical, TPT Global Tech, Vaxart Pharmaceuticals, Atyu Biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics Inc., Seres Therapeutics, Tonix Pharmaceuticals Holding Corp., and Charlotte's Web Holdings, Inc, as well as previously owned stock options in Amarin, Viking and Moderna Pharmaceuticals; outside the submitted work. S. Song reports grants or contracts from Georgia CTSA, outside the submitted work. S. Stortecky reports grants or contracts from Edwards Lifesciences, Medtronic, Abbott, and Boston Scientific; consulting fees from BSC/BTG, and Teleflex; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Boston Scientific; all outside the submitted work. J. Sundström reports stock or stock options in Anagram Kommunikation AB, MinForskning AB, and Symptoms Europe AB, all outside the submitted work. K.M. Tabb reports grants or contracts from All our Kids Networks and PCORI Engagement Award as payments to their institution, and from a NIH Research Award; consulting fees from University of Massachusetts; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, with State of Illinois Maternal Mortality for Violent Deaths review committee; all outside the submitted work. A. Tichopad reports a research grant from CEEOR; stock or stock options in Amgen; all outside the submitted work. M. Tonelli reports leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, as President-elect of International Society of Nephrology outside the submitted work. E. Upadhyay reports patents issued for a system and method for electricity generation through crop stubble by using microbial fuel cells, a system and method of reusable filters for antipollution mask, a system for disposed personal protection equipment (PPE) into biofuel through pyrolysis, and a novel herbal pharmaceutical aid for formulation of gel and method thereof; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, as joint Secretary of Indian Meteorological Society, Jaipur Chapter (India); all outside the submitted work. D. Vervoort reports grants or contracts from Canadian Institutes of Health Research through the Vanier Canada Graduate

Scholarship; participation on a Data Safety Monitoring Board or Advisory Board with Global Alliance for Rheumatic and Congenital Hearts as a Medical Advisory Board member; all outside the submitted work. M.Y. Wei reports grants or contracts from National Institutes of Health (NIH) as institutional support; support for attending meetings and/or travel from the NIH; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, with Society of General Internal Medicine as Research Committee Chair; outside the submitted work. Y. Yasufuku reports grants or contracts from Shionogi & Co. Ltd through payments to Osaka University, outside the submitted work. L. Yperzeele reports grants or contracts from the World Stroke Organization and the University of Antwerp; consulting fees from BMS as payments to their organization; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Vives Hogeschool and UCLL Genk as payments to their organization; support for attending meetings and/or travel from the World Stroke Organization; participation on a Data Safety Monitoring Board or Advisory Board as a Member of the steering committee for Librexia Stroke study (Janssen/BMS); leadership or fiduciary role in other board, society, committee, or advocacy group, unpaid, with Belgian Stroke Council, SAP-E, and CASES study; all outside the submitted work. M. Zielińska reports other financial or nonfinancial interests in AstraZeneca as their employee, all outside the submitted work. Z. Zou reports support for the present manuscript from National Natural Science Foundation of China (82073573). E. Zweck reports support for attending meetings and/or travel from Abiomed Inc, outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.